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Abstract
Chronic obstructive pulmonary disease (COPD) is the 4th leading cause of death worldwide
and accounts for the highest rate of hospital admissions in Canada. The need for sensitive
regional and surrogate measurements of lung structure and function in COPD continues to
motivate the development of non-radiation based and sensitive imaging approaches, such as
hyperpolarized helium-3 (3He) and xenon-129 (129Xe) magnetic resonance imaging (MRI).
The static ventilation images acquired using these approaches allows us to directly visualize
lung regions accessed by the hyperpolarized gas during a breath-hold, as well as quantify the
regions without signal referred to as the percentage of the thoracic cavity occupied by
ventilation defects (VDP). The lung micro-structure can also be probed using diffusionweighted imaging which takes advantage of the rapid diffusion of 3He and

129

Xe atoms to

generate surrogate measurements of alveolar size, referred to as the apparent diffusion
coefficient (ADC).

Here we evaluated COPD lung structure and function using

hyperpolarized gas MRI measurements longitudinally, following treatment and in early
disease. In COPD ex-smokers, we demonstrated 3He VDP and ADC worsened significantly
in only 2 years although there was no change in age-matched healthy volunteers, suggestive
of disease progression. We also evaluated COPD ex-smokers pre- and post-bronchodilator
and showed regional improvements in gas distribution following bronchodilator therapy
regardless of spirometry-based responder classification; the ADC measured in these same
COPD ex-smokers also revealed significant reductions in regional gas trapping postbronchodilator. Although 3He MRI has been more widely used, the limited global quantities
necessitates the transition to hyperpolarized
and

129

129

Xe, and therefore we directly compared 3He

Xe MRI in the same COPD ex-smokers and showed significantly greater gas

distribution abnormalities for

129

Xe compared to

3

He MRI that were spatially and

significantly related to lung regions with elevated ADC. Finally, we demonstrated that exsmokers with normal spirometry but abnormal diffusion capacity of the lung for carbon
monoxide (DLCO) had significantly worse symptoms, exercise capacity and 3He ADC than
ex-smokers with normal DLCO. These important findings indicate that hyperpolarized gas
MRI can be used to improve our understanding of lung structural and functional changes in
COPD.
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CHAPTER 1
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INTRODUCTION

Chronic Obstructive Pulmonary Disease (COPD), a common preventable and treatable
disease, is characterized by persistent airflow limitation that is usually progressive and
associated with an enhanced chronic inflammatory response in the airways and the lung
to noxious particles or gases.1 The objective of Chapter 1 is to provide motivation for the
work presented in the remaining chapters of this thesis, as well as to provide an overview
of the current standard measurements of pulmonary function, the natural history and
progression of lung function decline, the underlying disease mechanisms and finally
discuss how nuclear medicine, computed tomography (CT) and magnetic resonance
imaging (MRI) have been used to evaluate COPD and provide imaging biomarkers that
can be used to evaluate disease progression and treatment response.

1.1

Burden of COPD

According to the World Health Organization estimates in 2004, 64 million people, or
10% of the population, was suffering from COPD.2 Three million people died of COPD
which equaled just over 5% of all global deaths and ranked COPD as the 4th leading
cause of death worldwide.2;3 By the year 2030, it is predicted that COPD will increase to
the 3rd leading cause of death worldwide, as shown in Figure 1-1.2 It is suggested that
the projected increase in the global burden of COPD is due to the aging population and
the increasing levels of tobacco smoking in many middle- and low-income countries.2

Figure 1-1 The top four leading causes of death in the world in 2004 and the predicted
top four leading causes of death in 2030 compared
Adapted from The global burden of disease: 2004 update, World Health Organization.2;3
Similarly, in Canada alone, respiratory disease is ranked the 3rd leading cause of death
behind cardiovascular disease and cancer, and among all respiratory diseases that results
in death, COPD is responsible for the greatest proportion of all deaths for both men and
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women as shown in Figure 1-2.4 In addition to being a leading cause of death and
disability,2 COPD also imposes significant healthcare costs with exacerbations of COPD,
defined as COPD-related symptoms including one or more of the following lasting at
least 3 days: cough, wheeze, dyspnea, or sputum production,5 accounting for the greatest
proportion of the total COPD burden on the Canadian healthcare system. The Canadian
Institute for Health Information showed that in 2006, COPD accounted for the highest
rate of hospital admission among the major chronic illnesses.6 This rate also included
single and repeat hospitalizations indicating that there is a much higher readmission rate
for COPD than any other chronic illness including angina, asthma, heart failure, diabetes
and epilepsy, as shown in Figure 1-3. A study by Mittmann and colleagues5 indicated
that the average cost of an exacerbation requiring hospitalization in Canada was nearly
$10,000, with an average length of stay of 10 days. The authors also estimated that the
national cost burden for the direct costs associated with COPD exacerbations ranged from
$646 million to $736 million per annum.5

Figure 1-2 Proportion of all deaths due to respiratory disease for men and women in
Canada
Adapted from the Life and Breath: Respiratory Disease in Canada 2007 report, Public
Health Agency of Canada.4

Cigarette smoking has long been recognized as the most important risk factor for the
development of COPD,7 greater than that of atmospheric pollution or occupational
exposure, although the association between occupational exposure (airborne dusts, fumes
and vapors) and COPD has been demonstrated independent of cigarette smoking.7-9
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Although there has been less evidence to support the association between second-hand
smoke exposure and the risk of developing COPD,10;11 more recent studies suggest there
is a causal relationship between exposure to second-and smoke and COPD. There is also
a genetic risk factor, alpha-1-antitrypsin deficiency, that has been shown to be associated
with an increased risk of COPD.12;13 Other COPD risk factors have been suggested,1
such as prior tuberculosis, socioeconomic status and asthma, however more work must be
done to understand the effect of these and other risk factors on the development of COPD
as COPD in those who have never smoked remains poorly understood.14

Figure 1-3 Repeat Hospitalizations by Condition at First Admission
This graph shows the number of patients with a single hospitalization, one repeat
hospitalization and two or more repeat hospitalizations by condition at first admission.
Reproduced with permission from the Canadian Institute for Health Information’s (CIHI)
publication entitled Health Indicators 2008.6
Recent international epidemiological studies have reported prevalence estimates that
suggest that approximately 9-10% of adults aged 40 years and older have COPD.14;15
Importantly, this estimate is much higher than previous estimates15 and studies have
shown that of these individuals that were determined to have COPD, only 19% had been

4

previously diagnosed and were being treated.16 These studies indicate that the prevalence
of COPD is much higher than previously believed and that the majority of the individuals
that have the disease are not diagnosed and are not being treated.
In the following section I will describe the structure and function of the lung, introduce
the basic mechanisms by which this structure and function is abnormal in COPD, as well
as describe the current gold standards for assessing lung function.

1.2

The Respiratory System: Structure and Function

In humans, the respiratory system includes the oral and nasal cavities, the lungs, the
conducting airways, the parts of the central nervous system concerned with the control of
the muscles of respiration, and the chest wall structures.17;18 The respiratory system
serves several functions, however, the main function of the respiratory system is to
supply the tissues of our body with oxygen for cellular metabolism and to eliminate the
carbon dioxide waste that is produced by cellular metabolism, and this process, known as
gas exchange, occurs in the lungs.17-19 In this section I will discuss the process by which
air moves from the environment, through the conducting zone and to the respiratory zone
for gas exchange.

1.2.1

The Airways: Conducting Zone

During inspiration, air passes through the nose or mouth into the pharynx. The pharynx
branches into two tubes: the esophagus, which passes food to the stomach, and the
larynx. Air passes through the larynx into the trachea which then branches into the two
main bronchi; one of which enters the left lung and the other the right lung.17-19 Within
the lungs, air passes through more than 20 generations, or airway branches, and as the
airway generation increases the airways become narrower, shorter and more numerous.
As shown in Figure 1-4, the conducting zone extends from the top of the trachea
(generation 0) to the terminal bronchioles (generation 16).20
contain alveoli and therefore there is no gas exchange.17-19

These airways do not
However, following

inspiration, some of the inhaled air remains in the conducting zone. The air that resides
within the conducting zone at the end of inspiration is known as the anatomic dead space.
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The average anatomic dead space is approximately 150 ml in healthy adults,21 however,
this volume has been shown to increase with age.22

Figure 1-4 Schematic of the Human Airways
The conducting zone of the lungs does not participate in gas exchange and extends
from generation 0 to generation 16. The respiratory zone is the site of gas exchange
and extends from generation 17 to generation 23. Adapted from West JB. Respiratory
Physiology: the essentials, Ninth edition.19

1.2.2

The Airways: Respiratory Zone

The terminal bronchioles branch into the respiratory bronchioles (generation 17-19),
which marks the beginning of the respiratory zone. Due to the large number of airway
branching in the respiratory zone, the total cross sectional area of the airways increases
rapidly (Figure 1-5). Accordingly, the respiratory zone constitutes approximately 90%
of the lung volume, while the airways and the blood vessels of the conducting zone
constitute the remaining 10%.20 The respiratory bronchioles, as shown in Figure 1-4,
have few alveoli lining their walls. Finally, the respiratory bronchioles divide into the
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alveolar ducts and the alveolar sacs. The number of alveoli increases from the respiratory
bronchioles to the alveolar sacs which consist entirely of alveoli.18 The part of the lung
that branches from the respiratory bronchiole and includes the alveolar duct and sac is
referred to as an acinus. The acinus represents the functional respiratory unit of the lung
where gas exchange occurs.

Figure 1-5 Schematic showing the rapid increase in the cross sectional area of the
airways as the airway generation increases within the respiratory zone.
Adapted from West JB. Respiratory Physiology: the essentials, Ninth edition.19

1.2.3

Ventilation

Ventilation is the process by which gas is brought from the environment to the blood-gas
barrier.19

The volume of gas inhaled and exhaled with each breath, or during one

respiratory cycle, is referred to as the tidal volume. Total ventilation is defined as the
volume of gas leaving the lung each minute. Therefore, since the average person has a
tidal volume of 500 ml and takes approximately 15 breaths/min,19 the volume of gas
entering the lung each minute is 7500 ml/min. However, as discussed above, the air that
resides within the conducting zone at the end of inspiration does not participate in gas
exchange. Therefore, the volume of gas entering the lung each minute that participates in
gas exchange, otherwise known as alveolar ventilation, is approximately 5250 ml/min.
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1.2.4

The Alveoli: Site of Gas Exchange

The alveoli are small air sacs at the end of the respiratory bronchioles where gas
exchange occurs. It has been estimated that there are approximately 480 million alveoli
in the human lungs with a mean size of 4.2x106 μm3, or a diameter of roughly 200 μm23
Within each alveoli, oxygen is transported from the alveoli to the pulmonary capillaries
by diffusion. The factors that determine the rate of diffusion of O2 from the alveoli to the
pulmonary capillaries is described by Fick’s law for diffusion, as shown in equation (1):
A ⋅ D ⋅ ( P1 − P2 )
Diffusion =
T

(1)

where A=surface area of the lung for diffusion, D=diffusion coefficient of gas, P1P2=partial pressure difference of the gas across the alveolar capillary membrane, and
T=thichness across the alveolar capillary membrane. Therefore, gas diffusion rate is
directly proportional to the surface area of the lung, the diffusion coefficient of the gas
and the partial pressure difference, and it is inversely proportional to the thickness across
the lung membrane.
The total surface area of an average adult’s lungs available for gas exchange is estimated
to be approximately 70 m2.24 The gas in the alveoli follows the basic rule of a pressure
gradient and diffuses from an area of high pressure within the alveoli (Partial Pressure of
Oxygen, [PA02] > 100 mm Hg) to an area of low pressure within the pulmonary
capillaries (PA02 = 40 mm Hg).25 The gas diffusion is slowed by the alveolar capillary
membrane and the thickness of the alveolar capillary membrane of an average healthy
adult is approximately 0.2-0.5 μm.17

1.3

Established Tests of Lung Function

Pulmonary function tests may be used in a hospital setting or a physician’s office to aid in
the diagnosis and management of pulmonary diseases or in research studies. These tests
are used to evaluate overall lung function by measuring air flow or volume, symptoms or
exercise capacity.
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1.3.1

Pulmonary Function Tests

Pulmonary Function tests measure the volume and flow of air during inspiration and
expiration as well as provide information regarding gas exchange within the lung. These
measurements are used for clinical diagnosis of lung disease, for monitoring disease
progression as well as for treatment recommendations in patients with respiratory disease.

1.3.1.1

Spirometry

Figure 1-6 Measurement of the Forced Expiratory Volume in 1 second (FEV1) and the
Forced Vital Capacity (FVC)
Body Plethysmograph (MedGraphics Corporation. 350 Oak Grove Parkway St. Paul,
MN, USA) is used to measure airflows, lung volumes and capacities (A) and a schematic
depicting the airflow curve used to measure FEV1 and FVC (B).
Spirometry is a physiological test that measures how an individual inhales or exhales
volumes of air as a function of time.26 The two most common spirometric measurements
are the forced expiratory volume in 1 second (FEV1) and the forced vital capacity (FVC).
As shown in Figure 1-6, these measurements are made while the subject is in the seated
position in the Body Plethysmograph chamber. The subject begins with tidal breathing
and then is instructed to inhale maximally and then exhale as fast as possible and then
continue to exhale as long as possible. Following maximum inhalation, the volume that
is exhaled in 1 second is the FEV1 and the total volume that could be maximally exhaled,
following maximum inhalation, is the FVC.
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According to the American Thoracic Society (ATS)/ European Respiratory Society
(ERS) task force, an adequate test requires a minimum of three acceptable maneuvers be
performed.26 An acceptable maneuver is one in which all three phases, defined as 1)
maximal inspiration; 2) a “blast” of exhalation; and 3) continued complete exhalation to
the end of test, were performed correctly and for the required duration. The maneuvers
must also be repeatable with the difference between the largest and the next largest FVC
≤ 0.15 L.26
In Canada, the Canadian Thoracic Society (CTS) clinical guidelines specify that
spirometry measurements be used to diagnose asthma and COPD, and therefore
spirometry should be conducted by trained and qualified personnel, to assure that
ATS/ERS spirometry testing standards are met.27 However, even with technologists
trained to meet these standards, spirometry is well-known to be difficult to perform in
children and in those with lung disease.

Figure 1-7 The Volumes and Capacities of the Lung Measured using Body
Plethysmography
Adapted from Respiratory Care: Principles and Practice.28

1.3.1.2

Plethysmography

As shown in Figure 1-7, there are eight static lung volume and capacity measurements
that can be determined using body plethysmography. The definition of the lung volumes
and capacity measurements are as follows: tidal volume (TV) is defined as the volume of
gas inhaled or exhaled during normal breathing; the inspiratory reserve volume (IRV) is
the maximum volume of gas that can be inspired from the end of a normal inspiration; the
expiratory reserve volume (ERV) is the maximum volume of gas that can be expired
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from the end of a resting expiration; the residual volume (RV) is the volume of gas
remaining in the lungs after a maximal expiration; the vital capacity (VC) is the
maximum volume of gas that can be exhaled from the lungs after a maximal inspiration
or inhaled from a point of maximal exhalation; inspiratory capacity (IC) is the maximum
volume of gas that can be inspired from the normal end-expiratory position; functional
residual capacity (FRC) is the volume of gas remaining in the lungs at the end of a resting
expiration; and, the total lung capacity (TLC) is the volume of gas in the lungs at the end
of a maximal inspiration.28
Clearly, many of these static volumes can be measured directly from normal breathing by
instructing the subject to perform the four static positions: maximal inhalation, end
inspiration, end expiration, and maximal exhalation. However, the gas remaining in the
lung after a maximal expiration, known as the residual volume (RV), and the volume of
gas in the lung after a normal expiration, known as the functional residual capacity
(FRC), must be measured with body plethysmography using Boyle’s law.28 The subject
is placed in an air-sealed plethysmograph chamber, as shown in Figure 1-6A, and
breathes through a mouthpiece with a shutter. At the end of a normal expiration the
shutter closes and the subject is instructed to inhale. As the subject tries to inhale, the
pressure changes within the box and at the airway can be measured. Since the box
volume is known, the volume of gas in the lungs when the shutter was closed (FRC) can
be calculated.

1.3.1.3

Diffusing Capacity

The diffusing capacity of the lung for carbon monoxide (DLCO) is another pulmonary
function test that provides an indirect measure of diffusion of gases across the alveolar
membrane into the blood. The body plethysmograph, as shown in Figure 1-6A, with the
attached Medgraphics gas analyzer allows DLCO to be measured. DLCO is measured by
instructing the subject to exhale to RV and then perform a maximum inhalation to TLC.
As shown in Figure 1-8, during the inhalation the subject inhales a gas mixture that
contains a very low concentration of carbon monoxide (CO) (0.3%) and helium (10%)
with air; the subject is then instructed to hold their breath for 10 seconds before
exhalation.29 The volume of gas exhaled is collected and analyzed. The gas first exhaled
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is discarded as it represents the anatomic dead space volume and is defined as 2.2 ml x kg
body weight.29

The remaining volume is analyzed by comparing the exhaled

concentrations of CO and helium to the inspired concentrations to determine the amount
of CO diffusing across the alveolar membrane.

Figure 1-8 Measurement of the Diffusing Capacity of the Lung for Carbon Monoxide
The subject inhales a mixture of 10% helium and 0.3% CO, holds his/her breath for 10
seconds then exhales. The anatomic dead space volume is discarded and the remaining
alveolar sample is analyzed. Adapted from West JB. Respiratory Physiology: the
essentials, Ninth edition.19
According to the ATS/ERS task force, there should be at least two acceptable tests that
meet the repeatability requirement of either being within 3 ml CO standard temperature
(273 Kelvin), pressure (101.3 kPa, 760 mmHg) and dry (STPD)·min-1·mmHg-1 of each
other or within 10% of the highest value.29 Factors that affect the DLCO include diseases
that reduce the volume of pulmonary capillary blood such as anemia, and diseases that
affect the area and thickness of the alveolar capillary membrane including emphysema,
interstitial lung disease and pulmonary hypertension.29 Cigarette smoking has also shown
to reduce DLCO30 and the ATS/ERS task force recommends that subjects refrain from
smoking on the day the test is performed.29
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Pulmonary function test measurements are usually interpreted by comparing measured
values in individual subjects with the values that are predicted for healthy subjects based
on age, sex, height and race, and expressing the observed value as a percent of
predicted.31

1.3.2

6 minute Walk Test

The 6 minute walk test (6MWT) is a self-paced exercise test that measures the distance a
subject can walk on a flat, hard surface in a period of 6 minutes. The 6MWT is thought
to reflect the functional exercise level for daily physical activities in subjects with
respiratory disease. The 6MWT has been used for measuring the efficacy of inhaled
corticosteroids in the treatment of COPD.32 It has also been used as a measure of
functional status for COPD subjects33 and the 6 minute walk distance (6MWD) has been
demonstrated to correlate significantly with mortality.34-36

1.3.3

St. George’s Respiratory Questionnaire

The St. George’s Respiratory Questionnaire (SGRQ)37 is a questionnaire designed to
measure impact on overall health, daily life, and perceived well-being in patients with
obstructive airways disease.

The questionnaire contains three component scores:

symptoms, activity and impact (on daily life), and a total score. Scores range from 0 to
100, with higher scores indicating more severe limitation. In asthmatics and COPD
subjects, the test-retest reproducibility has been determined to be high,38;39 and significant
correlations have been shown between the SGRQ symptom score with frequency of
wheeze, the SGRQ activity score with the 6MWD and between the SGRQ impact score
with anxiety.38

1.3.4

Other Pulmonary Function Tests

The Global initiative for chronic Obstructive Lung Disease (GOLD)40 recommends the
use of the Modified British Medical Research Council (mMRC)41 questionnaire or the
COPD Assessment Test (CAT) for the assessment of COPD symptoms. The mMRC
questionnaire is grading system that is used to assess a patient’s level of dyspnea that
range from Grade 0 (breathless with strenuous exercise) to Grade 4 (breathless when
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dressing or undressing).

The mMRC score correlates with standard lung function

measurements,42 the 6MWD43 and, importantly, predicts mortality better than evaluating
disease severity using the FEV1.44
The CAT is an 8-item questionnaire that assesses the impact of cough, sputum, dyspnea
and chest tightness on health status. The CAT scores range from 0 to 40 with the higher
scores indicating a more severe impact of COPD symptoms on health status.45 CAT
scores have been shown to correlate significantly with SGRQ scores in COPD.45;46
Another test that has been recently developed uses four factors that were determined to
have the strongest association with one-year morality, called the BODE index: the body
mass index (B), the degree of airflow obstruction (O) measured using FEV1 as a
percentage of the predicted value, dyspnea (D) measured from the score on the mMRC
dyspnea scale, and exercise capacity (E) measured using the 6MWD.47 The BODE index
after lung volume reduction surgery correlates with survival in COPD patients48 and has
been shown to better predict hospitalization for COPD than FEV1 alone.49

1.4
1.4.1

Lung Function Decline
The Aging Lung

As we age, the most important physiological changes that occur in the lung are, 1)
decreased elastic recoil, 2) decreased compliance of the chest wall, and, 3) decreased
strength of the respiratory muscles.50 The decline in elastic recoil of the lung with age is
attributed to changes in the lung connective tissue,51 and the decrease in chest wall
compliance is thought to occur due to structural changes within the rib cage, such as
decalcification of the ribs, calcification of costal cartilage, changes in rib-vertebral
articulations, changes in the shape of the chest, narrowing in intervertebral disk spaces
and age-related osteoporosis, which all result in stiffening of the chest.50;51 Finally,
respiratory muscle strength is known to decrease with age. Respiratory muscle strength
has been shown to be related to nutritional status, which is often poor in the elderly. An
age-related decrease in respiratory muscle strength is also related to a decrease in muscle
mass and a decrease in the number of muscle fibres.50;52
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Another important structural change that occurs during aging is the structural changes
within lung parenchyma – known as “senile emphysema.” Studies have demonstrated
that homogeneous airspace size enlargement occurs over 60 years of age in the normal
lungs, without a loss of alveolar attachments and chronic inflammation.53 It has also been
demonstrated that there is thickening of alveolar walls and a reduction in the number of
peripheral airways.53 A consequence of the reduction in supporting tissues around the
airways is a tendency for the small airways to collapse at higher lung volumes.50
The lung physiological changes that occur during aging result in changes in lung
function. Figure 1-9 shows the changes in lung volumes that occur during aging. Early
studies have shown that during normal aging, the RV increases while the TLC remains
constant.54 The increase in RV that occurs with age is likely due to the decreased
strength of the expiratory muscles and the tendency of the small airways to collapse.50
There is also an increase in anatomic dead space that occurs during aging22 and this is
thought to be due to calcification of the bronchial cartilage. The DLCO is also been
shown to decrease with age and this is likely a result of the decreased alveolar surface
area as well as a decrease in the pulmonary capillary blood volume.55
In the landmark study by Fletcher and Peto in 1977,56 airflow obstruction measured using
FEV1 was evaluated for 103 men who were non-smokers aged 30-59. As shown in
Figure 1-10, FEV1 was shown to decline continuously with age. However, this study
was only performed in men and was cross-sectional. Subsequent studies evaluating FEV1
decline with age showed the rate of decline was greater in men than women,57 and the
rate of decline was found to be much higher in longitudinal studies.58
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Figure 1-9 Lung volume changes that occur with age
TCV = Thoracic Cavity Volume, VC = Vital Capacity, RV = Residual Volume.
Adapted from Norris et. al. (1956).54

1.4.2

COPD: Accelerated Lung Aging

As described in the previous section on risk factors for COPD, smoking cigarettes,
although not the only risk factor, is the main source of inhaled noxic particles that leads
to the development of COPD.40;59 However, not all smokers develop airflow limitation;
early studies demonstrated that cigarette smoking is associated with inflammation in both
the large and small airways60;61 and the lung parenchyma62 in smokers with normal FEV1.
Although it is unclear why some smokers develop COPD while others do not, it is known
that the inflammatory response in COPD is amplified63 and persists long after smoking
cessation.64

Irreversible airflow limitation is the defining feature of COPD and is

associated with “lesions that obstruct the small conducting airways, produce
emphysematous destruction of the lung’s elastic recoil force, or both.”65 Importantly, the
disease that occurs within the airways and the lung parenchyma are independent disease
processes that may develop in tandem or in isolation. In this section I will first introduce
how COPD is diagnosed using spirometry and the natural history of COPD. Finally, I
will discuss the underlying disease mechanisms that are thought to be responsible for the
functional lung changes.

1.4.2.1

Diagnosis and Classification of COPD

When COPD is suspected based on symptoms, such as dyspnea, chronic cough or sputum
production, and/or a history of exposure to risk factors,59 airflow limitation is measured
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using spirometry and the presence of a post-bronchodilator FEV1/FVC <0.70 confirms
the diagnosis of COPD.1;59

As shown in Table 1-1, COPD severity is determined

according to the GOLD criteria, which uses specific spirometric cut-points that are
obtained after inhalation of a short-acting bronchodilator in order to minimize
variability.59
Table 1-1 Classification of Severity of Airflow Limitation in COPD
GOLD Stage

Severity

Post-Bronchodilator FEV1 Criteria

GOLD Stage I

Mild

FEV1 ≥ 80% predicted

GOLD Stage II

Moderate

50% ≤ FEV1 < 80% predicted

GOLD Stage III

Severe

30% ≤ FEV1 < 50% predicted

GOLD Stage IV

Very Severe

FEV1 < 30% predicted

Adapted from the Global strategy for the diagnosis, management, and prevention of
chronic obstructive pulmonary disease (Revised 2011), Global Initiative for Chronic
Lung Disease1
Although this approach has been introduced due to its diagnostic simplicity and ease of
use in the primary care setting, the FEV1/FVC cut off has been acknowledged to
potentially result in an over-diagnosis of COPD in the elderly,66 as well as underdiagnosis of mild or early stage COPD.67 Moreover, there is only a weak correlation
between GOLD spirometric severity classification and symptom scores reflecting healthrelated quality of life.

1.4.2.2

Natural History of Airflow Obstruction in COPD

Figure 1-10 reproduces the landmark study by Fletcher and Peto56 that shows the
different rates of lung function decline, as measured by FEV1, for healthy individuals that
have never smoked in comparison with those individuals who were current cigarette
smokers that exhibit the amplified inflammatory response that is associated with the
development of COPD. This study indicates that while the rate of decline of FEV1 in
healthy non-smokers is 42±6 ml/year, this rate is accelerated to 47±3 ml/year in light
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smokers and to 66±4 ml/year in heavy smokers. Interestingly, this study also showed that
the rate of FEV1 decline was slower in individuals that had quit smoking (32±4 ml/year),
suggesting that decline in lung function can be slowed by smoking cessation. However,
as described previously, this was a cross-sectional study in men.
The more recent longitudinal Lung Health Study68;69 also evaluated smokers that were
randomized into three groups: a group of smokers who received no intervention, a group
of smokers who received smoking cessation intervention, and a group of smokers who
received smoking cessation intervention and bronchodilator therapy, and followed the
subjects over 11 years. In accordance with the findings by Fletcher and colleagues,56 this
study found that men who quit smoking at the beginning of the study had a FEV1 decline
of 30 ml/year while men who continued to smoke had an accelerated declined of 66
ml/year. In contrast to the study performed by Fletcher and colleagues,56 the Lung
Healthy Study also evaluated women and showed that women who quit smoking at the
beginning of the study had a FEV1 decline of 22 ml/year while women who continued to
smoke declined by 54 ml/year.69 Interestingly, when decline in FEV1 was expressed as a
percentage of the predicted normal value, there were no significant differences between
the sexes.69
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Figure 1-10 Lung Function Decline
Lung function declines in never-smokers during aging and declines at an accelerated rate
in current smokers. However, lung function declines return to normal rates following
smoking cessation. Adapted from Fletcher et. al. (1977).56

1.4.2.3

Chronic Bronchitis

Chronic bronchitis is defined as “the presence of cough and sputum production for at
least 3 months in each of two consecutive years.”1 Early work investigating chronic
bronchitis attributed the mucous hypersecretion with thickening of the bronchial gland.7072

Reid70 reported that this thickness was related to gland hypertrophy and that there was

a correlation between the amount of sputum produced and gland thickness. It was later
shown that chronic bronchitis was associated with bronchial inflammation.60 Mullen and
colleagues60 demonstrated that smokers with chronic bronchitis had greater inflammation
of the cartilaginous airways (> 4 mm in internal diameter) than smokers without chronic
bronchitis, and that there was a significant correlation between inflammation of the
cartilaginous airways and mucous gland thickness. These data suggest that chronic
cough and sputum production was associated with an inflammatory response due to the
cigarette smoke in the cartilaginous (or central) airways. Interestingly, it has also been
demonstrated that this inflammatory response persists in the central airways of smokers
who had quit but continued to report mucus hypersecretion.64
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Much of this early work was performed in smokers with and without airflow limitation
measured using FEV1 and therefore more recent studies have focused on evaluating
whether there is a predictive relationship between the presence of chronic cough and
sputum production and the future occurrence of COPD. de Marco and colleagues73
recently evaluated a group of young subjects, aged 20-45, with normal lung function over
a period of approximately 9 years. It was shown that at the baseline visit, 9% of subjects
reported chronic cough and sputum production and of these subjects that reported
persistent symptoms at follow-up, there was a threefold increased risk of developing
COPD.73 Another study demonstrated that chronic cough and sputum production was
associated with an increased decline in FEV1 and subsequent hospitalization due to
COPD.74

1.4.2.4

Small Airways Disease

Based on the study by Weibel and Gomez20 it is known that as the airway generation
increases, due to the dichotomous branching pattern of the airways, the number of
airways rapidly increases and therefore the total cross-sectional area increases, as shown
in Figure 1-5.

Although the smaller airways could be considered the major site of

resistance in normal lungs based on Poiseuille’s equation that indicates that resistance in
a single tube is inversely proportional to the radius of the tube to the 4th power, by
inspection of the airways and according to Weibel’s data20 we must also consider the
number of airways and their total cross-sectional area.

Although the radius of the

airways decrease as airway generation increases, the number and cross-sectional area of
the airways increases.17 Since these airways are arranged in parallel, the resistances are
added as reciprocals and therefore the overall resistance is very small in the small
airways.
Early studies by Hogg and Macklem75 that directly measured small airway pressure using
a retrograde catheter confirmed that in healthy subjects, the small airways contributed
very little to the total airway resistance.

However, they also demonstrated that in

subjects with mild and severe emphysema, as well as subjects with bronchiectasis and
bronchiolitis that there was a marked increase in the resistance of the small airways (<2
mm in diameter), while there was little or no change in total lung resistance. The authors
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observed that the bronchioles were often narrowed and occluded with mucus plugging
and defined these changes in the small airways as “small airways disease,” where disease
changes may occur without being detected by measuring total airway resistance or by
FEV1. Taken together, since the total resistance is determined largely by the more central
airways, disease may accumulate in the small airways without being detected.
It was later shown in histopathological studies that inflammation was present in the
peripheral airways of smokers76 and that the most characteristic lesion in the small
airways of smokers was respiratory bronchiolitis.61 However, these early reports did not
perform spirometry in the smokers and therefore the subjects may or may not have had
COPD. A more recent study by Hogg and colleagues77 evaluated the pathology of the
small airways in relation to COPD severity, as measured by the GOLD COPD stages
(Table 1).1 These authors found that although the degree to which the lumen was filled
with mucous was significantly correlated with the severity of COPD, the strongest
parameter associated with progression of COPD from GOLD stage 0 to GOLD stage IV
was with thickening of the airway wall.77

It was also shown that the extent of

inflammation was significantly correlated with COPD severity.77 Figure 1-11A shows a
normal small airway of a non-smoker in comparison with a small airway filled with
mucus (Figure 1-11B), a small airway with thickened airway walls and a lumen partially
filled with mucus (Figure 1-11C) and a small airway with wall thickening that is thought
to restrict airway caliber with lung inflation (Figure 1-11D).

1.4.2.5

Emphysema

Emphysema was first described by Laennec in 1834. He described emphysema of the
lungs as “dilation of the air cells” that “may affect both lungs at the same time, one only,
or a part of one or of both.”78 More recently, the National Heart, Lung, and Blood
Institute defined emphysema as “a condition of the lung characterized by abnormal,
permanent enlargement of airspaces distal to the terminal bronchiole, accompanied by the
destruction of their walls, and without obvious fibrosis.”79 It is well known that smokers
develop two distinct forms of emphysema: centrilobular and panlobular emphysema.80-82
Centrilobular emphysema results from dilation and destruction of the respiratory
bronchioles, as shown in Figure 1-11E, and has been demonstrated to have a more
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uneven pattern of tissue destruction, predominantly occurring in the upper lung lobes.
Conversely, panlobular emphysema has a more homogenous pattern and is more likely to
be associated with genetic disorders such as alpha-1 antitrypsin deficiency (Figure 111F).81;82

Moreover, early studies indicated that there was a relationship between

cigarette smoking and centrilobular emphysema, but not with panlobular emphysema.83
Studies in smokers and non-smokers demonstrated that inflammatory cells play a role in
the parenchyma tissue destruction in smokers,62 and that this cigarette smoke-induced
inflammation is amplified in subjects with emphysema versus smokers without
emphysema.63
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Figure 1-11 Small Airways Disease and Emphysema in COPD
A. Normal small airway. B. Small airway containing plug of mucus. C. Acutely
inflamed airway with thickened wall in which the lumen is partly filled with an
inflammatory exudate of mucus and cells. D. Airway surrounded by connective tissue,
which appears as if it might restrict normal enlargement of the lumen and unfolding of
the epithelial lining that occurs with lung inflation. E. Early lesions of centrilobular
emphysema (CLE) that have destroyed central portions of several acini of a single
secondary lobule. D. More even destruction of the lobule in panacinar emphysema.
Reproduced with permission from Hogg (2004).65
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1.5
1.5.1

Imaging Lung Structure and Function in COPD
Chest X-ray

Chest x-ray and x-ray computed tomography (CT) are the two most common lung
imaging procedures performed.

Chest x-ray is often the first line imaging method

because it is widely available, inexpensive, allows visualization of pulmonary structures,
including the trachea, carina and major bronchi, mediastinum and hilar regions and the
diaphragm, as shown in Figure 1-12, and has a relatively low radiation dose.84 In the
posterior-anterior view, as shown in Figure 1-12A, the patient is upright with the x-ray
source positioned so that the x-rays enter through the back (posterior lung) and the
anterior surface of the chest is against the film holder. The patient’s hands are place on
their hips with the elbows rolled slightly forward so that the scapulae (or shoulder blades)
are removed from the lung field.85 In the lateral view, as shown in Figure 1-12B, the
patient is positioned with their side against the film with their arms over their head so that
the arms are not in the lung field.85 The different lung structures described above can be
depicted with a chest x-ray because the x-rays are attenuated differently by the various
body tissues. For example, the ribs show up as bright structures because they attenuate
the x-rays more than the lung tissue, which are air-filled, and show up as dark regions in
the image. This is also the reason why the arms and the scapulae are removed from the
lung field.
The radiation dose associated with a typical chest x-ray is approximately 0.01
millisieverts (mSv) which is equivalent to approximately 3 days of background
radiation.85;86 Although there is very low radiation dose associated with chest x-ray, and
identification of lung structures allows abnormalities in the lungs to be detected, such as
increased translucency and flattening of the diaphragm which is commonly associated
with gas trapping in respiratory diseases, the limitation of chest x-ray is that all anatomic
structures are superimposed onto each other. This results in difficulty diagnosing COPD
and in particular for the early disease stages where disease-related structural changes may
be subtle. While there is some conflicting views on the utility of chest radiography in
assessing COPD,87;88 and more specifically for the assessment of emphysema, a study
comparing chest x-ray with a morphologic diagnosis of emphysema post-mortem
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indicated that a diagnosis of emphysema using chest x-ray was made in only 16% of
subjects that were pathologically proven to have mild to moderate emphysema and in
only 42% of subjects with moderately severe to severe emphysema.88

Figure 1-12 Chest x-ray of a COPD subject
Posterior-anterior chest x-ray (A) and lateral chest x-ray (B) for a 62-year-old male
smoker. Reproduced with permission from Parraga et. al (2007).89

1.5.2

X-ray Computed Tomography

Since its introduction in the early 1970s, CT scanning technology has become so
advanced that it is now considered by many as the imaging technology of choice for
many diseases. As described above, a limitation of conventional x-ray imaging is that it
provides a two-dimensional image of a three-dimensional object. CT overcomes this
limitation by acquiring the image in slices thereby providing images of three-dimensional
objects. Each slice in a CT image is composed of voxels and each voxel is assigned a CT
value or Housfield unit (HU) based on the attenuation coefficient relative to water.
Therefore, a voxel that contains water will have a value of 0 HU, while air will have a
value of -1000 HU and tissues or structures that have a higher attenuation coefficient than
water will have a positive HU value; bone has CT values up to 2000 HU.85
Emphysema is characterized by airspace enlargement,79 and therefore the air-filled
emphysematous regions in the lung will appear dark in CT images. Figure 1-13A shows
a central slice CT image for a healthy subject and a COPD subject with emphysema. The
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air filled regions, including the trachea as well as the large left apical bullae in the COPD
subject with emphysema appear dark in the image. Early pathological correlative studies
demonstrated that regions of the lung that visually appeared to be emphysematous on CT
images were confirmed as emphysematous in post-mortem evaluations.90 Later, studies
that used radiologist CT grading and pathological grading systems demonstrated that
there were strong and statistically significant correlations between CT and pathology
emphysema scores,91-93 however it was found that CT could not differentiate mild
emphysema from normal parenchyma confirmed by pathology in some patients.92
Although CT was demonstrated to be very accurate in the determination of the presence
and extent of moderate to severe emphysema, with strong and significant correlations
found with both pathology91-93 and measurements of airflow limitation and diffusion
capacity,93 these early visual scoring systems were subjective and therefore there was
considerable inter-observer and intra-observer variability.93 Because visual assessment
was based on the presence of voxels with abnormally low attenuation, the extent of
emphysema could be assessed by highlighting voxels within specified ranges of HU
called “density masks.”94 Density mask emphysema scores were demonstrated to be
comparable to visual emphysema scores and had strong and significant correlations with
pathologic scores,94 and importantly, eliminated the inter-observer and intra-observer
variability introduced by visual assessment. Figure 1-13B shows the CT density mask
with all voxels with attenuation values less than -950 HU highlighted in red. Although
there are several thresholds that have been introduced, and some contrasting results on
which threshold is most appropriate,94-96 it has been demonstrated that the low attenuating
areas quantified on CT are indicative of the lung tissue destruction that accompanies
emphysema.
Although strong and significant correlations between CT measurements of emphysema
and diffusion capacity measurements have been reported, there have been only moderated
correlations with measurements of airflow.93;95 This finding is not surprising given that
measurements of airflow limitation (FEV1) are measuring the contributions of the loss of
elastic recoil due emphysematous tissue destruction (emphysema) as well as airway
narrowing and obstruction (chronic bronchitis and small airways disease). Therefore, it is
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also of great interest to obtain measurements of the airway dimensions from CT. Figure
1-14 shows an airway tree segmentation that was generated in three-dimensions from the
CT image. The cross-section of the airway of interest can then be identified and the
airway dimensions can be measured.

Nakano and colleagues were the first to

demonstrate that the percentage of the total airway (airway wall area plus lumen area)
that was airway wall (wall area percent, WA%) significantly correlated with airflow
limitation, but not DLCO, in COPD smokers independent of emphysema.97 However,
these measurements were based on a large central airway and it is well known, as
described above, that the major site of airflow limitation in COPD occurs in the small
airways less than 2 mm in diameter.75

Accordingly, more recent studies have

demonstrated that the correlation between CT wall area dimensions with airflow
limitation was stronger for higher generation airways.98

Figure 1-13 Coronal CT of a healthy smoker and a COPD ex-smoker
The central slice coronal CT image (A) with the corresponding density mask with all voxels
with attenuation values less than -950 HU highlighted in red (B) for a healthy subject and a
COPD subject with emphysema.

27

Figure 1-14 CT airway analysis of a COPD subject
The airway tree segmentation in three-dimensions is obtained from the original CT
image, with the surrounding lung parenchyma removed from view, to identify the
airway of interest for measurement of the airway dimensions, as shown in red. The
airway tree and airway measurements were performed using the Pulmonary Workstation
2.0 (VIDA Diagnostics, Inc., Coralville, IA).
Although thoracic CT is capable of measuring both emphysema and airways disease in
COPD, CT is not without its costs and the field of medicine has observed a considerable
increase in the number and type of CT scans performed for clinical investigation where
now, in the United States, CT accounts for 24% of all radiation exposure and 50% of all
medical radiation exposure.99 Importantly, the increase in CT scans was also observed in
the paediatric population and a study by Mettler and colleagues100 reported that children
aged 0-15 years old accounted for 11.2% of all CT scans performed. This is a concern
because the effective dose for a thoracic CT is approximately 8 mSV, which is equivalent
to 400 chest x-rays or approximately 4 years of background radiation.85 In COPD, serial
imaging is important for evaluating disease progression and response to treatment or
intervention, and therefore the increase in radiation exposure from CT has been a major
concern because there is an increased risk of radiation-induced cancer from the
cumulative dose related to repeated CT investigations.101
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1.5.3

Nuclear Medicine

In their seminal study on the site and nature of airway obstruction in COPD, Hogg and
colleagues stated that as a result of the obstruction of the small airways in the lung, there
is a “strong likelihood that, at some stage, chronic obstructive airway disease causes
significant abnormalities in the distribution of ventilation, and presumably in gas
exchange.”75 Therefore, in COPD ventilation may be highly inhomogeneous across the
lung or absent in certain lung regions all together. Ventilation scintigraphy can be
performed with radioaerosols or radioactive gases for visualization of the regional
distribution of ventilation in the lung.102 Images can be acquired during the gas wash-in
phase, at the “steady state” and during the gas wash-out phase.103 The breathing protocol
utilized depends largely on the half-life of the isotope. For example, the short half-life of
Krypton-81m of 13 seconds limits its use for evaluating the gas in the wash-in or steady
state phase as decay occurs prior to exhalation.103

Studies have demonstrated that

subjects with abnormal pulmonary function tests also have abnormal aerosol deposition
patterns,104 and smokers with reported symptoms and normal pulmonary function
measurements often had abnormalities with xenon-133 or aerosol lung imaging,105;106
suggesting that functional lung imaging may be more sensitive than spirometry for
detecting early disease changes. However, central aerosol deposition is often reported
and may be caused by the large particle size or by abnormally rapid or shallow breathing
patterns, or both.105 Taplin and colleagues105 showed that 10% of subjects having central
deposition at one imaging time-point showed normal distribution 1-2 hours later.
The lung attempts to match blood flow to ventilation to maintain optimal efficiency of
gas exchange, and therefore subjects with ventilation abnormalities may have perfusion
abnormalities as well. Perfusion scintigraphy is often performed using technetium-99m
(99mTc) labeled macro-aggregated albumin (MAA) injected in a peripheral vein.103
Studies have shown that there is a significant correlation between perfusion and aerosol
lung imaging106 suggesting that regional perfusion abnormalities are likely related to
diminished ventilation within those areas.
While lung scintigraphy acquires two-dimensional projection images, single photon
emission tomography (SPECT) allows three-dimensional assessment of ventilation and
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perfusion. Studies have recently shown that ventilation/perfusion SPECT with

99m

Tc-

labled carbon (Technegas) is the aerosol of choice for COPD lung imaging, providing
more homogeneous distribution within the lungs with less focal deposition in both larger
and smaller airways.107

It was also recently demonstrated that the extent of

ventilation/perfusion abnormalities in COPD subjects was significantly correlated with
both spirometric measurements of lung function and with the extent of emphysema
measured

using

CT,

but

not

with

COPD-related

symptoms.108

Although

ventilation/perfusion SPECT has been demonstrated to regionally evaluate abnormalities
in COPD, it is limited by its low spatial resolution, long image acquisition times and the
necessity for inhalation of a radioactive substance.

1.6

Magnetic Resonance Imaging

In contrast to other diagnostic imaging methods, magnetic resonance imaging (MRI) does
not require the use of x-rays or other ionizing radiation, offering the potential for
intensive serial and longitudinal studies in the same patient. MRI is also becoming an
important imaging tool because MRI can provide both structural and functional lung
information.

1.6.1

Conventional Proton MRI

MRI is an imaging tool that provides unique tissue contrast with high spatial and
temporal resolution. However, despite these very practical advantages, MRI of the lung
has some unique technical challenges. Figure 1-15 illustrates the lower visibly obvious
information content provided by conventional proton (1H) MRI as compared to chest CT
for evaluating COPD. Using conventional 1H MRI alone, without special attention to
echo time, the thoracic cavity appears as a black hole because in the normal lung, tissue
density (and consequently 1H density) is relatively low in comparison to gas density.
Second, the 1H MRI lung tissue signal is degraded due to the air-tissue interfaces that
introduce microscopic magnetic field inhomogeneities.109 Third, the signal is further
degraded by respiratory and cardiac motion because of the relatively slow image
acquisition time relative to CT. Therefore, the application of conventional 1H MRI for

30

the detection of structural abnormalities in the lung has not progressed beyond the
research setting, even though there is great potential for its use.110

Figure 1-15 Comparison of CT and Conventional MRI in a COPD subject
Yellow arrows point to a large left upper lobe bullae that is not as visually obvious with
MRI as CT.
To overcome these shortcomings, numerous studies have endeavoured to develop more
sensitive 1H MRI techniques for lung imaging, including ultra-short echo time (UTE)
methods,111-113 oxygen-enhanced MRI114-124 and Fourier decomposition methods.125-129
Although experience is limited in COPD, MRI of cystic fibrosis has been shown to be
comparable to CT for identifying morphological changes, such as bronchiectasis,
bronchial wall thickening, mucus plugging, air fluid level, consolidation and
segmental/lobar destruction.130 Although it is clear that MRI lacks the spatial resolution
achieved by CT to identify the more subtle morphological changes that are likely to occur
in mild disease,130 the advantage of MRI is that assessment of lung function is also
possible. Oxygen-enhanced MRI allows regional visualization of oxygen diffusion from
the alveoli into the capillaries,114 and initial studies in COPD demonstrated measurements
of oxygen enhancement can differentiate between healthy volunteers and subjects with
pulmonary emphysema,120 and showed strong and significant correlations with
FEV1120;122 and DLCO in subjects with emphysema.119;120;122 Fourier decomposition MRI
allows lung perfusion and ventilation to be assessed, with no contrast enhancement, and
preliminary studies demonstrated that Fourier decomposition MRI is feasible and
reproducible in respiratory disease.

125-129

These previous studies suggest that oxygen-
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enhanced MRI and Fourier decomposition MRI have the potential to provide
reproducible structural and functional measurements in COPD.
1.1. Hyperpolarized Noble Gas MRI
Over the last two decades, MRI using inhaled hyperpolarized noble gases helium-3
(3He)131-144 and xenon-129 (129Xe)145;146 have been shown to provide structural and
functional measurements in healthy volunteers as well as subjects with a range of
respiratory conditions. These approaches are based on the serendipitous finding of Albert
and colleagues145 in 1994 that showed the potential of inhaled hyperpolarized or
magnetized noble gas for pulmonary MRI. Albert and colleagues145 recognized that
polarization of 3He and

129

Xe gases could be enormously enhanced through spin-

exchange with an optically pumped alkali metal vapour – rubidium.147
demonstrated that gas-phase collisions between

129

Albert

Xe and the polarized rubidium atoms

resulted in the transfer of angular momentum from the rubidium valence electron to the
129

Xe nucleus and thereby increased the signal by ~100 000 times.145 Although the first

investigations utilized the isotope 129Xe,145;146 the field quickly transitioned to 3He due to
the nearly 3-fold higher gyromagnetic ratio (3He: 32.4 MHz/T,

129

Xe: 11.8 MHz/T) and

higher enrichment – both of which contribute to a greater MRI signal with 3He than
129

Xe. Importantly, excellent subject safety and tolerability across a wide spectrum of

volunteers has been reported with both 3He148and 129Xe MRI.142;149
1.1.1. Biomarkers
Hyperpolarized gas MR imaging allows the quantification of several structural/functional
components of the lung, commonly referred to as “biomarkers”. The most established
measurements are the ventilation defect percent150;151 and the apparent diffusion
coefficient (ADC).152-154

Figure 1-16 shows the static ventilation images and the

corresponding ADC maps for a representative subject with normal lung function in
contrast with three representative COPD subjects with varying lung function.
1.1.1.1.

Ventilation Defect Measurements
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Early in vivo studies in humans obtained these “spin density” or “static ventilation”
images in healthy subjects and demonstrated homogenous signal intensity within the
lung, with clear delineation of the diaphragm, heart, chest wall and blood vessels, which
appeared as signal voids in the images.155-157 The 1st 3He MRI investigation in COPD
was performed by Kauczor and colleagues131 and they demonstrated heterogeneous signal
intensity and ventilation abnormalities or “defects,” which were thought to represent local
hypoventilation or non-ventilated regions of the lung.

Subsequent studies also

demonstrated extensive ventilation defects in subjects with severe emphysema that
corresponded to defects seen on xenon-133 ventilation (wash-in) scintigraphy.132 A
larger study evaluating hyperpolarized 3He MRI with xenon-133 scintigraphy also found
fairly good concordance between the two modalities for depiction ventilation
abnormalities in 15 subjects.158
Although the first

3

He MRI ventilation analyses were based on a radiologist’s

interpretation of the ventilated lung regions,132;158-160 more recent investigations have
utilized scoring and manual volumetric analysis approaches.89;150;151;158;160-170 Using these
quantitative approaches it was demonstrated that ventilation defect measurements were
highly reproducible in COPD for same day evaluations as well as for the images acquired
one week later.89 Importantly, 3He ventilation defect measurements in COPD were also
shown to correlate significantly with spirometric measurements of airflow limitation.151
1.1.2. Apparent Diffusion Coefficient
Another type of hyperpolarized gas MR image that is commonly acquired uses diffusionweighted MRI. Hyperpolarized gas diffusion-weighted MRI is sensitive to the selfdiffusion of the gas atoms within the lung microstructure. During the diffusion time
interval, the hyperpolarized gas atoms diffuse by Brownian motion and the walls of the
alveolar structures act as barriers by restricting the gas atoms motion or displacement.
Therefore, an “apparent” diffusion coefficient (ADC) can be derived that reflects the
level of restriction of the gas atoms within the airways and airspaces of the lung. It is
important to note that in contrast to 3He, 129Xe gas is capable of transmembrane diffusion
across the alveolar wall, providing both measurements of alveolar size and
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transmembrane diffusion kinetics;134-146 in contrast 3He gas is biologically inert and
therefore it cannot be passively transported across intact biological tissues and
membranes.
Importantly, both 3He and

129

Xe ADC measurements have been demonstrated to

significantly correlate with age,140;171 with standard measurements of pulmonary
function140;152;172;173 and with CT emphysema measurements.169;172-174 The 3He ADC has
been more extensively evaluated and was shown to be highly reproducible89;163;175;176 and
significant correlations with histology measurements of airspace size have been
demonstrated.177 Abnormally elevated 3He ADC has also been reported in asymptomatic
smokers without COPD,174;178 suggesting that 3He ADC provides a way to sensitively
measure regional lung tissue destruction in early disease.
Another advantage of hyperpolarized gas MR diffusion-weighted imaging is that by
changing the diffusion time and gradient strength, different features of the lung microstructure may be evaluated. For example, short-range diffusion experiments are most
sensitive to changes in local microstructure (e.g. alveolar destruction), while long-range
diffusion experiments are sensitive to the connections between airways and larger lung
structures and possibly collateral ventilation in COPD.179;180

Moreover, obtaining

diffusion-weighted images at multiple b-values, measurements of the geometric
parameters at the level of the alveoli can be made.181-184
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Figure 1-16 Hyperpolarized 3He MRI Static Ventilation Image and ADC Map in a
Healthy ex-smoker and COPD ex-smokers
Healthy ex-smoker is a 70 yr old male: FEV1=101%pred, FEV1/FVC=0.75; COPD
subject 1 (S1) is a 74 yr old male: FEV1=86%pred, FEV1/FVC=0.54; COPD S2 is a
72 yr old female: FEV1=64%pred, FEV1/FVC=0.65; COPD S3 is a 60 yr old female:
FEV1=50%pred, FEV1/FVC=0.38.
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1.7

Thesis Hypotheses and Objectives

Hyperpolarized 3He MRI provides high spatial and temporal resolution images of the
lung air spaces in subjects with COPD. These images allow us to directly visualize the
lung regions accessed by the hyperpolarized gas during a breath-hold, as well as the
regions of the lung not accessed which appear as signal voids and are referred to as
“ventilation defects.” The lung micro-structure can also be probed using diffusionweighted imaging which takes advantage of the rapid 3He and

129

Xe atom Brownian

motion to generate surrogate measurements of alveolar size. Since the establishment of
inhaled gas MRI for pulmonary imaging in 1994, there have been significant
advancements in the type and scope of images that can be acquired, however, in order for
broader translation of this imaging technology to occur, and for the potential translation
of hyperpolarized gas MRI for clinical use, it must be demonstrated that these
measurements relate to clinically meaningful outcomes. The overarching objective of
this thesis was to generate hyperpolarized gas MRI measurements and measurement tools
for the regional quantitative evaluation of hyperpolarized gas MRI with sufficient
precision to evaluate COPD disease progression and treatment response.

Another

important step in the broader translation of this imaging technology is transitioning to
129

Xe MRI, and comparison of hyperpolarized

129

Xe with 3He MRI is important in order

to realize the potential of 129Xe MRI for respiratory research. The specific objectives and
hypotheses tested in each chapter of this thesis are described below.
To better understand the potential for hyperpolarized 3He MRI to provide quantitative
longitudinal COPD endpoints, the objective of Chapter 2 was to quantitatively evaluate a
small group of COPD ex-smokers and healthy volunteers over 2 years using
hyperpolarized 3He MRI. As described above, much of our current understanding of the
natural history of COPD arises from the landmark study of Fletcher and colleagues56 who
showed that lung function measured using FEV1 declines as we age, and that this decline
is accelerated in smokers with COPD; in ex-smokers, however, they showed that this
decline in FEV1 returned to normal rates.

Therefore, based on the Fletcher curve

prediction, we hypothesized that the longitudinal changes in 3He MRI measurements in
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the COPD ex-smokers would be similar to those observed in elderly healthy neversmokers.
This previous work evaluating longitudinal changes in 3He MRI measurements was
performed using manual segmentation approaches, which clearly increases segmentation
time and, importantly, introduces the potential for inter- and intra-observer variability.
For serial evaluation of 3He MRI it is critical that the change measured over time
represents physiological change that has occurred and is not due to measurement error.
Therefore, the objective of Chapter 3 was to generate a semi-automated segmentation
method for 3He MRI to enable its use in longitudinal and serial studies, and to compare
the reproducibility and spatial agreement of the developed semi-automated segmentation
algorithm to manual segmentation. We hypothesized that semi-automated measurements
would not be statistically significantly different from manual measurements and have
significantly reduced inter- and intra-observer variability.
Using the segmentation algorithm developed in Chapter 3, the objective of Chapter 4 was
to evaluate a group of COPD subjects using 3He MRI prior to and immediately following
bronchodilator therapy. A significant bronchodilator response is currently defined as an
increase in post-bronchodilator spirometry, however, based on the findings in Chapter 2
we hypothesized that 3He MRI would provide the necessary sensitivity as well as
precision to detect any potential regional functional lung changes after bronchodilator
therapy in COPD subjects regardless of spirometry based responder classification.
In the same group of COPD ex-smokers evaluated using 3He MRI pre- and postbronchodilator therapy in Chapter 4, the objective of Chapter 5 was to further evaluate
the regional effects of bronchodilator administration in COPD using 3He MRI ADC
measurements. Regional evaluation of tissue micro-structure using 3He MRI ADC would
provide important insight into the lung alterations that accompany the improvements in
regional 3He gas distribution after bronchodilator administration that were previously
observed. In order to do this we first developed image registration/segmentation methods
for quantifying ADC in the lung regions newly ventilated post-bronchodilator.

We

hypothesized that the regions of the lung that were newly ventilated following

37

bronchodilator therapy were not more emphysematous than the remaining lung tissue,
and that the 3He ADC could measure significant reductions in regional gas trapping
following bronchodilator therapy.
Despite the unique potential of 3He MRI and the previous work demonstrating its
potential for use in evaluating COPD outcomes, the broader adoption of hyperpolarized
gas MRI requires a transition from 3He gas, which has limited and unpredictable global
quantities and high cost, to

129

Xe gas, which is substantially more abundant in nature

existing in measurable quantities in the atmosphere. The objective of Chapter 6 was to
quantitatively compare hyperpolarized 3He and 129Xe MRI acquired within a few minutes
in healthy volunteers and subjects with COPD, and to evaluate the correlations between
3

He and

129

Xe MRI measurements with standard measurements of pulmonary function.

We hypothesized that the different properties of
differences in

129

129

Xe gas would result in significant

Xe compared to 3He gas distribution measurements in COPD but not in

healthy volunteers.
To better understand the morphological determinants for the ventilation differences
observed between hyperpolarized 3He and

129

Xe MRI in COPD in Chapter 6, the

objective of Chapter 7 was to evaluate the same group of COPD subjects using the image
registration/segmentation methods for quantifying ADC on a regional basis developed in
Chapter 5. We hypothesized that emphysematous regions in the lung would more readily
fill with 3He as compared to 129Xe gas, leading to decreased 129Xe MRI ventilation.
While it is important to demonstrate that 3He MRI measurements relate to important
clinical outcomes, such as disease progression and treatment response, another goal of
imaging is to identify early disease changes. The objective of Chapter 8 was to evaluate
and

compare

well-established

clinical,

physiological

and

emerging

imaging

measurements in ex-smokers with normal spirometry and abnormal DLCO with a group of
ex-smokers with normal spirometry and DLCO and ex-smokers with GOLD stage I
COPD. We hypothesized that ex-smokers with normal spirometry but abnormal DLCO
would have significantly worse symptoms, exercise capacity and 3He MRI ADC than exsmokers with normal DLCO.
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The objective of Appendix A was to establish imaging measurement reproducibility in
adult cystic fibrosis subjects over a short period of time (7 ± 2 days) in the absence of
therapeutic intervention using hyperpolarized 3He MRI. We hypothesized that 3He MRI
would provide the necessary and sufficient spatial and temporal sensitivity to detect dayto-day changes in lung function.
A case report of a COPD ex-smoker that was evaluated serially over 4 years using
hyperpolarized 3He MRI, twice prior to and twice following an acute exacerbation
requiring hospitalization is provided in Appendix B. Based on our previous studies
demonstrating the high sensitivity of 3He MRI for measuring improvements in the
absence of FEV1 improvements, we hypothesized that following hospitalization and
treatment, visibly obvious improvements in 3He gas distribution would be observed prior
to improvements in FEV1.
Finally, in the last chapter of this thesis I will provide an overview and summary of the
important findings and conclusions of Chapters 2-8. I will also address the study specific
limitations as well as general limitations of the hyperpolarized gas MRI studies
presented, and provide some potential solutions. Finally, based on the findings and
limitations discussed, I will outline a roadmap for future hyperpolarized gas MRI studies.
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CHAPTER 2
To better understand the potential for hyperpolarized 3He MRI to provide quantitative
longitudinal COPD endpoints, here we quantitatively evaluated a small group of COPD
ex-smokers and healthy volunteers over 2 years using hyperpolarized 3He MRI.
The contents of this chapter have been previously published in Radiology and permission
to reproduce the article was granted by the Radiological Society of North America
(RSNA®) and is provided in Appendix C.
M Kirby, L Mathew, A Wheatley, GE Santyr, DG McCormack and G Parraga. Chronic
Obstructive Pulmonary Disease: Longitudinal Hyperpolarized 3He MR Imaging.
Radiology 2010; 256(1): 280-9.

2

Longitudinal Hyperpolarized 3He Magnetic Resonance
Imaging of COPD
2.1

Introduction

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and
mortality affecting at least 600 million people worldwide.1 It is the world’s fourth
leading cause of death, and the most common chronic, terminal respiratory disease.2 Due
to the heterogeneous nature of COPD, studies of its natural history and progression are
complex, typically requiring large study sample sizes and long durations to obtain
relevant longitudinal endpoints. Accordingly, much of our current understanding of the
natural history of COPD arises from the landmark study of Fletcher and colleagues,3 and
based on the cross-sectional spirometry measurements of the forced expiratory volume in
one second (FEV1). The current functional definition of COPD4 is also based on FEV1
and changes in FEV1 over time are still the most widely-accepted measure of COPD
progression.

However, a number of limitations of spirometry for the diagnosis,

classification and longitudinal monitoring of COPD are motivating the development of
new COPD measurements5 including those derived from non-invasive imaging.6;7 For
example, high resolution multi-detector x-ray computed tomography (CT)8-11 has been
recently used to identify phenotypes of both emphysema and airway disease12-14 and
detects statistically significant COPD changes over relatively short periods of time.15
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Hyperpolarized helium-3 (3He) magnetic resonance imaging (MRI) has recently emerged
as another research method for the evaluation of COPD.16-20 In particular, previous work
showed that the

3

He apparent diffusion coefficient (ADC)16;21-23 was a sensitive

measurement of emphysematous destruction19;23;24 and airspace size16;17;25;26, correlating
with pulmonary function (FEV1 and DLCO),27 as well as histological measurements of
lung surface area.28 Importantly, 3He MRI ADC is also age-dependent,29 and reflects
differences in patient anatomical position,30 disease severity31 and smoking history.32
Quantitative focal 3He MRI ventilation defects have also been shown in COPD,24;32-34 and
these reflect differences in subject age35 and disease status.20 To better understand the
potential for hyperpolarized 3He MRI to provide quantitative longitudinal COPD
endpoints, we designed a pilot longitudinal 3He MRI study of COPD. The objective of
this study was to quantitatively evaluate a small pilot group of COPD ex-smokers and
healthy volunteers over 2 years using hyperpolarized 3He MRI.

2.2
2.2.1

Materials and Methods
Subjects

Twenty subjects were enrolled from the general population of the local tertiary health
care center as previously described.20 All subjects provided written informed consent to
the study protocol approved by the local research ethics board and Health Canada and the
study was compliant with the Personal Information Protection and Electronic Documents
Act (PIPEDA, Canada) and the Health Insurance Portability and Accountability Act
(HIPAA, USA). COPD subjects were enrolled who were ex-smokers between the ages
of 50-70, with a clinical diagnosis of COPD and were categorized according to the
Global initiative for chronic Obstructive Lung Disease (GOLD) criteria,4 with a smoking
history of at least 10-pack-years and fewer than three COPD exacerbations within the last
12 months. Exacerbations during the follow-up period were defined as hospitalization
for COPD or the patient’s first-time need for antibiotic or prednisone therapy and these
were reported from hospital records,36 subject charts and additionally verified in a
telephone interview with the subject after follow-up imaging was completed. COPD
subjects were excluded during a screening visit if post-salbutamol FEV1 was greater than
3%. Healthy elderly volunteers were enrolled (same age range as the COPD subjects)
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who had a smoking history of <1 pack–year with no smoking in the previous 25 years,
and with no history of previous chronic or current respiratory disease. All tests and
imaging were performed at baseline and at 26 months ± 2 (standard deviations).

2.2.2

Pulmonary Function Tests

Spirometry was performed using an ndd EasyOne spirometer (ndd Medizintechnik AG,
Zurich, CH) reporting FEV1 and forced vital capacity (FVC) with a minimum of three
acceptable spirometry maneuvers with the best FEV1 and FVC selected for analysis
according to American Thoracic Society guidelines.37 Whole body plethysmography was
performed using a MedGraphics’ Elite Series stand-alone body plethysmograph
(MedGraphics Corporation. 350 Oak Grove Parkway St. Paul, MN USA) for the
measurement of total lung capacity (TLC), inspiratory capacity (IC), residual volume
(RV), and functional residual capacity (FRC).

2.2.3

Imaging

Subjects were screened for MRI and coil compatibility (inner diameter of elliptical coil =
50cm) prior to scanning, and digital pulse oximetry was used to monitor arterial blood
oxygenation levels during MR breathhold scanning. A turn-key, spin-exchange polarizer
system (HeliSpin™, GEHC, Durham, NC) was used to polarize 3He gas to 30-40%, as
previously described.38 Doses of hyperpolarized 3He gas (5 mL per kilogram of body
weight) were administered in 1 L plastic bags (Tedlar®, Jensen Inert Products, Coral
Springs, FL) diluted with ultrahigh purity, medical grade nitrogen (Spectra Gases, Alpha,
NJ). Polarization of the diluted dose was quantified by a polarimetry station (GENC,
Durham, NC) immediately prior to 3He gas administration to subject.
MRI was performed on a whole body 3.0 Tesla Excite 12.0 MRI system (GEHC,
Milwaukee, WI USA). 1H images were acquired prior to 3He MRI during breath-hold of
a 1 L 4He/N2 mixture from FRC;33 diffusion-weighted imaging and ventilation or spin
density imaging were also performed during breath-hold of a 1 L 3He/N2 mixture from
FRC.33 All scanning was completed within approximately 7-10 minutes of subjects first
lying in the scanner.
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2.2.4

Image Analysis

The signal-to-noise ratio (SNR) for all images acquired was determined by calculating
the mean pixel value within a 10 x 10 voxel region of interest (ROI) for four
representative ROI within the lung parenchyma, and dividing by the standard deviation of
the mean pixel values for noise inside a ROI of the same size at the corners of the image
where there was no lung structure. SNR was determined for each slice and then averaged
to obtain a single SNR value for each subject and time-point. Images were analyzed in a
controlled image visualization environment with room lighting levels equivalently
established for all image analysis sessions.
ADC maps were processed using in-house software programmed in the IDL Virtual
Machine platform (Research Systems Inc., Denver, CO) as previously described33 with b
= 1.6 s/cm2. Spin density images were examined for analysis of ventilation defects in all
coronal slices by two expert observers (MK and LM) blinded to subject identity, disease
status, and time point, as well as the other observer’s measurements. As previously
described,39 a ventilation defect was identified by each observer independently as any
lung region of diminished signal intensity but not those areas of signal loss associated
with the pulmonary vascular structures, heart, hilum and mediastinum. Images were
reviewed such that 3He and 1H images were visible on a digital workstation monitor
system (consisting of identical 19 inch flat panel monitors). Manual segmentation of
ventilation defects was performed using custom-designed image visualization software
which also provided a method for two-dimensional rigid single point image registration
(1H and 3He slices) based on the carina, facilitating the manual segmentation of
ventilation defects in all slices. Ventilation defect volume (VDV) and thoracic cavity
volume (TCV) were recorded following manual segmentation of 3He and 1H images
respectively, and used to calculate ventilation defect percent (VDP).16;25;26;40 VDV was
derived from the manually segmented ventilation defect area for each slice and this was
multiplied by the slice thickness; VDV for all slices was summed to obtain a whole lung
(WL) VDV. For the center slice (CS), which is the middle slice acquired that clearly
shows the carina and two main bronchi, VDV was also manually segmented and
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reported. Additionally, WL and CS measurements were recorded for TCV for calculation
of both WL and CS VDP, as well as for ADC.

2.2.5

Statistical Methods

For 3He MRI ventilation measurements, observer reproducibility was evaluated for 2
different observers using the interclass correlation coefficient (ICC), coefficient of
variation (COV) and linear regression (r2) using SPSS 16.00 (SPSS Inc., LEAD
Technologies Inc. Chicago, IL, USA). Comparison of baseline and follow-up means
were performed using a Wilcoxon matched pairs two-tailed t-test using SPSS 16.00. The
relationship between changes in 3He MRI measurements and changes in pulmonary
function measurements at follow-up were determined using linear regression and
Spearman correlation coefficients using GraphPad Prism version 4.00 (GraphPad
Software Inc, San Diego California, USA). The relationship between the changes in 3He
MRI VDV and smoking history was also determined using linear regression and
Spearman correlation coefficients using GraphPad Prism version 4.00.

A Holm-

Bonferroni correction41 was used for multiple paired t-tests and all correlations. The
Holm-Bonferroni adjusted p-values were determined by ordering p-values from smallest
to largest, with the smallest p-value multiplied by k, where k is the number of hypotheses
to be tested. If the resulting modified p-value was less than α (Type I error rate) the
hypothesis was rejected. The next smallest p-value was then multiplied by k-1 and the
new modified p-value was compared to α. This process was repeated until the modified
p-value could not be rejected.

In all statistical analyses, results were considered

significant when the probability of making a Type I error was less than 5% (p < 0.05). A
retrospective sample size ( n ) calculation was also performed to detect a signficant
change (δ) in FEV1 with α = 0.05 and power β = 0.80 and where SD is standard deviation;
accordingly, Zα = 1.96 and Zβ = 0.2, and n was calculated according to Equation 2-1:42
n=

2( Z α + Z β ) 2 SD 2

δ

2

(1)
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2.3

Results

Demographic characteristics are provided in Table 2-1. All COPD subjects were nonsmokers at baseline with a mean smoking history of 47 ± 22 pack-years (range = 11 - 85
pack-years) and mean years not-smoking at baseline of 11 ± 10 years (range = 10 weeks 34 years). Three subjects experienced a single COPD exacerbation each over the followup period.
Table 2-2 shows mean and median WL and CS hyperpolarized 3He MRI measurements
for the healthy never-smokers and COPD subjects. The absolute change and annualized
rates of change of FEV1 and hyperpolarized 3He MRI measurements for COPD subjects
are provided in Table 2-3. For ADC, annualized rate of change for ex-smokers with
COPD was 0.01 cm2/s and that for never-smokers was 0.002 cm2/s. There was no
significant association between the changes in image SNR and the changes in ADC (r=.51, p=.12) and VDV (r=-.17, p=.55). Inter-observer reproducibility of 3He MRI VDV
was previously evaluated for 3 different observers and this was the same as intra-observer
variability (COV=10%, unpublished results).

For two observers, inter-observer

reproducibility was assessed for WL VDV (ICC=.93, COV=38% and r2=.84 (p<.0001))
and WL VDP (ICC=.91, COV=43% and r2=0.81 (p<.0001)). Figure 2-S1 shows the
relationship between ventilation defect measurements for Observer 1 and Observer 2;
WL VDV (r2=.84, p<.0001) and WL VDP (r2=.81, p<.0001). The change at follow-up
for Observer 1 and Observer 2 were significantly correlated for WL VDV (r2=.51,
p=.0004) and WL VDP (r2=.39, p=.007). We provide the change in WL VDV and WL
VDP for each observer and the mean for both observers in Table 2-S1 within the online
supplement, and throughout the main body of the manuscript a single observer’s results
are described. Table 2-S2 is also provided in the online supplement and shows a subject
listing of baseline and follow-up pulmonary function and 3He MRI measurements.
Wilcoxon matched pairs two-tailed t-tests indicated that all 3He MRI measurements were
significantly different at follow-up for COPD subjects. There was also no significant
change observed in FEV1%predicted for the COPD subjects at follow-up.

For healthy

never-smokers, there was no detectable change in any pulmonary function or imaging
measurement.

The changes detected in the COPD ex-smokers were significantly
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different than the changes measured in the healthy volunteers for WL VDV (p=.04) and
WL VDP (p=.01), but not significantly different for WL ADC (p=.96) or FEV1 (p=.21).
Table 2-1 Subject Demographics
Healthy Never-smokers
COPD Ex-smokers
(n=5)
(n=15)
Baseline
Follow-up
Baseline
Follow-up
Age yrs
69
72
68
70
(±SD) [range]
(6) [58-74]
(6) [61-76]
(6) [59-75]
(5) [61-77]
Male Sex
2
2
8
8
Body Mass Index
25
25
28
27
(±SD) [range]
(2) [24-29]
(2) [23-28]
(5) [19-38]
(5) [18-37]
FEV1 L (±SD)
2.77 (1.01)
2.62 (0.93)
1.51 (0.63)
1.43 (0.56)
FEV1 % (±SD)
110 (23)
107 (23)
53 (15)
52 (15)
FEV1/FVC % (±SD)
77 (4)
78 (15)
45 (14)
49 (16)
IC % (±SD)
106 (18)
88 (23)
82 (22)
RV % (±SD)
95 (15)
157 (48)
132 (33)
FRC % (±SD)
101 (12)
145 (65)
131 (33)
TLC % (±SD)
105 (12)
109 (17)
105 (10)
FEV1= Forced Expiratory Volume in 1s, FVC= Forced Vital Capacity, IC= Inspiratory
Capacity, RV= Reserve Volume, FRC= Functional Residual Capacity, TLC= Total Lung
Capacity, SD=Standard Deviation

Table 2-2 3He MRI ADC and Ventilation Defect Measurements at Baseline and Followup
Healthy Never-smokers
COPD Ex-smokers
(n=5)
(n=15)
Baseline
Follow-up
Baseline
Follow-up
Mean/Median Mean/Median Mean/Median Mean/Median
WL ADC (±SD) cm2/s
0.27/0.25
0.29/0.29
0.43/0.45
0.46/0.46
(0.02)
(0.03)
(0.08)
(0.07)
CS ADC (±SD) cm2/s
0.28/0.27
0.28/0.30
0.44/0.45
0.47/0.46
(0.02)
(0.03)
(0.09)
(0.08)
WL VDV (±SD) L
0.023/0.006
0.020/0.017
0.52/0.24
0.92/0.77
(0.04)
(0.02)
(0.54)
(0.93)
CS VDV (±SD) L
0.003/0.000
0.002 /0.001
0.056/0.023
0.11/0.11
(0.005)
(0.002)
(0.053)
(0.11)
WL VDP (±SD) %
0.5/0.2 (0.9)
0.5/0.5 (0.4)
9/6 (9)
16/15 (14)
CS VDP (±SD) %
0.6/0.2 (0.9)
0.4/0.2 (0.4)
9/11 (13)
16/16 (22)
ADC=Apparent
Diffusion
Coefficient,
VDV=Ventilation
Defect
Volume,
VDP=Ventilation Defect Percent, CS=Center Slice, WL= Whole Lung, SD=Standard
Deviation
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Table 2-3 Annualized changes in pulmonary function and 3He MRI measurements for
COPD subjects at follow-up
Absolute
Annualized Rate of
Significance of difference
Change
Change (/year)
p*
p**
FEV1 (%)
-1
-0.4
0.97
0.97
2
WL ADC (cm /s)
0.02
0.01
0.01
0.02
CS ADC (cm2/s)
0.03
0.01
0.004
0.02
WL VDV (L)
0.4
0.20
0.007
0.03
CS VDV (L)
0.05
0.03
0.003
0.02
WL VDP (%)
7
4
0.0009
0.006
CS VDP (%)
7
3
0.01
0.03
FEV1=Forced Expiratory Volume in 1s, ADC=Apparent Diffusion Coefficient,
VDV=Ventilation Defect Volume, VDP=Ventilation Defect Percent, CS=Center Slice,
WL= Whole Lung
* Wilcoxon matched pairs two-tailed t-tests, ** Holm-Bonferroni adjusted significance
values
Figure 2-1 shows ventilation images, ADC maps and ADC histograms for two
representative healthy never-smokers at baseline and follow-up.

Figure 2 shows

ventilation images, ADC maps and histograms for two representative COPD subjects at
baseline and follow-up.
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Figure 2-1 Representative hyperpolarized 3He MR at baseline and follow-up in healthy
never-smokers
Left panel subject 1001 58 year old male: top panel is baseline and bottom panel is
follow-up:
(A) ventilation image (B), ADC map (C) and ADC histogram.
Right panel subject 1007 73 year old male: top panel is baseline and bottom panel is
follow-up:
(A) ventilation image (B), ADC map (C) and ADC histogram.

Table 2-4 shows Spearman correlation coefficients for the changes in FEV1 (absolute and
%predicted) with 3He MRI ADC, VDV and VDP for COPD subjects. As shown in Figure
2-3, the change in FEV1 (absolute) showed a significant negative association with the
change in CS VDV (r=-.70, p=.02), CS VDP (r=-.70, p=0.03), but not ADC. TCV was
calculated for all subjects from the thoracic cavity 1H MRI and for all subjects, the
change in TCV was significantly correlated with the change in TLC measured using
plethysmography (r=.81, p=.001). Figure 2-4 shows the relationships between COPD
patient smoking history (pack-years smoking) with the changes in 3He MRI VDV and
FEV1. There was no significant correlation between pack-years smoking and the change
in FEV1 (r=.05, p=.83), and the relationship between pack-years smoking and WL VDV
was moderate, but once corrected for multiple tests, this relationship was on the threshold
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of significance (WL VDV [r=.52, p=.02, uncorrected, p=.06 Holm Bonferroni
corrected]).

Figure 2-2 Representative hyperpolarized 3He MR VDV and ADC changes during
follow-up in COPD
Left panel subject 3004 75 year old male stage III COPD: top panel is baseline and
bottom panel is follow-up: (A) ventilation image (B), ADC map (C) and ADC histogram
Right panel subject 2009 61 year old male stage II COPD: top panel is baseline and
bottom panel is follow-up: (A) ventilation image (B), ADC map (C) and ADC histogram
Table 2-4 Relationship between changes in FEV1 and 3He MRI measurement changes for
COPD subjects over time
Spearman Correlation Coefficients
FEV1 L (p/p*)
FEV1%predicted (p/p*)
WL ADC (cm2/s)
-0.02 (0.93/0.93)
0.17 (0.56/1.0)
2
CS ADC (cm /s)
-0.06 (0.84/1.0)
0.15 (0.60/0.60)
WL VDV (L)
-0.56 (0.03/0.09)
-0.53 (0.04/0.12)
CS VDV (L)
-0.70 (0.003/0.02)
-0.67 (0.007/0.04)
WL VDP (%)
-0.60 (0.02/0.08)
-0.55 (0.03/0.12)
CS VDP (%)
-0.70 (0.005/0.03)
-0.70 (0.005/0.03)
FEV1=Forced Expiratory Volume in 1s, ADC=Apparent Diffusion Coefficient,
VDV=Ventilation Defect Volume, VDP=Ventilation Defect Percent, CS=Center Slice,
WL= Whole Lung
* Holm-Bonferroni adjusted significance values
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Figure 2-3 Relationship between 3He MRI
measurements and changes in FEV1
Scatterplots show the relationship between
changes in FEV1 and changes in center slice
(CS) ventilation defect volume (VDV), CS
ventilation defect percent (VDP) and WL
apparent diffusion coefficient (ADC). The 95%
confidence intervals for the regressions are
shown as dotted lines. (A) Changes in FEV1
showed a significant negative correlation with
changes in CS VDV (r=-.70, p=.02), and (B) CS
VDP (r=-.70, p=.03). (C) Changes in FEV1
showed no significant correlation with changes
in WL ADC.

Figure
2-4
Relationship
3
between He MRI VDV, FEV1
and smoking history
Scatterplot
showing
the
relationship between smoking
history and change in WL VDV
(r=.52,
p=.02/p=.06
Holm
Bonferroni
corrected)
and
change in FEV1%predicted (r=.05,
p=.83).

71

2.4

Discussion

Several observations were made in this small longitudinal pilot study. First, we observed
that mean 3He ADC, VDV and VDP significantly increased during the 26 month followup period in the 15 COPD ex-smokers whereas pulmonary function measurements did
not significantly change over the same period of time. Based on the previously reported
and pioneering epidemiological findings of Fletcher and colleagues,3 as well as the more
recent tiotropium intervention trial,43 we were not surprised to find that in COPD exsmokers, FEV1 did not significantly change. Indeed, this study was not powered to detect
such changes in FEV1 over a 2 year timeframe; a retrospective power analysis shows that
a sample size of approximately 1000 COPD and 1000 healthy volunteers would be
required to detect significant change in FEV1 in this study. Unlike the Fletcher curve
prediction that longitudinal changes in hyperpolarized 3He measurements in the COPD
ex-smokers would be similar to those observed in elderly healthy never-smokers, we
observed an annualized rate of change in 3He MRI ADC of 0.01 cm2/s/y -an order of
magnitude greater than the rate previously reported (0.001cm2/s/y) for healthy nonsmokers in a cross-sectional multi-center study at 1.5T,29 and for the healthy neversmokers reported in this study (0.002 cm2/s/y). Additionally, we observed no significant
change in 3He MRI ADC, ventilation defect measurements or in pulmonary function
measurements for the healthy never-smokers at follow-up.

These preliminary

longitudinal findings suggest that regional disease markers derived from non-invasive
imaging methods can be used in a small number of COPD subjects over short time
periods, to quantitatively detect significant changes.
We also showed that the change in 3He MRI VDV and VDP indicated a significant
inverse correlation with the change in FEV1, whereas the change in ADC showed no such
relationship. This result suggests that 3He MRI ventilation defect measurements may be
more predictive of airflow limitation than 3He MRI ADC, which necessitating further
testing of this hypothesis. Although we observed statistically significant improvements in
FEV1 <20 mL in five COPD subjects, we did not observe a corresponding improvement
in 3He MR imaging-derived measurements over this time period. On the contrary, for
these five subjects we observed a statistically significant increase in 3He MRI ADC
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(p=.02) and no change in ventilation measurements. We believe this discordant finding
highlights the sensitivity of using both ventilation and ADC measurements in detecting
disease changes in COPD. In a related finding, Ohara and colleagues15 showed the
significant inverse correlation between annual changes in FEV1 and the CT measurement
of wall area percent (WA% - a surrogate of airway wall thickness) and similar to our
results, there was no significant relationship between the change in FEV1 and emphysema
(percent low attenuation areas, %LAA). It is important to note that for five of the 15
COPD subjects evaluated in this pilot analysis, both imaging and spirometry suggested
disease progression. This finding generates a number of hypotheses for testing in larger
or longer imaging studies of COPD progression evaluating the relationship between
exacerbations, treatment changes and changes in quality of life with imaging and
pulmonary function measurements. Future COPD studies that include hyperpolarized
3

He MRI will likely focus on a critical balance between longitudinal time frame and finite

numbers of subjects because of the relative complexity of these studies and the prediction
for increased costs and decreased availability of 3He gas for clinical research.44
Nevertheless, the preliminary findings of this pilot hyperpolarized 3He MRI longitudinal
study provide clear guidance for future COPD imaging studies using established and
emerging imaging tools such as optical coherence tomography,45 oxygen enhanced and
proton MRI methods46;47 and hyperpolarized xenon-129 MRI.
Finally, we showed in an exploratory analysis, the potential relationship between
smoking history and changes in 3He MRI VDV but not with changes in FEV1. We note
that previous cross-sectional studies suggest ongoing inflammation in ex-smokers with
COPD3;29 and that smoking history correlated with current inflammatory markers such as
eosinophils48 and vascular endothelial growth factor49 supporting the hypothesis that
there is a predictive relationship between pack-years and inflammation post smoking
cessation. The results of this exploratory analysis of 3He MRI changes and smoking
history generate important hypotheses that future studies should explore in more detail.
Although this pilot study reports significant increases in 3He MRI measurements in just
over two years, we must acknowledge a number of specific limitations of our approach.
We recognize that the relatively small group of COPD subjects and healthy never-
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smokers that were evaluated, and the relatively short period of follow-up compared to
other COPD longitudinal studies5 certainly limits the applicability of our results. The
small sample size necessitates cautious interpretation of the results as well as the future
requirement for larger studies to test the hypotheses generated. For example, because of
the small number of healthy volunteers and COPD subjects evaluated, significant
differences were not detected for pulmonary function measurements in either group. In
addition, although we have previously demonstrated that ventilation defects are highly
reproducible,20 the lack of longitudinal information regarding the variability of
ventilation defects necessitates that the findings of this study be interpreted with caution.
It is also important to note that although this pilot study showed that ex-smoking COPD
patients differed from elderly never-smokers, it was not designed to show the relationship
between the significant imaging changes and more established clinical measurements of
COPD worsening. To make the important conclusion that 3He MRI measurements are
specifically related to clinical measurements of COPD worsening, future work in longer
or larger studies must show that the detected 3He MRI changes occurred in patients who
had measureable clinical changes.

Nevertheless, the results suggest that 3He MRI

provides a sensitive method for the detection of the lung structural and functional
changes that accompany COPD longitudinally. In future, larger studies that directly
compare

3

He MRI and other well-established clinical measurements of COPD

progression will be required in order to better understand the relationship between 3He
measurements and other changes that occur in COPD over time.

Additionally, a

comparison of COPD ex-smokers, healthy smokers and COPD current smokers may help
to establish and directly compare rates of lung structural and functional decline. It will
also be critical to track patient exacerbations and changes in treatment over longer
periods of time to probe potential treatment effects with imaging. We also acknowledge
that for this pilot study, we limited the COPD cohort to those with minimal FEV1
reversibility, although clearly many COPD subjects have varying degrees of FEV1
reversibility which necessitates further work in such patients. CT images were not
prospectively acquired for this study and therefore, our results cannot be directly
compared to more established CT measurements such as LAA% (a measurement of the
extent of emphysema), or WA% (a measurement of airway wall thickness). Clearly, a
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direct comparison of CT and hyperpolarized 3He derived measurements in the same
subjects will allow for a better understanding of differences in measurement sensitivity
these imaging modalities provide. Previous work has shown significant correlations
between ADC and the measurement of the diffusion capacity of carbon monoxide
(DLCO).32 A direct comparison here would have provided another quantitative measure
of global emphysematous changes in these subjects. It is also important to note that
while Woods and colleagues have previously shown the significant correlation between
3

He ADC and histological measurements of emphysema,28 we have not yet determined

the underlying pathology that results in 3He ventilation defects we observe, which may be
a result of small airway occlusion, mucous plugs, airway wall thickening and
inflammation or bullous disease. Related to this is the fact that there is significant
information in regions of intermediate signal intensity and in both hyper- and hypointense signal regions that have not yet been quantitatively or spatially exploited. The
development and validation of 3He image analysis techniques that quantify heterogeneous
signal information are required in the future to fully characterize the important ventilation
information contained in the image. Whether regions of diminished ventilation and
emphysema develop independently and the extent to which one leads to the other cannot
be ascertained by this preliminary longitudinal study and is yet to be determined in other
longitudinal imaging studies. Importantly however, our group previously described the
high reproducibility of 3He ventilation defects in COPD,20 suggesting that the significant
changes measured here may be due to changes in lung morphology or function and not
due to the variability of the imaging or measurement technique, nor due to short-term
changes in small airway diameter or patency.
In summary, in this small pilot study of COPD ex-smokers, we detected significant lung
changes using 3He MRI that occurred over a relatively short period of time, perhaps
before FEV1 changes could be detected or perhaps because such longitudinal changes
occurred within the FEV1 silent zones, where disease might have accumulated without
detection.
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2.6

Supplementary Tables

Table 2-S1 Hyperpolarized 3He MRI ventilation measurement observer reproducibility
Mean Difference at Follow-up (Significance)
Observer 1
Observer 2
Mean (Observers 1 & 2)
WL VDV (L)
0.30 (0.007)
0.41 (0.02)
0.35 (0.004)
WL VDP (%)
5.0 (0.002)
6.2 (0.04)
5.6 (0.01)
VDV=ventilation defect volume, VDP=ventilation defect percent

82

Table 2-S2-2 Baseline and follow-up subject listing of pulmonary function test results and 3He MRI measurements

Subject Age
(yr)

Pulmonary Function
Measurements
(Baseline/Follow-up)
FEV1/
RV
TLC (L)
FVC
(%)

3

He MRI Measurements
(Baseline/Follow-up)

Pack- FEV1
ADC
Dw TCV (L) VDV (L)
VDP
SV
year
(%)
(cm2/s) SNR
(%)
SNR
(yr)
2001
73
39
64/71 50/54 148/100 4.67/5.12 .50/.55 64/37 6.57/4.32 0.03/0.10 0.4/2.2 233/153
2002
74
11
51/53 41/49 157/127 4.88/4.53 .41/.44 52/25 3.95/3.84 0.24/0.55 6.0/14.3 183/196
2003
71
72
80/71 61/54 132/126 8.10/7.79 .29/.37 49/18 6.01/5.18 0.04/0.34 0.7/6.3
136//61
2004
72
40
58/51 46/42 139/131 5.65/5.74
-/.60
51/31 6.06/4.53 1.59/1.08 26.3/23.8 51/169
2005
72
30
62/38 48/37
164/7.93/.40/.40 44/27 6.96/6.57 0.622.25 9.0/34.2 90/113
2006
62
52
62/62 53/51 116/71 5.19/5.49 .49/.48 56/42 4.70/4.22 0.09/0.23 1.9/5.4 125/148
2007
68
24
66/66 77/89 116/124 4.30/5.04 .46/.44 12/17 4.08/3.47 0.04/0.16 1.1/4.6
37/39
2008
59
65
59/68 50/70 174/141 8.09/7.53 .36/.38 48/42 6.11/5.07 0.03/0.09 0.5/1.9 162/118
2009
61
85
68/64 60/62 132/120 8.31/7.88 .30/.36 27/29 7.62/5.20 0.19/1.09 2.5/21.0
53/33
3001
74
52
43/56 29/42 265/157 9.6/7.45 .50/.55 45/28 6.57/6.28 1.23/1.21 18.6/19.3 115/102
3002
62
49
35/43 29/38 212/170 8.58/7.37 .44/.47 56/26 6.23/6.18 0.59/1.28 9.5/20.8 75/142
3004
75
20
41/45 46/48 94/113 6.01/5.88 .34/.38 40/18 4.86/4.19 0.16/0.22 3.4/5.3
90/102
3005
65
66
42/42 32/30
210/6.56/.47/.48 60/50 5.54/5.30 0.57/0.77 10.3/14.5 145/155
3008
71
70
32/23 37/34 193/200 8.37/8.01 .47/.48 32/14 5.72/6.79 1.40/3.50 24.5/51.5 72/24
3009
62
30
27/33 23/32 431/237 9.64/6.70 .58/.58 27/27 6.10/5.62 0.99/0.98 16.2/17.5 93/131
FEV1=Forced Expiratory Volume in 1s, FVC=Forced Vital Capacity, RV=Reserve Volume, TLC=Total Lung Capacity,
ADC=Apparent Diffusion Coefficient, Dw=Diffusion-weighted image, SNR=Signal-to-Noise Ratio, TCV=Thoracic Cavity
Volume, VDV=Ventilation Defect Volume, VDP=Ventilation Defect Percent, SV=Static Ventilation Image
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2.7

Supplementary Figures

Figure 2-S1 Relationship between VDV and VDP for Observer 1 and Observer 2
Scatterplots show the relationship for Observers 1 and 2 whole lung (WL) ventilation
defect volume (VDV) and ventilation defect percent (VDP). The 95% confidence
intervals for the regressions are shown as dotted lines. (Ai) Observer 1 and 2 VDV
(r2=.84, p<.0001) and (Aii) Observer 1 and 2 VDP (r2=.81, p<.0001). The change at
follow-up for Observer 1 and Observer 2 are significantly correlated for VDV (r2=.51,
p=.0004) (Bi) and VDP (r2=.39, p=.007) (Bii).
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CHAPTER 3
A limitation of the longitudinal study performed in Chapter 2 was that 3He MRI
measurements were performed using manual segmentation approaches, which clearly
increases segmentation time and, importantly, introduces the potential for inter- and
intra-observer variability. Here we generated a semi-automated segmentation method
for 3He MRI to enable its use in longitudinal and serial studies.
The contents of this Chapter have been previously published in Academic Radiology and
permission to reproduce the article was granted by John Wiley and Sons and is provided
in Appendix C.
M Kirby, M Heydarian, S Svenningsen, A Wheatley, DG McCormack R Etemad-Rezai
and G Parraga. Hyperpolarized 3He Magnetic Resonance Functional Imaging
Semiautomated Segmentation. Acad. Radiol. 2012; 19(2):141—52.

3

Hyperpolarized 3He Magnetic Resonance Imaging Semiautomated Segmentation
3.1

Introduction

Pulmonary hyperpolarized helium-3 (3He) magnetic resonance imaging (MRI) is a
functional imaging method that detects ventilation abnormalities in elderly neversmokers1 and patients with chronic obstructive pulmonary disease (COPD),2-9 asthma,1013

cystic fibrosis (CF),14-16 radiation-induced lung injury,17;18 and lung transplant

recipients.19;20

Over the last few years, this approach has been enhanced by

improvements in laser optical pumping techniques,21 parallel imaging,22 single-scan
acquisition of ventilation and diffusion-weighted images,23 single-scan acquisition of
ventilation and 1H MRI anatomical images24 and dynamic imaging.25;26 While this large
body of work has advanced the scope and type of functional images that can be acquired,
there have been fewer improvements related to image analysis methods.27-29 As we move
forward with functional noble gas imaging and transition to hyperpolarized xenon-129
(129Xe) MRI, a less expensive and more readily available approach, image analysis
methods are urgently required for quantitative evaluation across a wide variety of
respiratory diseases.
Previous 3He functional/ventilation analyses were based on a radiologist’s interpretation
of the ventilated lung regions,27;30 and quantification of ventilation defects was performed
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using scoring1;8;11 and volumetric analysis approaches.1;8 While in these studies, imaging
measurements were correlated with well-established measures of disease, a limitation of
manual methods is the inherent reliance upon highly trained observers that increases
segmentation time and introduces the potential for inter- and intra-observer variability.
Although straightforward automated threshold methods have been used for segmentation
of ventilation,27 automated segmentation of the 3He ventilation defects themselves,
previously demonstrated by Tustison et. al.28 as a feature that differentiated asthma and
healthy subject images, has proven to be much more difficult. Subjects with severe
obstructive disease, such as COPD or asthma, have numerous ventilation defects that
appear in 3He images as signal voids. Hyperinflation is also commonly observed in
obstructive lung disease due in part to gas trapping and therefore changes in the thoracic
cavity shape vary from patient to patient and within individual patients over time. Thus,
segmentation of ventilation defects likely requires an understanding of the relationship
between 3He functional information with the anatomy of the thoracic cavity derived from
proton (1H) MRI. Furthermore, because there appear to be regions with 3He signal voids,
as well as regions of hypo- and hyper-intensity, segmentation methods are required for
the visually different classes of 3He MRI signal.
Therefore, our objective was to develop a semi-automated segmentation method by
applying two well-established image segmentation approaches, seeded region-growing31
for segmentation of the thoracic cavity from 1H MRI and K-means clustering32 to
classify 3He MRI pixel intensities as previously investigated,29;33;34 to generate 3He MRI
ventilation measurements. The combination of these well-established and widely used
segmentation methods allows for quantification and characterization of the important
ventilation information contained in the image.

3

He MRI segmentation methods must

have high intra-observer and inter-observer reproducibility across a variety of respiratory
diseases and subjects. Therefore, here we evaluated the reproducibility as well as the
spatial and quantitative relationships between manual and semi-automated functional
measurements in subjects with asthma, COPD and CF.
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3.2
3.2.1

Materials and Methods
Subjects

All subjects provided written informed consent to protocols approved by Health Canada
and a local research ethics board. COPD subjects were ex-smokers, with a clinical
diagnosis of COPD and categorized according to the Global initiative for chronic
Obstructive Lung Disease (GOLD) criteria,35 with a smoking history of at least 10-packyears as previously described.5

Adult asthmatics between 18-50 years of age were

enrolled with FEV1%pred > 60% with a physician diagnosis of asthma and adult CF
subjects (18-40 years of age) were also enrolled with FEV1%pred > 50% .

3.2.2

Image Acquisition

MRI was performed on a whole body 3.0 Tesla Excite 12.0 MRI system (GEHC,
Milwaukee, WI USA) with broadband imaging capability as previously described,1 and
3

He MRI was enabled using a single channel, rigid elliptical transmit/receive chest coil

(RAPID Biomedical GmbH, Wuerzburg Germany). Pulse oximetry was used to measure
arterial oxygen saturation (SaO2) for all subjects during scanning sessions and considered
an adverse event occurred when SaO2 decreased below 88% continuously for ≥ 15
seconds at any time during the scanning session. Study withdrawal was required when
SaO2 decreased to 80% for 10 seconds or longer.

It is important to note that we

endeavoured to minimize the potential for differences in the levels of inspiration between
the breath-hold scans for each subject by: 1) training and practice for all subjects prior to
MRI related to the inspiration breath-hold maneuver from functional residual capacity
(FRC), and, 2) continuous coaching and monitoring at the MR bedside by a pulmonary
function technologist during all inspiration breath-hold scans.
Conventional 1H MRI was performed prior to hyperpolarized 3He MRI with subjects
scanned during 1.0 L breath-hold of 4He/N2 using the whole body radiofrequency (RF)
coil and 1H fast spoiled gradient recalled echo sequence (16s total data acquisition,
repetition time (TR) / echo time (TE) / flip angle = 4.7 ms / 1.2 ms / 30o, field-of-view
(FOV) = 40 × 40 cm, matrix 256 × 128, 14 slices, 15 mm slice thickness, 0 gap), as
previously described.1
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Prior to 3He MRI, a polarizer system (HeliSpin™, GEHC, Durham, NC) was used to
polarize 3He gas to 30—40 % and doses (5 mL/kg body weight) were administered in 1.0
L Tedlar bags diluted with ultrahigh purity, medical grade nitrogen (Spectra Gases,
Alpha, NJ). As previously described,1 hyperpolarized 3He MRI coronal static ventilation
images were acquired during breath-hold of a 1L 3He/N2 mixture (14s data acquisition,
TR / TE / flip angle = 4.3 ms / 1.4 ms / 7o, bandwidth = 31.25, FOV = 40 × 40 cm, matrix
128 × 128, 14 slices, 15 mm slice thickness, 0 gap).

3.2.3

Manual Segmentation

Manual segmentation was repeated five times to estimate observer reliability using the
approximation method developed by Walter et. al.36 All subjects were first randomized
and subsequently manually segmented by a single observer blinded to subject identity
and disease status, and all subjects measurements were repeated five times each (15
subjects × 5 repetitions = 75 image datasets). To minimize memory bias, at least 24
hours was required between repetition rounds and randomization of subject image
datasets was performed between each repetition round. The observer (MK) had three
years experience performing manual 3He MRI segmentation having been trained by an
experience chest radiologist (RER). As previously described,1 ventilation volume (VV)30
was recorded following manual segmentation of the ventilated lung regions and
ventilation defect volume (VDV)1;8 was recorded following manual segmentation of the
3

He MRI focal ventilation defects, using custom-designed image visualization software,37

providing a method for two-dimensional rigid single point image registration (1H and 3He
slices) based on fiducial markers located on the carina. As previously described,38 a
ventilation defect was identified by the observer as any lung region of diminished signal
intensity but not including those areas of signal loss associated with the pulmonary
vascular structures, heart, hilum and mediastinum.

3.2.4

Semi-automated Segmentation: Overview of Method

Multi-step segmentation software was generated using MATLAB R2007b (The
Mathworks Inc., Natick, Massachusetts). All subjects, following randomization, were
segmented using the semi-automated method by two observers blinded to subject identity
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and disease status, and measurements were repeated five times each (15 subjects × 5
repetitions × 2 observers = 150 image datasets). To minimize memory bias, at least 24
hours was required between repetition rounds. The observer (blinded) had one year
experience developing and performing semi-automated 3He MRI segmentation, and the
observer (blinded) had 1 month experience performing semi-automated 3He MRI
segmentation. Figure 3-1 provides a summary of our method. Briefly, 3He MR images
(Step 1) were segmented automatically using a hierarchical version of K-means
clustering algorithm,32 and 1H MR images were segmented automatically using a seeded
region-growing algorithm (SRGA)31 (Step 2).
39

1

H MR segmented images were

3

registered to He MR segmented images (Step 3) to differentiate the ventilation defects
from the background and therefore generating a 3He voxel cluster map, with clusters
ranging from 1 to 5, representing gradations of signal intensity from no signal (Cluster 1,
C1) and hypo-intense signal (C2) to hyper-intense signal (C5). This approach was first
tested in a training dataset of 5 COPD subjects (5 subjects × 10 slices = 50 image slices)
for comparison to manual segmentation. Results from the training dataset indicated that
the semi-automated algorithm completed all tasks with image signal-to-noise-ratio
(SNR) ≥ 13, and this was the case for nearly all but the most anterior slices for each
subject. The combination of 4 initial clusters and re-clustering the initial C1 yielding a
total of 5 clusters provided the best qualitative correlation with manual expert observer
(chest radiologist) results. We also quantitatively compared K-means with the initial user
input of 4 to 10 clusters and the hierarchical K-means approach (4 initial clusters and reclustering the initial C1) with manual segmentation on the training dataset, and
determined that hierarchical K-means provided the highest correlation and lowest BlandAltman bias with manual segmentation and was subsequently used for the testing dataset
(Supplementary Table, Table 3-S1).

3.2.5
3

3

He MRI Automated Segmentation: K-means Clustering
Algorithm

He MRI of obstructive (COPD and asthma) and restrictive (CF) lung disease are

typically characterized by heterogeneous 3He MRI signal intensity that reflect gas
distribution heterogeneity during the inspiration breath-hold scan. The expert observer
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typically can distinguish between 4 visually apparent classes of 3He MRI signal – signal
void, hypo-intense (or partial volume), normal intensity, and hyper-intense signal. For
this reason, a hierarchical K-means clustering method,32 similar to previously described
methods for 3He MRI segmentation,29;33;34 was used to partition the signal intensity
frequency distribution histogram into 4 clusters, based on an expert chest radiologist’s
interpretation of the clinical meaning of the visible signal intensity differences. Because
the first round of K-means clustering resulted in a single cluster C1 that included both
signal void and hypo-intense regions (partial volumes and/or partially ventilated
volumes), K-means clustering was re-applied to the C1 to separate signal void from the
hypo-intense signal regions.

This was accomplished in three steps as follows: 1) K-

means with four clusters was initially applied to the 3He image, 2) K-means with four
clusters was then re-applied to C1, 3) the first two clusters from step 2 were merged to
represent the background and ventilation defects and the last two clusters from step 2
were merged to represent the hypo-intense signal regions. For both steps 1 and 2, a
standard initialization method was performed to produce the initial centroids by dividing
the full pixel range of 0-255 into four equal regions: 0-63, 64-127, 128-191, 192-255, and
selecting the interval center as the centroid for each cluster.
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Figure 3-1 Schematic of 3He semi-automated segmentation methodology
Semi-automated segmentation was accomplished in three steps: 1) hierarchical K-means
clustering of 3He MR images into 5 clusters where cluster 1 (C1) represented regions of
ventilation defect and background, and cluster 2 to cluster 5 (C2-C5) represented
gradations of signal intensity/ventilation, 2) 1H MRI segmentation using seeded regiongrowing algorithm, and 3) landmark-based registration of 1H and 3He MRI segmentation
to differentiate the ventilation defects from the background, and therefore generating a
3
He voxel cluster map.

3.2.6

1

H MRI Automated Segmentation: Seeded Region-growing

In conventional 1H MRI anatomical images, low 1H density in the lung produces a weak
MR signal, thus providing sufficient contrast for segmentation methods such as a seeded
region-growing algorithm (SRGA)31 to segment the contour of the thoracic cavity to
differentiate ventilation defects from the edge of the lung. Prior to application of SRGA,
all 1H images were pre-processed to protect the region-growing algorithm from leaking
into regions extending beyond the lung boundary with similar signal intensities. Preprocessing of the 1H images was performed using a 2D radially symmetric Gaussian lowpass filter of size 15×15 with standard deviation 2.0. The images were then converted to
a binary mask using a threshold that was selected equal to the half the maximum intensity
of the first cluster of K-mean clustering with four clusters. Seed points were then
automatically selected in both the left and right lungs of the binary mask by finding the
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columns in the image binary mask that contained 20 vertically adjacent pixels.

A

morphological closing algorithm with a structuring element disk of radius equal to 15
(function imclose in MATLAB) was applied to fill areas within the segmented left and
right lung separately.

3.2.7

Landmark-based Image Registration

Because of the extensive coaching to minimize the potential for differences in the levels
of inspiration between the breath-hold scans for all subjects, 3He and 1H images were
registered using a landmark-based image affine registration approach.39 Briefly, the
center slices, defined as the 2D MR slice that clearly showed the carina and primary
bronchi, were first displayed side-by-side. Three to seven fiducial markers were selected
on the 3He image based on the carina, trachea, and primary bronchi, as well as any other
distinguishing features located within the lung or near the lung periphery such as
pulmonary vessels and regions near the diaphragm. The same landmarks were selected in
the same order on the 1H image. Geometric operations consisting of rotation, translation
and scaling (same in both x and y directions) were used to transform the 1H image to
align it with the corresponding landmarks selected in the 3He image.
1

transformation map was applied to the remaining H MR image slices.

3

The same

He VDV was

generated using the lowest signal intensity cluster (C1) and 3He VV was generated as the
sum of the remaining clusters (C2-C5).

3.2.8

Statistical Analysis

A two-way analysis of variance (ANOVA) was performed for comparison of manual and
semi-automated volume measurements with segmentation method and repetition (5
repeated measurements) treated as within subject factors using SPSS 16.00 (SPSS Inc.,
Chicago, IL, USA LEAD Technologies, Inc., Chicago, IL). The relationship between
manual and semi-automated segmentation was also determined using linear regression
(r2) and Pearson correlation coefficients (r) and the agreement between the methods was
determined using Bland-Altman analysis using GraphPad Prism version 4.00 (GraphPad
Software Inc, San Diego, CA, USA). Intra-observer and inter-observer reproducibility
was determined for manual and semi-automated segmentation results using the
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coefficient of variation (CV), calculated as the standard deviation (SD) of the five
measurements divided by the mean. Two-way random effects single measure intra-class
correlation coefficients (ICC) (absolute agreement) were also determined for the five
repeated measurements for both manual and semi-automated segmentation using SPSS
16.00. The 95% confidence intervals (CI) for CV and ICC were determined using the
Modified McKay’s method40 using SPSS version 16.00. To compare the reproducibility
of manual and semi-automated measurements, approximate tests were performed by
examining the overlap in 95% CI. The smallest detectable difference (SDD), defined as
the smallest difference that can be measured with prospectively determined confidence
not due to measurement error (variability), was calculated using the manual and semiautomated five repeated 3He measurements according to Eliasziw et. al.41 and shown in
Equation 3-1:
SDD ≥ zα 2 SEM int ra

(1)

where zα is 1.96 corresponding to a significance level of α =.05 and SEM int ra is the
standard error of measurement due to intra-observer variability and was calculated as
shown in Equation 3-2:
SEM int ra = σˆ e 2

where σˆ e 2 is the intra-observer repeated measures variance. The Dice coefficient

(2)

42

,

calculated as the area of the intersection of two datasets divided by the average area of
the two sets, was determined to measure the agreement or similarity between each of the
five repeated measurements for both manual and semi-automated segmentation (5
repetitions = 10 comparisons), as well as between each of the repeated manual and semiautomated segmentation measurements (5 repetitions for manual and semi-automated =
25 comparisons) as shown in Equation 3-3:
Dice( A, B) =

2 A∩ B
A+B

(3)
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where A and B are the two data sets. For semi-automated segmentation, two observers
performed all measurements and therefore the mean Dice coefficient for the two
observers was used. In all statistical analyses, results were considered significant when
the probability of making a Type I error was less than 5% (p < 0.05).

3.3

Results

Demographic characteristics are provided in Table 3-1 for 15 subjects in total including
five subjects with asthma (n=3 males, mean age=36 (±13), range=20-53), five subjects
with COPD (n=2 males, mean age=67 (±6), range=61-77) and five subjects with CF (n=2
males, mean age=25 (±9), range=20-41). COPD subjects were GOLD stage II (n=1) and
GOLD stage III (n=4).
Figure 3-2 shows the centre coronal 3He MRI slice, where the trachea and two main
bronchi are clearly visible, for each of two representative asthma, COPD and CF
subjects; 3He ventilation displayed in red registered to the greyscale 1H MRI of the
thorax, with the segmentation results obtained by manual and semi-automated
segmentation.

It is important to note that manual segmentation of the 3He images

required approximately 60 to 90 minutes for all slices per subject, whereas semiautomated 3He segmentation required approximately four to eight minutes of supervised
computational time for all slices per subject.
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Table 3-1 Subject Demographics
Asthma (n=5)
(±SD) [range]
36 (13) [20-53]
3
27 (3) [21-30]

COPD (n=5)
(±SD) [range]
67 (6) [61-77]
2
26 (5) [18-30]

CF (n=5)
(±SD) [range]
25 (9) [20-41]
2
25 (3) [21-29]

FEV1%pred
FVC %pred
FEV1/FVC
TLC %pred

69 (23) [31-108] 91 (16) [72-108]
87 (12) [65-110] 96 (13) [77-110]
64 (18) [27-86]
77 (8) [65-86]
114 (21) [94-175] 100 (5) [97-108]

74 (4) [69-79]
87 (1) [85-89]
73 (6) [65-80]
111 (12) [94-120]

IC %pred

101 (18) [71-138]

42 (11) [31-61]
78 (11) [65-90]
41 (9) [27-51]
129 (27) [106175]
86 (11) [71-96]

Parameter
Age yrs
Male Sex
BMI kg·m-

All (n=15)
(±SD) [range]
43 (20) [20-77]
7
26 (4) [18-30]

2

FRC %pred

‡

113 (15) [98138]
121 (44) [65-243] 88 (15) [65-107]
‡

†

104 (18) [90-128]
†

164 (45) [132109 (23) [88-139]
†
243]
RV %pred
157 (55) [82-285]
108 (29) [82195 (53) [143172 (42) [109‡
144]
285]
197]†
SD=Standard Deviation, BMI=Body Mass Index, FEV1= Forced Expiratory Volume in
1s, %pred=Percent Predicted, FVC= Forced Vital Capacity, TLC= Total Lung Capacity,
IC= Inspiratory Capacity, FRC= Functional Residual Capacity, RV= Reserve Volume,
†
n=4, ‡n=14
‡

Table 3-2 shows the mean whole lung 3He volume measurements for manual and semiautomated segmentation. There was no significant difference between manual VDV and
semi-automated VDV (C1) for asthma, COPD and CF subjects (p=.10). There was also
no significant difference between manual VV and semi-automated VV (C2-C5) for
asthma, COPD and CF (p=.48).
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Figure 3-2 Manual and semi-automated segmentation results for representative
asthma, COPD and CF subjects.
3
He MRI center slice registered to 1H MRI, 3He VDV and VV mask generated by
manual segmentation, and 3He cluster map generated by semi-automated
segmentation for two representative asthma, COPD and CF subjects.
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Table 3-2 Manual and semi-automated 3He volume measurements
All
Asthma
COPD
CF
Parameter
(n=15)
(n=5)
(n=5)
(n=5)
Manual
VDV L (±SD)
0.92 (0.80)
0.13 (0.15)
1.40 (0.68)
1.23 (0.74)
VV L (±SD)
4.19 (0.53)
4.37 (0.34)
4.12 (0.73)
4.08 (0.52)
Semi-automated
VDV L* (±SD)
0.76 (0.55)
0.26 (0.19)
1.26 (0.45)
0.76 (0.45)
VV L* (±SD)
4.26 (0.61)
4.43 (0.83)
3.99 (0.90)
4.37 (1.05)
C2 L (±SD)
0.66 (0.17)
0.51 (0.06)
0.80 (0.07)
0.68 (0.20)
C3 L (±SD)
1.77 (0.41)
1.64 (0.43)
1.81 (0.35)
1.86 (0.50)
C4 L (±SD)
1.27 (0.33)
1.55 (0.17)
0.98 (0.32)
1.28 (0.22)
C5 L (±SD)
0.56 (0.20)
0.73 (0.17)
0.41 (0.16)
0.54 (0.13)
SD=Standard Deviation, VDV=Ventilation Defect Volume, VV=Ventilation Volume,
C2=Cluster 2, C3=Cluster 3, C4=Cluster 4, C5=Cluster 5.
*Semi-automated VDV=Cluster 1, Semi-automated VV=Sum of Clusters 2-5

Figure 3-3 shows the correlations and Bland-Altman plots between manual and semiautomated VDV.

Manual VDV was significantly and highly correlated with semi-

automated VDV for asthma (r=.89, p<.0001), COPD (r=.84, p<.0001) and CF subjects
(r=.89, p<.0001). Bland-Altman analysis indicated that there was negligible bias between
manual

and

semi-automated

VDV

for

asthma

(bias=-0.01±0.01L),

COPD

(bias=0.01±0.05L), and CF subjects (0.05±0.04L).
Figure 3-4 shows the correlations and Bland-Altman plots between manual and semiautomated VV. Manual VV was significantly and highly correlated with semi-automated
VV for asthma (r=.99, p<.0001), COPD (r=.91, p<.0001) and CF subjects (r=.84,
p<.0001). Bland-Altman analysis indicated that there was negligible bias for manual and
semi-automated VV for asthma (bias=-0.003±0.02L), COPD (bias=0.01±0.04L) and CF
subjects (-0.03±0.06L).
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Figure 3-3 Correlations and Bland-Altman plots between manual and semi-automated
VDV for all slices.
A Manual VDV was significantly correlated with semi-automated VDV for asthma
(r=.89, p<.0001, r2=.80, p<.0001, y=0.87x+0.02), COPD (r=.84, p<.0001, r2=.70,
p<.0001, y=0.69x+0.03), and CF subjects (r=.89, p<.0001, r2=.79, p<.0001,
y=0.61x+0.001). B The mean difference (±SD) between manual and semi-automated
VDV was -0.01L±0.01L (lower limit=-0.03L, upper limit=-0.0006L), 0.01L±0.05L
(lower limit=-0.08L, upper limit=-0.10L), and 0.05L±0.04L (lower limit=-0.03L, upper
limit=-0.12L) for asthma, COPD, and CF subjects, respectively. Solid lines indicate the
mean difference and dotted lines indicate the 95% limits of agreement.
Table 3-3 shows the intra-observer reproducibility of 3He volume measurements for
manual and semi-automated segmentation for all subjects. Intra-observer reproducibility
was significantly higher for semi-automated VDV compared to manual VDV as indicated
by the non-overlapping 95% CI for both CV (manual: CV=12%, 95% CI=9%-19%, semiautomated: CV=5%, 95% CI=4%-8%) and ICC (manual: ICC=.98, 95% CI=.96-.99,
semi-automated: ICC=1.00, 95% CI=.99-1.00). Intra-observer reproducibility was also
significantly higher for semi-automated VV compared to manual VV as indicated by the
non-overlapping 95% CI for both CV (manual: CV=4%, 95% CI=3%-7%, semi-
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automated: CV=.2%, 95% CI=.2%-.4%) and ICC (manual: ICC=.90, 95% CI=.81-.96,
semi-automated: ICC=1.00, 95% CI=1.00-1.00).
Table 3-3 Intra-observer reproducibility of manual and semi-automated 3He volume
measurements
All
Asthma
COPD
CF
Parameter
(n=15)
(n=5)
(n=5)
(n=5)
Manual
VDV CV % [95%
12 [9-19]
9 [5-26]
9 [5-25]
12 [7-36]
CI]
ICC [95% CI]
0.98 [0.960.99 [0.980.97 [0.900.96 [0.870.99]
1.00]
1.00]
1.00]
VV
CV % [95%
4 [3-7]
2 [1-5]
5 [3-13]
6 [3-16]
CI]
ICC [95% CI]
0.90 [0.810.96 [0.850.94 [0.680.83 [0.560.96]
1.00]
0.99]
0.98]
Semi-Automated
VDV* CV % [95%
5 [4-8]
6 [4-18]
4 [3-13]
4 [2-11]
CI]
ICC [95% CI]
1.00 [0.990.99 [0.970.98 [0.951.00 [0.981.00]
1.00]
1.00]
1.00]
VV*
CV % [95% 0.2 [0.2-0.4] 0.2 [0.1-0.5]
0.2 [0.0-0.1]
0.4 [0.2-1.1]
CI]
ICC [95% CI]
1.00 [1.001.00 [1.001.00 [1.001.00 [1.001.00]
1.00]
1.00]
1.00]
C2
CV % [95% 0.6 [0.5-1]
1 [0.5-2]
0.3 [0.2-1]
1 [0.5-2]
CI]
ICC [95% CI]
1.00 [1.000.99 [0.971.00 [1.001.00 [1.001.00]
1.00]
1.00]
1.00]
C3
CV % [95% 0.3 [0.2-0.5] 0.2 [0.1-0.6]
0.2 [0.1-0.3]
0.5 [0.3-1]
CI]
ICC [95% CI]
1.00 [1.001.00 [1.001.00 [0.991.00 [0.991.00]
1.00]
1.00]
1.00]
C4
CV % [95% 0.1 [0.1-0.2] 0.1 [0.0-0.2]
0.1 [0.1-0.4]
0.2 [0.1-0.6]
CI]
ICC [95% CI]
1.00 [1.001.00 [0.991.00 [1.001.00 [0.991.00]
1.00]
1.00]
1.00]
C5
CV % [95% 0.1 [0.0-0.1] 0.1 [0.0-0.2]
0.0 [0.0-0.1]
0.1 [0.1-0.2]
CI]
ICC [95% CI]
1.00 [1.001.00 [1.001.00 [1.001.00 [1.001.00]
1.00]
1.00]
1.00]
VDV=Ventilation Defect Volume, VV=Ventilation Volume, CV=Coefficient of
Variation, ICC=Intraclass Correlation Coefficient, CI=Confidence Interval, C2=Cluster
2, C3=Cluster 3, C4=Cluster 4, C5=Cluster 5.
*Semi-automated VDV=Cluster 1, Semi-automated VV=Sum of Clusters 2-5
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Table 3-4 shows the inter-observer reproducibility of 3He volume measurements for
semi-automated segmentation for all subjects.

For the two observers, CV was low

(VDV: CV=7%, 95% CI=5%-11%, VV: CV=.4%, 95% CI=.3%-.6%) and ICC was high
(VDV: ICC=.96, 95% CI=.76-.99, VV: ICC=1.00, 95% CI=.83-1.00) across all three
respiratory diseases evaluated.
Table 3-4 Inter-observer reproducibility of semi-automated 3He volume measurements
Parameter
VDV* CV % [95%
CI]
ICC [95% CI]
VV*

C2

C3

C4

C5

CV % [95%
CI]
ICC [95% CI]
CV % [95%
CI]
ICC [95% CI]
CV % [95%
CI]
ICC [95% CI]
CV % [95%
CI]
ICC [95% CI]
CV % [95%
CI]
ICC [95% CI]

All
(n=15)
7 [5-11]

Asthma
(n=5)
12 [7-37]

COPD
(n=5)
6 [4-17]

CF
(n=5)
5 [3-15]

0.96
[0.76-0.99]
0.4 [0.3-0.6]

0.95
[0.02-1.00]
0.2 [0.1-0.6]

0.94
[0.43-0.99]
0.2 [0.1-0.7]

0.97
[0.41-1.00]
0.5 [0.3-1.5]

1.00
[0.83-1.00]
1 [0.6-1]

0.99
[0.60-1.00]
1 [1-3]

1.00
[0.79-1.00]
0.5 [0.3-1]

1.00
[0.85-1.00]
1 [1-3]

0.99
[0.54-1.00]
0.5 [0.3-0.7]

0.92
[0.03-0.99]
0.3 [0.2-0.9]

0.98
[0.08-1.00]
0.3 [0.2-0.8]

0.99
[0.25-1.00]
0.6 [0.4-1.9]

1.00
[0.92-1.00]
0.2 [0.2-0.3]

1.00
[0.96-1.00]
0.1 [0.1-0.2]

1.00
[0.78-1.00]
0.2 [0.1-0.6]

1.00
[0.98-1.00]
0.3 [0.9-0.2]

1.00
[1.00-1.00]
0.1 [0.1-0.2]

1.00
[1.00-1.00]
0.1 [0.1-0.2]

1.00
[1.00-1.00]
0.0 [0.0-0.1]

1.00
[1.00-1.00]
0.1 [0.1-0.4]

1.00
1.00
1.00
1.00
[1.00-1.00]
[1.00-1.00]
[1.00-1.00]
[1.00-1.00]
VDV=Ventilation Defect Volume, VV=Ventilation Volume, CV=Coefficient of
Variation, ICC=Intraclass Correlation Coefficient, CI=Confidence Interval, C2=Cluster
2, C3=Cluster 3, C4=Cluster 4, C5=Cluster 5.
*Semi-automated VDV=Cluster 1, Semi-automated VV=Sum of Clusters 2-5
Table 3-5 shows the SDD for measurements obtained by manual and semi-automated
segmentation. For manual segmentation, the SDD or the minimum change that could be
measured confidently in individual asthma, COPD and CF subjects that were not due to
technological or observer measurement variability (measurement error) was 310mL and
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480mL for 3He VDV and VV, respectively. For the semi-automated method, the SDD or
the minimum change that could be measured confidently in individual asthma, COPD
and CF subjects was 110mL and 30mL for 3He VDV and VV, respectively.
Table 3-5 Smallest detectable difference for manual and semi-automated segmentation
All
Asthma
COPD
CF
Parameter
(n=15)
(n=5)
(n=5)
(n=5)
Manual
VDV L (±SD)
0.31
0.03
0.34
0.42
VV L (±SD)
0.48
0.20
0.52
0.63
Semi-automated
VDV* L (±SD)
0.11
0.05
0.16
0.08
VV* L (±SD)
0.03
0.02
0.02
0.05
C2 L (±SD)
0.01
0.01
0.01
0.02
C3 L (±SD)
0.02
0.01
0.01
0.02
C4 L (±SD)
0.01
0.00
0.00
0.01
C5 L (±SD)
0.00
0.00
0.00
0.00
VDV=Ventilation Defect Volume, VV=Ventilation Volume, C2=Cluster 2, C3=Cluster
3, C4=Cluster 4, C5=Cluster 5.
*Semi-automated VDV=Cluster 1, Semi-automated VV=Sum of Clusters 2-5
Table 3-6 shows the Dice coefficients for manual and semi-automated segmentation.
Dice coefficients (D) were higher for repeated semi-automated segmentation than for
repeated manual segmentation measurements for both VDV (manual: D=.71; semiautomated: D=.88) and VV (manual: D=.95; semi-automated: D=1.00). The Dice
coefficient for manual and semi-automated VDV was 0.44 and the Dice coefficient for
manual and semi-automated VV was 0.91.
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Table 3-6 Dice coefficients for manual and semi-automated segmentation
All
Asthma
COPD
CF
Parameter
(n=15)
(n=5)
(n=5)
(n=5)
Manual – Manual
VDV
0.71 (0.09)†
0.69 (0.12)
0.74 (0.05)
VV
0.95 (0.03)†
0.97 (0.00)
0.92 (0.02)
Semi-automated – Semi-automated
VDV*
0.88 (0.06)
0.82 (0.03)
0.92 (0.04)
0.89 (0.06)
VV*
1.00 (0.00)
1.00 (0.00)
1.00 (0.00)
1.00 (0.00)
Manual – Semi-automated
VDV
0.36 (0.20)
0.15 (0.15) 0.52 (0.10)** 0.42 (0.11)
VV
0.90 (0.06)
0.95 (0.01)
0.88 (0.08)
0.87 (0.04)
*Semi-automated VDV=Cluster 1, Semi-automated VV=Sum of Clusters 2-5, †One
repetition of manual segmentation

3.4

Discussion

In contrast to the homogenous 3He MRI signal intensity observed in healthy subjects with
normal lung function,

3

He MRI of subjects with respiratory disease results in

heterogeneous signal intensity throughout the lung, which may be a result of small airway
occlusion, mucous plugs, airway wall thickening and inflammation or bullous disease.
Related to this, is the fact that there is significant functional information in the regions of
middle-intensity, and both hyper- and hypo-intense signal regions that have not yet been
quantitatively or spatially exploited. The development and validation of 3He image
analysis techniques, or the use of widely available and well established image processing
algorithms, that quantify heterogeneous signal information are required to fully
characterize the important ventilation information contained in the image, and may
enable a better understanding of the physiological changes that occur in disease
longitudinally and in response to treatment.

Here we evaluated the spatial and

quantitative agreement of a semi-automated segmentation method with manual
segmentation for the evaluation of 3He and 1H MRI of asthma, COPD and CF subjects
and report: 1) 3He manual and semi-automated VDV and VV measurements that were not
statistically significantly different, and were significantly correlated with good
agreement, 2) significantly higher intra-observer reproducibility for semi-automated
compared to manual measurements and high inter-observer reproducibility, 3) smallest
detectable differences that were lower for semi-automated measurements, and, 4) high
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Dice coefficients for manual and semi-automated VV, indicating excellent spatial
overlap.
3

He MRI measurements for asthma, COPD and CF subjects generated by manual and

semi-automated segmentation were not significantly different and were significantly and
strongly correlated and in good agreement. A small but insignificant bias was detected
by Bland-Altman analysis that may be due to the manual observers’ tendency to classify
hypo-ventilated areas as defects in some subjects and in some image slices and not in
others, or the inclusion of regions of signal loss associated with the pulmonary vascular
structures, not included with manual segmentation,38 by the K-means approach.
However, it is important to note that the inclusion of pulmonary vascular structures as
ventilation defects may not be a critical consideration for serial studies.

The

improvement in segmentation time afforded by the semi-automated approach and the
finding that the lung can be reliably segmented in a number of respiratory diseases,
demonstrates the potential for 3He MRI segmentation in large scale, multi-centre clinical
evaluations.
We also observed that intra-observer reproducibility of the 3He measurements was
significantly higher for semi-automated segmentation compared to the manual approach,
and inter-observer reproducibility was high for the semi-automated method and higher
than previously reported manual results.43 Clearly, segmentation methods that provide
high intra-/inter-observer reproducibility are required for future studies involving large
subject numbers and multiple research centers such that reliable measurements can be
obtained from multiple observers independent of the level of experience. To better
understand if the improvements in measurement reproducibility afforded by semiautomated segmentation could be translated to practical use, the SDD was determined for
both manual and semi-automated measurements, and the semi-automated method
developed here reported a lower SDD as compared to manual results. For serial studies it
is important to be confident that the changes measured between imaging time-points are
not due to measurement error.

Therefore, future 3He serial studies should utilize

segmentation methods with low measurement error to detect the important functional
measurement changes that occur following intervention or during disease progression.
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Furthermore, the excellent reproducibility and very low SDD for 3He VV suggests that
this measurement could be utilized in future studies for the analysis of treatment effects
in individual subjects.
Finally, we demonstrated high Dice coefficients between the semi-automated and manual
segmentation results. This finding suggests that along with the higher intra- and interobserver reproducibility of the volume measurements obtained by the semi-automated
method, the segmentation results are also highly spatially reproducible. However, we
also reported low Dice coefficients between the manual and semi-automated VDV
segmentation results for the asthma subjects and moderate Dice coefficients for the
COPD and CF subjects. The lack of spatial correspondence between the two methods,
particularly in the asthma subjects, is likely due to the small size of the ventilation
defects. It should be noted that K-means clustering is a histogram-based segmentation
approach, thus very small areas of signal void may be included as defects by the semiautomated method but overlooked due to the small size by the manual observer.
Therefore, the excellent spatial and quantitative agreement between manual and semiautomated segmentation suggests that semi-automated or automated segmentation
methods are important for future 3He imaging studies and should be utilized as we
transition to 129Xe MRI.
Although the semi-automated 3He segmentation method is very promising, we must
acknowledge that the physiological rationale for selecting the initial cluster number was
based on the expert observer’s visual assessment, and not based on a more objective
approach. However, we have previously evaluated K-means with the initial user input of
4 to 10 clusters and the hierarchical K-means approach described here, and determined
that hierarchical K-means provided the highest correlation and lowest Bland-Altman bias
with manual segmentation.
In conclusion, we employed a straightforward combination of previously developed,
well-described and widely available methods, namely hierarchical K-means, seeded
region-growing and non-rigid registration, to 3He MRI to enable semi-automated
segmentation of the unique functional information this method provides. Reproducible
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and robust segmentation methods that can be applied across many respiratory conditions
are urgently needed for larger scale pulmonary functional MRI studies.
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3.6

Supplementary Tables

Table 3-S3-1 Comparison of 3He VDV and VV generated by manual segmentation with
K-means clustering with 4 to 10 clusters and hierarchical K-means using Pearson
correlation coefficients and Bland-Altman analysis
Pearson Correlation
Bland-Altman
Coefficients
Analysis
Parameter
r
p-value
Bias Lower CI Upper CI
VDV L
4 Clusters
0.67
0.0001
-0.08
-0.06
0.21
5 Clusters
0.79
0.0001
-0.04
-0.06
0.14
6 Clusters
0.73
0.0001
-0.02
-0.09
0.14
7 Clusters
0.75
0.0001
-0.01
-0.10
0.12
8 Clusters
0.80
0.0001
-0.004 -0.10
0.09
9 Clusters
0.76
0.0001
-0.01
-0.12
0.10
10 Clusters
0.76
0.0001
-0.02
-0.12
0.09
Hierarchical K-means
0.84
0.0001
-0.006 -0.10
0.08
VV L
4 Clusters
0.80
0.0001
-0.09
-0.22
0.03
5 Clusters
0.89
0.0001
-0.06
-0.15
0.04
6 Clusters
0.88
0.0001
-0.04
-0.14
0.06
7 Clusters
0.89
0.0001
-0.03
-0.12
0.07
8 Clusters
0.91
0.0001
-0.01
-0.11
0.08
9 Clusters
0.88
0.0001
-0.007 -0.11
0.09
10 Clusters
0.88
0.0001
-0.001 -0.10
0.10
Hierarchical K-means
0.91
0.0001
-0.01
-0.10
0.08
VDV=Ventilation Defect Volume, VV=Ventilation Volume, r=Pearson correlation
coefficient, CI=95% Confidence Interval.
Significance (p<.05).

111

CHAPTER 4
Using the segmentation algorithm developed in Chapter 3, here we evaluated a group of
COPD subjects using 3He MRI prior to and immediately following bronchodilator
therapy.
The contents of this Chapter have been previously published in Radiology and permission
to reproduce the article was granted by the Radiological Society of North America
(RSNA®) and is provided in Appendix C.
M Kirby, L Mathew, M Heydarian, R Etemad-Rezai, DG McCormack and G Parraga.
Evaluating Bronchodilator Effects in Chronic Obstructive Pulmonary Disease Quantified
using Hyperpolarized Helium-3 Magnetic Resonance Imaging. Radiology 2011;
261(1):283-92.

4

Chronic Obstructive Pulmonary Disease: Quantification
of Bronchodilator Effects by using Hyperpolarized 3He
MR Imaging
4.1

Introduction

Chronic obstructive pulmonary disease (COPD) is characterized by progressive
expiratory flow limitation that develops due to the combined effects of large and small
airway dysfunction, and increased lung compliance due to the permanent destructive
changes of emphysema.1

Gas trapping and dynamic lung hyperinflation are major

consequences of decreased expiratory airflow that often lead to many of the disabling
symptoms associated with COPD, such as dyspnea and limitation of exercise capacity.2;3
After smoking cessation, bronchodilators are the first-line therapy in the symptomatic
management of COPD,3 and assessment of acute response to bronchodilators is often
based on spirometry measurements of the forced expiratory volume in 1 s (FEV1). While
spirometry provides the most common primary endpoint for clinical trials evaluating
therapeutic response, relatively poor correlations have been reported between FEV1 and
other clinical measurements of COPD.4-6 In other words, symptomatic relief following
bronchodilators often occurs with only modest improvements in FEV1,7-9 underscoring
the apparent discordance between spirometry and COPD symptoms, quality of life and
functional measurements.
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The discordance between spirometry and COPD symptoms, as well as the limitation of
standard measures of expiratory airflow for evaluating the regional nature of
bronchodilator response is motivating the evaluation of new methods,10;11 including those
derived from non-invasive imaging.12-15 For example, Computed Tomography (CT) has
been used to evaluate changes in airway morphology after administration of
salbutamol12;13 and tiotropium,14;15 and showed greater post-bronchodilator response in
COPD patients with mainly airways disease compared to those with mainly
emphysema.16

Additionally, a recent single photon emission computed tomography

(SPECT)-CT and multiple breath nitrogen washout study17 reported no significant change
in ventilation heterogeneity after tiotropium administration.
Pulmonary magnetic resonance imaging (MRI) using hyperpolarized helium-3 (3He) has
emerged as a functional imaging method providing high spatial and temporal resolution1823

images of the lung.

Regional ventilation abnormalities are clearly visualized as

decreased 3He signal in the lung that can be scored or quantified as a ventilation defect
percent (VDP)19 or percent ventilated volume (PVV).24
abnormalities have been previously evaluated in COPD,

25-30

3

He MRI ventilation

with measurements that are

sensitive to the pathological changes that accompany COPD,24 have high same-day and
short-term reproducibility,20;21 and detect significant longitudinal changes over two years
before changes in FEV1 are observed.18 Because of previous reproducibility20;21 and
longitudinal findings,18 we hypothesized that 3He MRI would provide the necessary and
sufficient spatial and temporal sensitivity as well as precision to detect any potential
regional functional lung changes after bronchodilator therapy. Therefore, our aim was to
evaluate short-acting bronchodilator effects in COPD using hyperpolarized 3He MRI,
spirometry and plethysmography.

4.2
4.2.1

Materials and Methods
Subjects

All subjects provided written informed consent to the study protocol approved by the
local research ethics board and Health Canada, and the study was compliant with the
Personal Information Protection and Electronic Documents Act (PIPEDA, Canada) and
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the Health Insurance Portability and Accountability Act (HIPAA, USA). The use of an
onsite 3He gas polarizer (HelispinTM; GE Healthcare, Durham, NC) was provided to
Robarts Research Institute through an agreement with GE Healthcare for which we pay
$100,000 ($CDN) annually.
Fourteen subjects with a clinical diagnosis of COPD who were ex-smokers with a
smoking history of at least 10-pack-years, and were GOLD stage II-IV were enrolled.
Subjects were required to withhold both short-acting and long-acting bronchodilators the
morning of the study. Pre-bronchodilator MRI was performed immediately following
pulmonary function tests; post-bronchodilator MRI and pulmonary function tests were
performed 25 minutes (±2 minutes) after administration of 400 μg salbutamol
(Salbutamol Sulphate USP; Apo-Salvent CFC Free Inhalation Aerosol, Apotex Inc.,
Toronto, Ontario/Canada) inhaled via a spacer device.

4.2.2

Pulmonary Function Tests

Spirometry was performed using an ndd EasyOne spirometer (ndd Medizintechnik AG,
Zurich, CH) according to the American Thoracic Society (ATS) guidelines. Static lung
volumes and diffusing capacity of carbon monoxide (DLCO) were measured using body
plethysmography (MedGraphics Corporation. 350 Oak Grove Parkway St. Paul, MN
USA).

4.2.3

Image Acquisition

MRI was performed on a whole body 3.0 Tesla Excite 12.0 MRI system (GEHC,
Milwaukee, WI USA) with broadband imaging capability as previously described21 and
3

He MRI was enabled using a single channel, rigid elliptical transmit/receive chest coil

(RAPID Biomedical GmbH, Wuerzburg Germany).

It is important to note that we

endeavored to minimize the potential for differences in the levels of inspiration between
the breath-hold scans for each subject by: 1) training and practice for all subjects prior to
MRI related to the inspiration breath-hold maneuver from functional residual capacity
(FRC), and, 2) continuous coaching and monitoring at the MR bedside by a pulmonary
function technologist during all inspiration breath-hold scans. Because of this extensive
coaching, no correction for differences in inspiration levels between breath-hold scans for
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individual subjects was required. Pulse oximetry was used to measure arterial oxygen
saturation (Sa02) for all subjects during scanning sessions and considered an adverse
event occurred when Sa02 decreased below 88% at any time during the scanning session.
Study withdrawal was required when Sa02 decreased to 80% for 10 seconds or longer.
Conventional 1H MRI was performed prior to hyperpolarized 3He MRI with subjects
scanned during 1.0 L breath-hold of 4He/N2 using the whole body radiofrequency (RF)
coil and 1H fast spoiled gradient recalled echo sequence (16s total data acquisition,
repetition time (TR) / echo time (TE) / flip angle = 4.7 ms / 1.2 ms / 30o, field-of-view
(FOV) = 40 × 40 cm, matrix 256 × 128, 14 slices, 15 mm slice thickness, 0 gap), as
previously described.21
Prior to 3He MRI, a polarizer system (HeliSpin™, GEHC, Durham, NC) was used to
polarize 3He gas to 30—40 % and doses (5 mL/kg body weight) were administered in 1.0
L Tedlar bags diluted with ultrahigh purity, medical grade nitrogen (Spectra Gases,
Alpha, NJ). As previously described,21 hyperpolarized 3He MRI coronal static ventilation
images were acquired during breath-hold of a 1L 3He/N2 mixture (14s data acquisition,
TR / TE / flip angle = 4.3 ms / 1.4 ms / 7o, bandwidth = 31.25 kHz, FOV = 40 × 40 cm,
matrix 128 × 128, 14 slices, 15 mm slice thickness, 0 gap).

4.2.4
3

Image Analysis

He MRI pulmonary ventilation semi-automated segmentation was performed using

custom software generated using MATLAB R2007b (The Mathworks Inc., Natick, MA,
USA), as previously described.31 Briefly, and as shown in the schematic in Figure 4-1,
3

He MR images were evaluated using K-means cluster analysis,32 similar to previously

described methods for 3He MRI segmentation,33-35 to classify the 3He MRI voxel
intensity values into clusters ranging from 1 to 5, representing gradations of signal
intensity from no signal (Cluster 1, C1) and hypo-intense signal (Cluster 2, C2) to hyperintense signal (Cluster 5, C5), and generating a 3He voxel cluster map (Figure 1B). To
obtain the external contour of the thoracic cavity to differentiate ventilation defects (C1)
from the edge of the lung, 1H MR images were segmented using a seeded region-growing
algorithm36 and registered to the 3He MR ventilation images as previously described.37
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VDP was generated using ventilation defect volume (VDV or C1) normalized to the
thoracic cavity volume as previously described.19 For the remaining ventilation clusters,
the segmented

1

H thoracic cavity volume was used to generate cluster percent

representing a normalized 3He cluster volume for the lung. All measurements were
performed by the same observer (MK) blinded to subject and time point with time point
randomized to reduce any potential measurement bias. The observer (MK) had three
years experience performing manual 3He MRI segmentation and one year experience
developing and performing semi-automated 3He MRI segmentation. Reproducibility of
the semiautomated method was determined on the basis of the pre- salbutamol
intraobserver variability of five repeated measurements for five COPD subjects. The
smallest detectable difference (SDD), or the minimum change in 3He measurements that
could be measured confidently in individual patients-not due to observer measurement
variability, for five of the COPD subjects was 2% for VDP and 0.4%, 1%, 0.6%, and
0.3% for clusters 2–5, respectively.

Figure 4-1 Overview of 3He MRI pulmonary ventilation semi-automated segmentation
3
He MRI (A) and 3He cluster map (B) generated by semi-automated cluster analysis and
segmentation for all slices. 3He ventilation defect volume (VDV)=cluster 1, ventilation defect
percent (VDP)=cluster 1 normalized to the thoracic cavity volume.

4.2.5

Statistical Methods

Multivariate analysis of variance (MANOVA) and repeated measures analysis of
variance (ANOVA) was performed for comparison of pre- and post-salbutamol
pulmonary function and lung volume measurements using SPSS 16.00 (SPSS Inc.,
Chicago, IL, USA LEAD Technologies, Inc., Chicago, IL). A two-way mixed design
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ANOVA was used to determine the interactions between subjects and treatment, imaging
slice and treatment, as well as bronchodilator response group and treatment for all 3He
MRI measurements using SPSS 16.00. Effect size (ES) calculations allow the magnitude
of an effect to be compared between disparate types of measurements.38 Therefore, for
comparison of the magnitude of the treatment effect between pulmonary function and
imaging measurements, treatment ES was calculated as the ratio of the mean difference
between pre- and post-salbutamol measurements and the pooled standard deviation for all
subjects, calculated using Hedges’ g as shown in Equation 4-1:
g=

x post − x pre

(1)

(n post − 1) SD post 2 + (n pre − 1) SD pre 2
n post + n pre − 2

where x pre and x post are the mean pre- and post-salbutamol measurement for all
subjects, respectively, SD pre and SD post are the standard deviations of the pre- and postsalbutamol measurements for all subjects, respectively, and n pre and n post are the
number of subjects evaluated pre- and post-salbutamol, respectively. The SDD, defined
as the smallest difference that can be measured with prospectively determined confidence
that is not due to measurement error (variability), was calculated for five repeated presalbutamol 3He VDP measurements according to Eliasziw et. al.39 and shown in
Equation 4-2:
SDD ≥ zα 2 SEM int ra

(2)

where zα is 1.96 corresponding to a significance level of α =.05 and SEM int ra is the
standard error of measurement due to intra-observer variability and is calculated as
shown in Equation 4-3:
SEM int ra = σˆ e 2

(3)

where σˆ e 2 is the intra-observer repeated measures variance. Linear regression (r2) and
Spearman correlation coefficients (r) were used to determine the relationships between
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pulmonary function and 3He MRI measurements using GraphPad Prism version 4.00
(GraphPad Software Inc version 4.00, San Diego, CA, USA). In all statistical analyses,
results were considered significant when the probability of making a Type I error was
less than 5% (p < 0.05).

4.3

Results

Demographic characteristics are provided in Table 4-1 for 14 COPD ex-smokers (GOLD
Stage II n=5; GOLD Stage III n=8; GOLD Stage IV n=1).
Table 4-2 shows mean pulmonary function and 3He MRI measurements for all subjects
and Table 4-S1 provides a subject listing of all measurements. Statistically significant
post-salbutamol changes were observed for FEV1 (p=.001, ES=.22), TLC (p=.04, ES=.34), and FRC (p=.03, ES=-.10).
Table 4-1 Subject Demographics
All Subjects (±SD) [range]
(n=14)
Age yrs
70 (6) [61-77]
Males
70 (6) [61-77]
Females
71 (6) [64-77]
Male Sex
8
-2
BMI kg·m
24.9 (3.8) [17.6-31.4]
FEV1 L
1.23 (0.50) [0.63-2.18]
FEV1%pred
45 (12) [28-61]
FVC L
2.98 (0.83) [1.52-4.44]
FVC %pred
83 (12) [65-107]
FEV1/FVC
41 (10) [22-60]
TLC L
7.12 (1.27) [4.82-8.96]
TLC %pred
122 (20)[101-175]
IC L
2.21 (0.54) [1.39-3.09]
IC %pred
83 (16) [58-108]
FRC L
4.89 (1.22) [3.14-7.27]
FRC %pred
155 (42) [110-243]
RV L
3.83 (0.94) [2.63-5.25]
RV %pred
170 (53) [104-285]
DLCO%pred
43 (19) [20-89]
SD=Standard Deviation, BMI=Body Mass Index, FEV1= Forced Expiratory Volume in
1s, %pred=Percent Predicted, FVC= Forced Vital Capacity, TLC= Total Lung Capacity,
IC= Inspiratory Capacity, FRC= Functional Residual Capacity, RV= Reserve Volume,
DLCO=Carbon Monoxide Diffusion Capacity of the lung.
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Table 4-2 Pre- and post-salbutamol measurements

Parameter

PreSalbutamol
(n=14)

PostSalbutamol
(n=14)

Significance of
Difference
(p)

Effect
Size

Pulmonary Function Measurements
FEV1 L (±SD)
1.23 (0.50)
1.35 (0.57)
0.001+
0.22
+
FVC L (±SD)
2.98 (0.83)
3.06 (0.85)
0.46
0.10
TLC L (±SD)
7.05 (1.22)
6.62 (1.26)†
0.04+
-0.35
IC L (±SD)
2.15 (0.58)
2.02 (0.66) †
0.39+
-0.21
FRC L (±SD)
4.89 (1.22)
4.61 (1.22) †
0.03+
-0.23
†
+
RV L (±SD)
3.79 (0.91)
3.59 (0.85)
0.23
-0.23
Hyperpolarized 3He MRI
VDP % (±SD)
28 (7)
24 (9)
<0.0001‡
-0.50
Cluster 2 % (±SD)
15 (2)
14 (2)
0.01‡
-0.50
Cluster 3 % (±SD)
31 (5)
32 (5)
0.03‡
0.20
‡
Cluster 4 % (±SD)
19 (4)
22 (5)
<0.0001
0.66
Cluster 5 % (±SD)
8 (3)
9 (3)
0.02‡
0.33
FEV1= Forced Expiratory Volume in 1s, FVC= Forced Vital Capacity, TLC= Total Lung
Capacity, IC= Inspiratory Capacity, FRC= Functional Residual Capacity, RV= Reserve
Volume, VDP=Ventilation Defect Percent, †n=13
+
Repeated measures ANOVA, ‡Two-way mixed design repeated measures ANOVA.
Figure 4-2 shows two of the central coronal 3He MRI slices, where the trachea and two
main bronchi are clearly visible with 3He ventilation displayed in red, registered to the
greyscale 1H MRI of the thorax for each of five representative subjects (S1 and
S2=GOLD II, S3 and S4=GOLD III and S5=GOLD IV) before and after salbutamol
administration. The change in 3He gas distribution after salbutamol is readily apparent in
the right and left apical regions for S1 and S5 and right mid apex for S3, whereas there is
little change visible for S2 and S4 for the two slices shown. To ensure that the increased
distribution of 3He gas post-salbutamol administration was not due to differences in the
volume of polarized gas administered at each time-point, we calculated the total pixel
intensity for each lung image, including the trachea and major airways, from the image
pixel intensity frequency histograms, as well as the total moles of polarized gas delivered
for each subject time-point (data not shown). These estimations showed that the amount
of polarized gas administered and inhaled was not significantly different between timepoints (p=.87). The signal-to-noise ratio for each pre- and post-salbutamol image pair
was also not statistically significantly different (p=.12). To minimize the potential of
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introducing intensity variations due to B1-field inhomogeneity, subjects were located in
the same position within the coil between imaging time-points.

Figure 4-2 3He MRI pre- and post-salbutamol
Pre- and post-salbutamol 3He MRI (red) registered to coronal thoracic 1H MRI (grey
scale) for five representative COPD subjects. Two center slices for GOLD Stage II
COPD (S1, S2), GOLD Stage III (S3, S4), and GOLD Stage IV COPD (S5).
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Table 4-2 shows mean normalized pre- and post-salbutamol 3He measurements and
Table 4-S2 (online) shows the mean pre- and post-salbutamol 3He volume and signal
intensity measurements. There was a significant decrease in VDP following salbutamol
administration (p<.0001, ES=-.50), and there was no relationship between postsalbutamol changes in VDP and image slice (as a region of interest) (p=.30), indicating
no bias for any measurable changes with respect to image slice. Following salbutamol
administration, there was a significant decrease in 3He C2 (p=.01, ES=-.50), and
significant increases in 3He C3 (p=.03, ES=-.20), C4 (p<.0001, ES=-.66) and C5 (p=.02,
ES=-.33). Based on the pre-salbutamol intra-observer variance, the SDD or the minimum
change in 3He measurements that could be measured confidently in individual subjects not due to observer measurement variability for five of the COPD subjects (n=1 stage II,
n=4 stage III) was 2% for VDP and 0.4%, 1%, 0.6% and 0.3% for C2-5, respectively.
As shown in Figure 4-3, there were significant and moderate Spearman correlations
between baseline 3He VDP and post-salbutamol changes in FEV1 (r=-.77, p=.001) and
between baseline FEV1%pred and post-salbutamol changes in FEV1 (r=.56, p=.04). There
was also a significant correlation between the changes measured in 3He C2 and changes
in FEV1 (r=-.62, p=.02) and FVC (r=-.59, p=.03).

Figure 4-3 Correlation between baseline FEV1 %pred and VDP and the post-salbutamol
change in FEV1.
BL FEV1%pred is significantly correlated with Δ FEV1 (r=.60, r2=.36, p=.02, y=0.006x0.13) (A), BL VDP is significantly correlated with Δ FEV1 (r=-.68, r2=.46, p=.008, y=0.01x+0.42) (B). Dotted lines indicate the 95% confidence intervals.
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Recently published ATS and European Respiratory Society (ERS) guidelines define a
significant bronchodilator response as an increase in post-salbutamol FEV1 and/or FVC
greater than 200mL and 12%.40 Accordingly, five subjects were classified as
bronchodilator responders (BR) and nine subjects were classified as bronchodilator nonresponders (BNR). As shown in Tables 4-3, and Table 4-S1, mean reductions in VDP
and C2, and corresponding increases in C3-5 were demonstrated for both BR and BNR
subjects. As shown in Figure 4-4, VDP was significantly lower for BR compared to
BNR at baseline and post bronchodilator (p=.03). As depicted by the parallel slopes for
pre- and post-salbutamol measurements shown in Figure 4, there was no significant
difference between BR and BNR for post-salbutamol change in 3He MRI (VDP, C2-5,
p>.05). It is important to point out that there was a single BNR subject that showed a
240ml and 12% improvement in FEV1 (just missing the greater than 12% change in FEV1
requirement for BR), and when this subject was re-categorized as BR the reported results
remained the same. It is also worth noting that there were no significant differences
between BR and BNR for baseline FEV1 (p=.44) or DLCO (p=1.00).

Figure 4-4 Mean changes in VDP for BR
and BNR.
3
He VDP pre- and post-salbutamol for BR
(black) and BNR (grey).
Means
calculated for all subject slices and error
bars are 95% confidence intervals of the
mean.
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Table 4-3 Subject listing of changes in spirometry and 3He MRI measurements after
salbutamol administration
3
Subject
Spirometry
He MRI
∆ FEV1
∆ FVC
∆ VDP ∆ C2
∆ C3
∆ C4
∆ C5
L
%*
L
%*
%
%
%
%
%
All Subjects
0.12
10
0.07
2
-4
-1
1
3
1
BR
1
0.14
11
0.46
14
2
-1
-1
0
0
3
0.18
16
0.42
13
2
-1
0
0
-2
5
0.32
15
0.36
10
-14
-2
2
9
5
7
0.18
25
0.24
16
0
1
1
0
-1
10
0.27
22
0.49
21
-11
-4
4
6
4
ALL
0.22
11
0.36
14
-4
-1
1
3
1
BNR
2
0.02
2
-0.01
0
0
0
1
0
-1
4
0.04
6
-0.25
-11
2
-1
0
-1
-1
6
0.00
0
-0.32
-12
3
-1
-2
0
-1
8
-0.06
-7
-0.07
-3
-6
-3
3
5
1
9
0.24
12
0.35
9
-2
0
-2
2
2
11
0.08
9
0.11
3
-8
0
-5
9
4
12
0.06
8
-0.08
-4
-20
-2
10
10
2
13
0.13
9
0.07
2
-3
-1
-1
2
3
14
0.07
4
-0.76
-17
-6
1
7
0
-2
ALL
0.06
5
-0.11
-3
-5
-1
1
3
1
*
%=Percent change from baseline absolute value in litres
BR=Bronchodilator Responder, BNR=Bronchodilator Non-Responder
Significant bronchodilator response defined as an increase in FEV1 and/or FVC greater
than 200mL and 12% from pre-salbutamol values according to ATS/ERS 40.

4.4

Discussion

In this pilot functional MRI evaluation of bronchodilator effects in COPD, we made a
number of observations and report the following: 1) significant post-bronchodilator
improvements in both spirometry and 3He MRI measurements of gas distribution, and
their effect sizes, 2) a significant relationship between 3He VDP and changes in FEV1
post-salbutamol, and, 3) changes in

3

He MRI post-bronchodilator that were not

significantly different for BR and BNR subgroups.
First, and as might be expected from previous work that demonstrated modest
improvements in lung function in patients with COPD following bronchodilator
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therapy,7;10;11;41-43 we observed statistically significant changes in mean FEV1, FRC, and
TLC. At the same time, significant decreases in 3He MRI VDP and C2 and significant
improvements in 3He MRI C3-5 were measured, suggesting regional gas distribution
improvements throughout the lung.

Additionally, the 3He gas distribution changes

occurred in different slices for each subject with no detected bias for specific regions of
gas distribution improvements. This finding is in agreement with a recent CT study15 that
demonstrated regionally dispersed airway wall structural alterations post-bronchodilator.
Moreover, when ES was evaluated, which allows the magnitude of the treatment effect to
be compared between disparate types of measurements, 3He MRI measurements provided
greater ES than FEV1. We also observed an overall mean change in VDP and all 3He
ventilation cluster measurements greater than the SDD indicating that the measured
improvement in 3He distribution post-salbutamol was not due to measurement error or
lack of reproducibility. Although this study did not include a control arm, it is important
to note that 11 of the 14 subjects evaluated here previously participated in a
reproducibility study20 approximately 2 years prior to pre- and post-salbutamol imaging.
In this previous study, the mean change in VDV for these subjects, approximately 7
minutes after scan, was 1 mL – not a significant or clinically relevant change. For the
same 11 subjects reported here, the mean change in 3He VDV (C1) was 62 mL. Taken
together, these results strongly suggest that the changes following treatment observed
here were not due to either scan-rescan variability or the intra-observer variability of the
measurement technique. We must also point out that although this is the first reported
study demonstrating improvements in 3He gas distribution following bronchodilator
therapy in COPD, previous 3He MRI studies have demonstrated changes in 3He gas
distribution following bronchial provocation tests with methacholine in asthma and
following therapy in cystic fibrosis subjects.25-29 Taken together, these imaging-based
treatment response studies indicate that functional MRI may be considered for evaluating
new respiratory therapies in clinical trials.
Second, we also observed a significant negative correlation between the baseline VDP
and changes in FEV1 post-salbutamol, and a significant positive correlation between
baseline FEV1 and changes in FEV1. These results suggest that subjects demonstrating
the greatest improvement in FEV1 post-salbutamol were those with milder disease. A
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recent CT study also evaluated a large number of COPD ex-smokers as part of the
National Emphysema Treatment Trial and in accordance with our MRI results,
demonstrated that significant bronchodilator reversibility was more likely in patients with
higher FEV1.44
Finally, we detected post-bronchodilator improvements in 3He VDP and gas distribution
that were not significantly different for the five BR and nine BNR subjects. Based on
this imaging finding, it appears that even COPD patients without a clinically relevant
improvement in FEV1 show improved regional gas distribution, post-bronchodilator. In
fact, both groups showed the same mean improvement in 3He MRI measurements.

This

important finding suggests that measurements derived from non-invasive imaging detect
functional lung changes that enable a better understanding of the COPD lung and its
regional response to therapy which may be important for drug development and drug
treatment trials in COPD. Future functional MRI studies with larger sample sizes will
help to confirm and extend these important findings.
We acknowledge that this pilot study is limited by the small number of subjects studied
and the fact that the analysis was restricted mainly to subjects with stage II and III
COPD. Another limitation is the lack of a true reference standard for the measurement of
treatment effects in COPD, such as dyspnea scores and measurements of exercise
tolerance for direct comparison to 3He MRI measurements to evaluate the clinical
meaning of the imaging changes.

In other words, whether improvements in gas

distribution are related to clinical or symptomatic improvement remains to be established
in a larger study. We note that subjects were provided training for inspiration breath-hold
scanning, they performed practice breath-holds and received coaching during breath-hold
MRI. Clearly, reproducible and comparable breath-hold volumes is critically important
for acute and chronic therapy repeated studies. We also acknowledge that although 3He
MRI ventilation defect measurements have been previously reported to have high sameday reproducibility20 in the majority of subjects included in this study, the prospective
inclusion of a control group would have strengthened the conclusion that changes postsalbutamol observed here were directly attributable to bronchodilator treatment. Another
important consideration is the high cost and limited access of 3He gas, however, it is
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important to note that hyperpolarized
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Xe MRI is a less expensive and more readily

available approach.
In conclusion, our results suggest that noninvasive pulmonary functional 3He MRI
provides a way to measure acute treatment effects by quantifying 3He gas distribution
before and after therapy.
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4.6

Supplementary Tables

Table 4-S4-1 Subject listing of pre- and post-salbutamol pulmonary function and hyperpolarized 3He MRI measurements
Pre-Salbutamol
Pulmonary Function Tests
Subject
1
2
3
4
5
6
7
8
9
10
11
12
13
14

FEV1
(L)
1.26
1.13
1.16
0.63
2.18
1.04
0.72
0.88
2.06
1.22
0.85
0.71
1.4
1.92

FVC
(L)
3.22
3.13
3.18
2.31
3.65
2.69
1.52
2.23
4.06
2.28
3.87
2.27
2.92
4.44

TLC
(L)
7.7
7.45
7.59
7.66
7.88
5.8
4.82
6.51
8.19
5.3
8.96
7.6
5.61
7.59

IC
(L)
2.56
1.39
1.85
1.69
3.08
2.03
1.39
2.09
3.09
2.17
1.7
1.75
2.39
2.93

FRC
(L)
5.15
6.06
5.57
5.97
4.8
3.77
3.43
4.42
5.1
3.14
7.27
5.85
3.22
4.66

Post-Salbutamol
3

Hyperpolarized He MRI
RV
(L)
4.02
4.1
4.02
5.25
2.95
3.14
3.09
3.92
4.06
2.86
5.11
5.11
2.63
2.81

VDP
(%)
27
38
23
36
26
34
23
31
13
26
31
37
20
29

C2
(%)
14
10
14
15
15
13
15
18
14
20
15
17
14
13

C3
(%)
32
20
37
31
26
29
32
33
38
32
35
28
35
25

C4
(%)
19
20
20
13
23
17
20
14
25
17
14
13
23
22

C5
(%)
7
12
6
5
11
7
9
5
10
6
5
5
8
10

Hyperpolarized 3He MRI

Pulmonary Function Tests
FEV1
(L)
1.4
1.15
1.34
0.67
2.5
1.04
0.9
0.82
2.3
1.49
0.93
0.77
1.53
1.99

FVC
(L)
3.68
3.12
3.6
2.06
4.01
2.37
1.76
2.16
4.41
2.77
3.98
2.19
2.99
3.68

TLC
(L)
7.37
7.56
7.74
6.7
5.25
4.71
6.41
7.53
4.9
8.31
5.9
5.49
8.19

IC
(L)
2.71
1.34
1.93
1.31
1.73
1.61
1.97
3.06
2.23
1.77
1.09
2.26
3.19

FRC
(L)
4.67
6.22
5.81
5.39
3.52
3.1
4.44
4.48
2.67
6.54
4.82
3.23
5.01

RV
(L)
3.82
4.63
3.99
4.36
2.77
2.76
4.08
3.08
2.16
4.66
3.52
2.52
4.3

VDP
(%)
29
38
25
38
11
37
23
25
11
15
23
17
17
24

C2
(%)
13
10
14
14
13
13
16
15
14
16
15
16
13
14

C3
(%)
31
20
38
30
28
27
32
36
36
37
30
38
34
32

C4
(%)
20
20
20
12
31
17
20
18
27
23
23
23
25
22

FEV1= Forced Expiratory Volume in 1s, FVC= Forced Vital Capacity, TLC= Total Lung Capacity, IC= Inspiratory Capacity,
FRC= Functional Residual Capacity, RV= Reserve Volume, VDP=Ventilation Defect Percent, C2=Cluster 2, C3=Cluster 3,
C4=Cluster 4, C5=Cluster

C5
(%)
7
11
4
5
16
6
8
6
12
9
9
7
12
8
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Table 4-S4-2 Pre- and post-salbutamol 3He volume and signal intensity measurements
Pre-Salbutamol
Parameter
Volume (L)
SI (x1012)
VDV (±SD)
1.76 (0.54)
0.48 (0.22)
Cluster 2 (±SD)
0.92 (0.16)
1.18 (0.20)
Cluster 3 (±SD)
1.93 (0.53)
2.63 (0.69)
Cluster 4 (±SD)
1.16 (0.34)
5.25 (0.89)
Cluster 5 (±SD)
0.48 (0.18)
8.73 (1.11)
SI=Signal Intensity, VDV=Ventilation Defect Volume

Post-Salbutamol
Volume (L)
SI (x1012)
1.51 (0.71)
0.60 (0.31)
0.87 (0.18)
1.72 (0.28)
1.98 (0.42)
3.86 (1.00)
1.33 (0.34)
7.68 (1.31)
0.53 (0.20)
11.86 (1.59)
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CHAPTER 5
In the same group of COPD ex-smokers evaluated using 3He MRI pre- and postbronchodilator therapy in Chapter 4, here we further evaluated the regional effects of
bronchodilator administration in COPD using 3He MRI ADC.
The contents of this Chapter have been previously published in the Journal of Applied
Physiology and permission to reproduce the article was not required by The American
Physiological Society.
M Kirby, M Heydarian A Wheatley, R Etemad-Rezai, DG McCormack and G Parraga.
Evaluating Bronchodilator Effects in Chronic Obstructive Pulmonary Disease using
Diffusion-Weighted Hyperpolarized Helium-3 Magnetic Resonance Imaging. J. Appl.
Physiol. 2012; 112(4):651-7.

5

Evaluating
Bronchodilator
Effects
in
Chronic
Obstructive Pulmonary Disease using Diffusion-weighted
Hyperpolarized Helium-3 Magnetic Resonance Imaging
5.1

Introduction

Chronic obstructive pulmonary disease (COPD) is characterized by progressive
expiratory flow limitation that develops as a result of the lung’s inflammatory response to
inhaled toxic gases and particles, primarily from tobacco smoke.1 Airflow limitation may
be caused by a number of factors such as lumen occlusion via mucus plugs,2 structural
alteration of the airway wall resulting in encroachment of the airway wall into the airway
lumen3;4 and/or a loss of elastic recoil within the lung parenchyma due to emphysematous
tissue destruction that leads to reduced tethering forces stabilizing the airways at forced
expiration.5

The prolongation of the time constants for lung emptying results in

numerous physiological and functional consequences including hyperinflation and gas
trapping as well as ventilation abnormalities that lead to many of the disabling symptoms
associated with COPD, such as dyspnea and limitation of exercise capacity.6;7
Administration of short-acting beta-agonist bronchodilators is first-line therapy in the
symptomatic management of COPD8 and this is thought to decrease airway smooth
muscle tone thereby improving lung emptying during expiration.9 While improvements
in airflow limitation and reductions in lung hyperinflation following bronchodilator
administration have been previously shown,10-12 there is still little understanding about
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the regional nature of bronchodilator response in COPD. In this regard, pulmonary
magnetic resonance imaging (MRI) using hyperpolarized helium-3 (3He) provides high
spatial and temporal resolution in vivo images of 3He gas distribution within lung in
COPD subjects.13-21
improvements

in

In COPD ex-smokers we previously observed significant
the regional

distribution

of

3

He

gas

after

bronchodilator

administration,22 however, it was unclear whether these regional improvements were
related to physiological or symptomatic improvements. The measurement of the 3He
apparent diffusion coefficient (ADC) has been demonstrated to be highly reproducible2325

and is sensitive to changes in the lung microstructure and airspace size,20;26;27

correlating with spirometry,28 diffusing capacity of carbon monoxide (DLCO),29 multislice CT measurements of emphysema,30 as well as lung surface area measurements.31
3

He MRI ADC measurements are also age-dependent,32 and reflect GOLD classification

of disease severity,13 smoking history,29 and detects gas trapping within the dependent
lung regions in COPD.33
We hypothesized that the improvements in 3He gas distribution we previously observed
after bronchodilation in COPD may be the direct source of symptomatic relief following
therapy. To help test this hypothesis, here we aimed to evaluate hyperpolarized 3He MRI
ADC as a surrogate of the extent of emphysematous tissue destruction within the newly
ventilated lung regions (post-bronchodilator) and to evaluate regional gas trapping
following

bronchodilator

administration.

We

evaluated

lung

microstructural

3

measurements using regional He MRI ADC in COPD before and after bronchodilator
administration,22 after developing image registration/segmentation methods for
quantifying ADC in the lung regions newly ventilated post-bronchodilator.

5.2
5.2.1

Materials and Methods
Subjects

All subjects were enrolled in a 3He MRI study of the acute effects of salbutamol
administration22 in which written informed consent to the protocol approved by the local
research ethics board and Health Canada was provided, and the study was compliant with
the Personal Information Protection and Electronic Documents Act (PIPEDA, Canada)
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and the Health Insurance Portability and Accountability Act (HIPAA, USA). COPD
subjects were enrolled who were ex-smokers between the ages of 50-85, with a clinical
diagnosis of COPD and were categorized according to the global initiative for chronic
obstructive lung disease (GOLD) criteria,1 with a smoking history of at least 10 packyears. Subjects were required to withhold short-acting bronchodilators the morning of
their study visit.

Pre-bronchodilator MRI was performed immediately following

pulmonary function tests, and post-bronchodilator MRI was performed 25 minutes (±2
minutes) after administration of 400 μg salbutamol inhaled via a spacer device. Digital
pulse oximetry was used to measure arterial oxygen saturation (Sa02) during scanning
sessions and a hypoxic adverse event was defined as a decrease in Sa02 below 88% at any
time during imaging. Study withdrawal was required when Sa02 decreased to 80% for 10
s or longer.

5.2.2

Pulmonary Function Tests

Spirometry was performed using an ndd EasyOne spirometer (ndd Medizintechnik AG,
Zurich, CH) reporting forced expiratory volume in 1 second (FEV1) and forced vital
capacity (FVC) with a minimum of three acceptable spirometry maneuvers with the best
FEV1 and FVC selected for analysis according to the American Thoracic Society (ATS)
guidelines. Total lung capacity (TLC), inspiratory capacity (IC), functional residual
capacity (FRC) and residual volume (RV) were measured using body plethysmography
(MedGraphics Corporation, 350 Oak Grove Parkway St. Paul, MN USA).

5.2.3

Image Acquisition

MRI was performed on a whole body 3.0 Tesla Excite 12.0 MRI system (GEHC,
Milwaukee, WI USA) with broadband imaging capability as previously described.34 All
helium imaging employed a whole body gradient set with maximum gradient amplitude
of 1.94 G/cm and a single channel, rigid elliptical transmit/receive chest coil (RAPID
Biomedical GmbH, Wuerzburg Germany). The basis frequency of the coil was 97.3
MHz and excitation power was 3.2 kW using an AMT 3T90 RF power amplifier (GEHC,
Milwaukee WI USA). Subjects were positioned supine in the MR scanner and Sa02 was
used to monitor arterial blood oxygenation levels during all MRI maneuvers. For both 1H
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and 3He MRI, subjects were instructed by a pulmonary function technologist to inhale a
gas mixture from a 1.0 L Tedlar bag (Jensen Inert Products, Coral Springs, FL) from
FRC, and image acquisition was performed under breath-hold conditions –a period of 8
to 15s.
Coronal proton (1H) MRI was performed prior to hyperpolarized 3He MRI with subjects
scanned during breath-hold after inspiration of a 1.0 L 4He/N2 gas mixture using the
whole body radiofrequency (RF) coil and 1H fast spoiled gradient recalled echo sequence
(16s total data acquisition, repetition time (TR) / echo time (TE) / flip angle = 4.7 ms /
1.2 ms / 30o, field-of-view (FOV) = 40 x 40 cm, matrix 256 x 128, 14 slices, 15 mm slice
thickness, 0 gap), as previously described.35
Prior to 3He MRI, a polarizer system (HeliSpin™, GEHC, Durham, NC) was used to
polarize 3He gas to 30—40 %. As previously described,36 hyperpolarized 3He MRI
diffusion-weighted images were acquired in breath-hold after inspiration of a 1.0 L
3

He/N2 mixture (does 5 mL/kg body weight) using a fast gradient-echo method (FGRE)

with centric k-space sampling. Two interleaved images were acquired (14s total data
acquisition, TR/TE/flip angle = 7.6 ms/3.7 ms/8o, FOV = 40 x 40 cm, matrix 128 x 128, 7
slices, 30 mm slice thickness), with and without additional diffusion sensitization (G =
1.94 G/cm, rise and fall time = 0.5 ms, gradient duration = 0.46 ms, Δ = 1.46 ms, b = 1.6
s/cm2).

5.2.4
3

Image Analysis

He MRI ADC analysis was performed using MATLAB R2007b (The Mathworks Inc.,

Natick, MA, USA).

To ensure ADC was generated for voxels corresponding to

ventilated lung regions, k-means cluster algorithm,36 previously developed for 3He MRI
segmentation,22;37;38 was applied to the non-diffusion-weighted images to obtain a binary
mask for each slice. The resulting binary masks were applied to the corresponding nondiffusion-weighted images, and the ADC maps were generated on a voxel-by-voxel basis
according to Equation 5-1:
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ADC =

1  S0 
ln 
b  S 

(1)

where S 0 is the segmented non-diffusion-weighted image, S is the diffusion-weighted
image and b = 1.6 s/cm2.
An overview of the 3He MRI analysis methodology is provided in Figure 5-1. To
minimize the potential for differences in the levels of inspiration between pre- and postsalbutamol imaging, extensive coaching was performed between the breath-hold scans
for all subjects. Pre- and post-salbutamol ADC maps were registered using landmarkbased image registration. Briefly, the center slice defined as the slice that clearly showed
the carina and primary bronchi, was identified in the non-diffusion-weighted images for
each imaging time-point and displayed side-by-side. Fiducial markers were identified on
both the pre- and post-salbutamol 3He images based on the carina and a translation
operation was used to transform the post-salbutamol image for registration with the
corresponding landmark in the pre-salbutamol image. The resultant transformation was
then applied to the 3He ADC maps for all slices. The trachea and visible major airways
were removed semi-automatically using a region of interest tool (function roipoly in
MATLAB) permitting ADC calculation within the lung parenchyma.
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Figure 5-1 3He MRI Image Analysis Methodology
Subject is 74 yrs old female with Stage II COPD (FEV1 =47%pred, FVC=92%pred,
FEV1/FVC=39%, DLCO=20%pred). 3He ADC maps pre- and post-salbutamol, binary
ventilation mask of lung regions of interest (ROI) with 3He signal at both time-points
following registration of pre- and post-salbutamol ADC maps, 3He ADC maps for the
previously ventilated (ADCP) lung ROI pre- and post-salbutamol, and 3He ADC maps for
newly ventilated (ADCN) lung ROI post-salbutamol with the CT density masks to outline
areas with attenuation values less than -950 HU. CT images were acquired 19 months
following pre- and post-salbutamol imaging.

Whole lung (WL) ADC values were determined for each slice and then averaged to
obtain a single ADC for each subject. Following registration of the pre- and postsalbutamol ADC maps, the lung regions of interest (ROI) with 3He signal at both timepoints were identified as the intersection of the pre- and post-salbutamol maps; mean
ADC within those ROI was generated for each slice and then averaged to obtain a
previously ventilated ADC (ADCP) for both pre-salbutamol and post-salbutamol
conditions.

Lung ROI with 3He signal at both time-points were used as a binary

ventilation mask on the post-salbutamol ADC maps to calculate mean ADC in newly
ventilated ROI post-salbutamol (ADCN). To ensure that ADC estimates were generated
for the newly ventilated lung regions post-salbutamol, and to minimize the contribution
of patient movement or breath-hold mismatch between imaging time-points, we used a
morphological closing algorithm on the post-salbutamol ADC maps (function imclose in
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MATLAB) with a disked-shaped structuring element with radius=1. The resultant binary
masks were applied to the ADC maps of the newly ventilated regions post-salbutamol,
and mean ADCN was determined.

5.2.5

Statistical Methods

All statistical analyses were performed using IBM SPSS Statistics 19.0 (IBM Inc.,
Chicago, IL). Multivariate analysis of variance (MANOVA) and repeated measures
analysis of variance (ANOVA) were performed for comparison of pre- and postsalbutamol pulmonary function measurements. Statistical comparisons of mean pre- and
post-salbutamol WL ADC and ADCP measurements were performed using a two-way
mixed design repeated measures ANOVA with imaging time-point (pre- and postsalbutamol) treated as the within-subject factor and subject treated as the betweensubjects factor.

Comparison between ADCP and ADCN post-salbutamol were also

performed using a two-way mixed design repeated measures ANOVA with region of
interest (previously ventilated or newly ventilated post-salbutamol) treated as the withinsubject factor and subject treated as the between-subjects factor. Anatomical differences
in ADC within the regions of the lung ventilated at both time-points were quantified by
determining the mean ADC in the most posterior slice and by calculating the absolute
difference in ADC between the most anterior and the most posterior slice (ΔAP).
Comparisons between mean ADC in the most posterior slice and ΔAP pre- and postsalbutamol were determined using a two-tailed Wilcoxon signed rank t-test. Spearman
correlation coefficients were used to determine the relationship between ADC and
pulmonary function measurements. In all statistical analyses, results were considered
significant when the probability of making a Type I error was less than 5% (p < 0.05).

5.3

Results

All subjects completed both scanning sessions and there were no serious or severe breathhold related or other adverse events reported, nor were there any other adverse events that
required subjects to withdraw from the study.

Table 5-1 shows study subject

demographics and mean pulmonary function measurements (n=3 Stage II, n=6 Stage III,
and n=1 Stage IV) before and after salbutamol administration. Statistically significant
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post-salbutamol changes were observed for FEV1 (p=.007), TLC (p=.02), FRC (p=.02)
and RV (p=.02).
Table 5-1 Subject Demographics
Pre-Salbutamol
Post-Salbutamol
Significance of
Parameter
(±SD) [range]
(±SD) [range]
Difference (p)*
(n=10)
(n=10)
Age yrs
70 (6) [61-77]
Male Sex
4
BMI kg·m-2
25 (4) [18-30]
FEV1 L
1.11 (0.42) [0.63-2.06] 1.23 (0.49) [0.67-2.30]
0.007
FVC L
2.67 (0.71) [1.52-4.06] 2.80 (0.86) [1.76-4.41]
0.20
FEV1/FVC
0.41 (0.09) [0.27-0.53] 0.45 (0.12) [0.32-0.70]
0.08
TLC L
6.68 (1.21) [4.82-8.19] 6.20 (1.12) [4.71-7.74]
0.02
IC L
2.10 (0.49) [1.39-3.09] 1.99 (0.60) [1.09-3.06]
0.23
FRC L
4.56 (1.11) [3.14-5.97] 4.21 (1.04) [2.67-5.81]
0.02
RV L
3.81 (0.89) [2.63-5.25] 3.31 (0.75) [2.16-4.36]
0.02
BMI=Body Mass Index, FEV1=Forced Expiratory Volume in 1s, FVC=Forced Vital
Capacity, TLC=Total Lung Capacity, IC=Inspiratory Capacity, FRC=Functional
Residual Capacity, RV=Reserve Volume
*
Repeated measures ANOVA
Figure 5-2 shows representative 3He ADC maps pre- and post-salbutamol for a single
subject and arrows identify visually obvious alterations in gas distribution. Figure 5-3A
shows mean pre- and post-salbutamol 3He MRI ADC measurements for all subjects.
There was no significant difference detected for WL ADC post-salbutamol (p=.516). As
shown in Table 5-2, no significant correlations were detected between the change in WL
ADC post-salbutamol and the change in pulmonary function measurements. However,
there was a significant correlation between pre-salbutamol WL ADC and the change in
IC (r=-.68, p=.03).
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Figure 5-2 3He WL ADC pre-salbutamol and post-salbutamol.
Subject is a 64 year old male with Stage III COPD (pre-salbutamol: FEV1=38%pred,
FVC=73%pred, TLC=115%pred, FRC=147%pred, RV=179%pred, DLCO=41%pred; postsalbutamol:
FEV1=43%pred, FVC=84%pred, TLC=110%pred, FRC=133%pred,
RV=170%pred). Pre- and post-salbutamol WL ADC maps with the corresponding mean
ADC measurement shown below for each image slice.

Table 5-2 Correlation between the post-salbutamol change in ADC and the change in
pulmonary function measurements
Spearman Correlation Coefficients (r)
Parameter
WL ADC (cm2/s)
WL ADCp (cm2/s)
TLC L
0.515 (0.133)
0.782 (0.011)
IC L
0.139 (0.707)
0.285 (0.427)
FRC L
0.636 (0.054)
0.806 (0.007)
RV L
0.479 (0.166)
0.733 (0.020)
Figure 5-4 shows for two representative COPD subjects the WL pre- and postsalbutamol ADC maps and the newly ventilated ADCN maps post-salbutamol. There was
no statistically significant difference between ADCN and ADCP post-salbutamol
(ADCP=.506±.072cm2/s, ADCN=.504±.082 cm2/s, p=1.00), nor were there any significant
interactions between the ADCN and ADCP post-salbutamol (p=.18), indicating no
significant change in ADC within the newly ventilated lung areas following
administration of salbutamol.
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Figure 5-3 Regional 3He MRI ADC
Mean WL ADC measurements, mean WL ADC for the previously ventilated (ADCP)
lung regions of interest (ROI), mean ADPP for the most anterior and posterior slices, and
the absolute change in ADCP for the most anterior to the most posterior slice (ΔAP) preand post-salbutamol for all subjects (A). Mean ADCP pre- and post-salbutamol for the
most anterior and most posterior slices. Error bars are the standard error of the mean (B).
Mean ΔAP for ADCP pre- and post-salbutamol. Error bars are the standard error of the
mean (C).

For ADCp measurements, there was a statistically significant decrease detected postsalbutamol (p=.013) (Figure 3A). As shown in Figure 5-3B, the mean ADC in the most
posterior slice was significantly lower post-salbutamol (p=.049). Additionally, ΔAP was
significantly higher post-salbutamol (p=.020), indicating that there was a difference in the
mean ADC in the AP direction following bronchodilator therapy (Figure 3C). As shown
in Table 5-2 and Figure 5-5, Spearman correlation coefficients indicate that the postsalbutamol change in ADCp was significantly correlated with the change in TLC (r=.782,
p=.011), FRC (r=.806, p=.007) and RV (r=.733, p=.020).
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Figure 5-4 Regional 3He MRI ADC
WL center slice 3He ADC maps pre-and post-salbutamol, 3He ADC maps for newly
ventilated (ADCN) lung ROI post-salbutamol, and CT density masks to outline areas
with attenuation values less than -950 HU, for a 74 yrs old female and a 64 year old
male both with Stage III COPD. CT images were acquired 15 months following preand post-salbutamol imaging for the 74 yr old subject and 28 months following preand post-salbutamol imaging for the 64 yr old subject.
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Figure 5-5 Correlations between the post-salbutamol change in 3He ADCp and
pulmonary function measurements.
ΔADCp was significantly correlated with ΔTLC (r=.782, p=.011, r2=.387, p=.055,
y=26.99x-0.30) (A), ΔFRC (r=.806, p=.007, r2=.604, p=0.008, y=23.13x-0.19) (B) and
ΔRV (r=.733, p=.020, r2=0.379, p=0.039, y=28.91x-0.31) (C). Dotted lines represent the
95% confidence intervals for the regressions.

5.4

Discussion

We previously evaluated COPD ex-smokers using hyperpolarized 3He MRI before and
after bronchodilator administration and provided evidence of significant and visually
obvious regional improvements in
therapy.22

3

He gas distribution following bronchodilator

Here, we extend these previous findings and explore the relationship of

regional hyperpolarized 3He ADC measurements in the pre- and post-bronchodilator lung
ROI. We aimed to determine if the newly ventilated regions were different than lung
ROI participating in ventilation before bronchodilation and based on previous
histological findings,31 we used the 3He MRI ADC as a surrogate measurement of tissue
microstructure. We made a number of observations and report the following: 1) mean
WL ADC did not change post-salbutamol, 2) mean ADC in newly ventilated lung regions
post-salbutamol was not different than mean ADC in previously ventilated lung regions,
3) mean ADC in previously ventilated lung regions was significantly different
(improved) post-salbutamol, and, 4) ADC anterior-posterior gradients significantly
improved post-salbutamol.
First, we observed no significant change in WL ADC measurements following
salbutamol administration, and this finding suggests that the alveolar structures that are
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probed by the 3He gas post-salbutamol are not more emphysematous than the other lung
ROI probed by the 3He gas pre-salbutamol. In other words, this finding indicates that the
bronchodilator was delivered primarily to the more normal lung regions. However, the
3

He ADC has been previously demonstrated to be sensitive to gas trapping in the

dependent lung regions33 that may lead to a reduction in the ADC measurement postbronchodilator.

Because we observed no change in WL ADC post-salbutamol we

developed methods to determine regional ADC as a way to tease apart the potential
combinations of reduced hyperinflation and gas redistribution to lung ROI with greater
emphysematous destruction.
We applied these image processing methods and post-salbutamol observed no significant
difference between mean ADC in the newly ventilated lung ROI (ADCN) and mean ADC
in the previously ventilated ROI (ADCP), indicating that the lung ROI that participated in
gas distribution following administration of salbutamol were not more emphysematous
than lung ROI participating in gas distribution before salbutamol administration. These
findings must be interpreted with an understanding of the limitations of the relatively
large voxel size (3.2mm x 3.2mm x 30mm) in this analysis and these images that reflect
the contributions of approximately 70,000 alveoli, estimated based on the mean size of a
single normal alveolus to be 4.2 x10 −6 cm3 as previously described.39 Additionally, the
contribution of subject motion between imaging time-points and the volume of gas within
the lungs during the breath-hold imaging may have contributed to measurement
uncertainty. Nevertheless, we have previously evaluated the ADC measurement within
one week with no treatment (scan, 7-day rescan)19 and determined that the estimated
standard uncertainty (standard deviation) of both the WL ADC and the center slice ROI
ADC measurement in Stage II and Stage III COPD subjects was 0.001cm2/s, indicating
that the ADC measurement in subjects with moderate to severe disease was remarkably
reproducible. A previous study evaluating asthma subjects using 3He MRI and multidetector CT demonstrated that there was a regional association between 3He MRI
ventilation abnormalities and CT measurements of gas trapping.40

Although it is

plausible in the current study that emphysematous tissue destruction may have reduced
the tethering or stabilization of the airways at forced expiration5 resulting in trapped gas
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and ventilation defects in severe COPD subjects, our findings suggest that defect regions
that become ventilated in response to bronchodilators do not reflect more severe
emphysema.

Moreover, these results indicate that the bronchodilator acted on the

obstructed small airways directly, allowing improvements in gas trapping and regional
hyperinflation, and not on airways obstructed due to surrounding emphysema. As shown
in Figure 5-3, both emphysematous and healthy regions of the lung participated in gas
distribution post-salbutamol. We must acknowledge that the very small number of newly
ventilated voxels in the post-salbutamol images may lead to biased ADC values due to a
low signal-to-noise ratio (SNR),41 although this would have generated a bias towards
higher ADC and this was not observed in the current study. To minimize the potential
for bias, we used a morphological closing algorithm to remove the contribution of small
isolated voxels to the mean ADC value and an SNR threshold greater than 15 for ADC
generation was used as previously described.41
We also observed a statistically significant reduction (improvement) in mean ADCP postsalbutamol.

This small but significant improvement may be explained by both a

reduction in the physical size of the airspaces due to the increased distribution of the 3He
gas (thereby effectively diluting the 1L dose) and bronchodilator-induced reduction in
lung hyperinflation. To determine whether the significant change in ADCP was related to
a reduction in lung hyperinflation, we compared the anatomical distribution of ADC
values pre- and post-salbutamol.

As previously described,33 airspaces are less

compressible in COPD compared to healthy subjects in the dependent lung likely because
of gas trapping. We detected a statistically significant increase in ΔAP and decreased
mean ADCP in the most posterior slice post-salbutamol, suggesting that bronchodilator
administration improved the expiratory time constants which in turn allowed the
dependent lung regions to empty more completely. Moreover, as demonstrated in our
previous study,22 there was no bias for any measurable changes in the distribution of 3He
gas post-salbutamol with respect to image slice, indicating that the reduction in mean
ADCP within the dependent lung regions was not due to increased gas distribution in
these regions. The significant correlation detected between the change in ADCP and
changes in TLC, FRC and RV post-salbutamol lends support to the hypothesis that the
reduction in ADCP post-salbutamol was related to a reduction in gas trapping.
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We recognize that this work was limited by the small number of subjects and the fact that
the analysis was restricted mainly to subjects with moderate to severe COPD. Therefore,
caution should be exercised in extrapolating these results to the general COPD population
and more specifically to patients with mild and very severe disease. An important
limitation of 3He MRI is that large regions of the lung are not ventilated or are poorly
ventilated preventing calculation of the ADC within these regions, and this may be due to
small airway occlusion, mucous plugs, airway wall thickening and inflammation, severe
emphysema or bullous disease.

We also acknowledge that without the inclusion of

dyspnea scores and measurements of exercise tolerance for comparison to 3He MRI, the
clinical meaning of the imaging changes remains unclear. In other words, the changes in
ADC measures post-salbutamol are related to clinical or symptomatic improvement
remains to be established in a larger study. The lack of validation by an imaging
reference method, such as computed tomography (CT) or proton MRI with ultra-short
echo times, is also a limitation of this work. Clearly, the direct comparison of functional
and structural 3He MRI, proton UTE MRI, CT and symptomatic measurements will allow
for a better understanding of the improvements in 3He gas distribution observed after
bronchodilator administration.

It must also be noted that 3He MRI ADC provides

structural information not only at the scale of the alveoli, probing emphysematous tissue
destruction, but also at the scale of the alveolar ducts and the respiratory and terminal
bronchioles,27 thus restriction to diffusion will differ in each of these structures and
alveoli diffusion will be more restricted than diffusion in the bronchioles. An important
point related to this is the issue of collateral ventilation. In patients with emphysema
there is substantial collateral ventilatory pathways,42 including the pores of Kohn, canals
of Lambert and the interbroncial communications of Martin. Although with the very
short diffusion times utilized in this study where the atoms are likely to be confined to the
alveoli and acinar structures, measurements of 3He diffusion over longer times and
distances are likely sensitive to collateral ventilation paths,43;44 which are significant in
patients with emphysema. A better understanding of collateral ventilation and collateral
pathways is required and noninvasive imaging measurements such as 3He MRI ADC may
be useful for treatment planning, such as bronchoscopic airway bypass, and evaluating
treatment effects.

Reproducible and comparable breath-hold volumes are critically
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important for acute and chronic therapy repeated studies and therefore training and
instruction for inspiration breath-hold scanning was performed during breath-hold MRI.
Although 3He MRI has limited access and high cost which has thus far restricted
translation of this functional imaging method,
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Xe MRI is a less expensive and more

readily available approach with which these reported findings can be directly tested.
In summary, this study demonstrated that 3He MRI provides a noninvasive approach for
the evaluation of regional structure-function measurements after bronchodilator
administration in COPD subjects. Lung micro-structure in ROI that participate in gas
distribution only after bronchodilator administration was not more emphysematous than
ROI participating in gas distribution before bronchodilator use. We also demonstrated
that regional ADC reflect significant changes in the anterior-posterior gradient following
bronchodilator therapy and this is possibly related to a reduction in regional gas trapping.
The regional evaluation of hyperpolarized 3He MRI ADC provides insights into regional
lung microstructure for lung ROI that participate in
bronchodilator administration.

3

He gas distribution after
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CHAPTER 6
The limited and unpredictable global supply of 3He necessitates the transition to 129Xe
gas, however a direct comparison of hyperpolarized 3He and 129Xe MRI acquired in the
same subjects is required in order for us to better understand the potential of 129Xe MRI
in respiratory research. Here we quantitatively compared 3He and 129Xe MRI acquired
in the same healthy volunteers and subjects with COPD.
The contents of this Chapter have been previously published in Radiology and permission
to reproduce the article was granted by the Radiological Society of North America
(RSNA®) and is provided in Appendix C.
M Kirby, S Svenningsen, A Owrangi, A Wheatley, A Farag, A Ouriadov, GE Santyr, R
Etemad-Rezai, HO Coxson, DG McCormack and G Parraga. Hyperpolarized Helium-3
and Xenon-129 Magnetic Resonance Imaging in Healthy Volunteers and Subjects with
Chronic Obstructive Pulmonary Disease. Radiology. 2012;265(2):600-10.

6

Hyperpolarized 3He and 129Xe MR Imaging in Healthy
Volunteers and Patients with Chronic Obstructive
Pulmonary Disease
6.1

Introduction

Magnetic resonance imaging (MRI) using hyperpolarized noble gases, such as helium-3
(3He) and xenon-129 (129Xe), provides a way to acquire high spatial and temporal
resolution pulmonary images.1-4

Hyperpolarized 3He MRI has dominated for the

evaluation of gas distribution and tissue abnormalities in healthy volunteers5 and in
patients with chronic obstructive pulmonary disease (COPD),6-9 asthma,10-14 cystic
fibrosis,15-18 radiation-induced lung injury,19;20 and lung transplant.21;22 Numerous studies
have shown that 3He MRI in COPD is highly reproducible,6;23-25 sensitive to early lung
micro-structural

changes,1;26-31

and

significantly

correlates

with

established

measurements of pulmonary function,1;32 multi-slice computed tomography (CT)
measurements32 and histology measurements of emphysema.33 Furthermore, longitudinal
3

He MRI of COPD has highlighted the sensitivity of the method to progressive

worsening8;34 and shown regional improvements post-bronchodilator.35;36
Unfortunately, despite the unique potential of 3He MRI, clinical translation has not
occurred in part because of limited and unpredictable global quantities and high cost.
129

Xe gas, on the other hand, is substantially more abundant in nature existing in
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measurable quantities in the atmosphere and it is relatively inexpensive.
hyperpolarized

129

Although

Xe MRI is technically challenging because of its nearly 3-fold lower
129

gyromagnetic ratio and lower enrichment, considerable improvements in
polarization and imaging methods
were reported.38-40

37

Xe gas

have been achieved since the first clinical studies

Recently, the tolerability of a 1.0L inhaled dose of

129

Xe and

diffusion-weighted MRI measurements were reported in COPD and healthy subjects.39;40
These important results suggested that

129

Xe MRI may be very useful for examining

structural and functional abnormalities in COPD and also generated numerous hypotheses
to test.

In this investigation, we hypothesized that the different properties of

would result in significant differences in

129

129

Xe gas

3

Xe compared to He ventilation defect percent

(VDP) in COPD but not in healthy volunteers. Accordingly, here our objective was to
quantitatively compare hyperpolarized 3He and 129Xe MRI acquired within a few minutes
in healthy volunteers and subjects with COPD, and to evaluate the correlations between
3

He and 129Xe MRI measurements with spirometry and plethysmography.

6.2
6.2.1

Materials and Methods
Subjects

All subjects provided written informed consent to the study protocol approved by the
local research ethics board and Health Canada, and the study was compliant with the
Personal Information Protection and Electronic Documents Act (PIPEDA, Canada) and
the Health Insurance Portability and Accountability Act (HIPAA, USA). COPD subjects
were ex-smokers 50-85 years of age, with a smoking history of at least 10 pack-years.
Pack-year was defined as the number of cigarette packs smoked per day multiplied by the
number of years smoked. Healthy volunteers were enrolled who had no history of
previous chronic or current respiratory disease. For all subjects, mean age was 71±8 yrs,
and mean age for men was 71±9 yrs and for women 72±6 yrs.

6.2.2

Pulmonary Function Tests

Spirometry was performed using an ndd EasyOne spirometer (ndd Medizintechnik AG,
Zurich, CH) according to the American Thoracic Society (ATS) guidelines.41 Static lung
volumes and diffusing capacity of carbon monoxide (DLCO) were measured using body
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plethysmography (MedGraphics Corporation. 350 Oak Grove Parkway St. Paul, MN
USA).

6.2.3

Image Acquisition

MRI was performed on a whole body 3.0 Tesla Discovery 750MR (General Electric
Health Care, Milwaukee, WI) MRI system with broadband imaging capability as
previously described.6 Subjects were instructed to inhale a gas mixture from a 1.0 L
Tedlar® bag (Jensen Inert Products, Coral Springs, New Jersey, USA) from functional
residual capacity (FRC), and image acquisition was performed in 8-15s under breath-hold
conditions. It is important to note that we endeavored to minimize the potential for
differences in the levels of inspiration between the breath-hold scans for each subject by:
1) training and practice for all subjects prior to MRI related to the inspiration breath-hold
maneuver from FRC, and, 2) continuous coaching and monitoring at the MR bedside by a
pulmonary function technologist during all inspiration breath-hold scans.
Conventional 1H MRI was performed prior to hyperpolarized

129

Xe and 3He MRI with

subjects scanned during 1.0L breath-hold of ultrahigh purity, medical grade nitrogen (N2)
(Spectra Gases, Alpha, NJ) using the whole body radiofrequency (RF) coil and 1H fast
spoiled gradient-recalled-echo sequence as previously described.6 Theoretical diffusion
coefficients for the 3He/N2 and

129

Xe/4He 50/50 mixtures were generated adopting

assumptions previously described.42
Hyperpolarized 3He MRI was enabled using a linear bird-cage transmit/receive chest coil
(RAPID Biomedical GmbH, Wuerzburg Germany). A turnkey system (HeliSpin™) was
used to polarize 3He gas to 30—40% and doses (5mL/kg body weight) were administered
in 1.0L Tedlar® bags diluted with N2. Hyperpolarized 3He MRI coronal static ventilation
images and diffusion-weighted (DW) images were acquired during breath-hold of a 1.0L
3

He/N2 mixture as previously described.6

Hyperpolarized

129

Xe MRI was enabled using a custom-made, unshielded quadrature-

asymmetric bird-cage coil model tuned to 35.34MHz similar to previous approaches43
and as previously described.44

129

Xe gas (86% enriched) was polarized to 10—60% using
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a turn-key polarizer (XeBox-E10, Xemed LLC, New Hampshire, USA).
hyperpolarized

129

Doses of

Xe gas were dispensed directly into the pre-rinsed 1.0L Tedlar® bags

pre-filled with 4He to generate a 50/50 mixture. Polarization of the diluted dose was
quantified by a Polarimeter (GEHC, Durham, NC).

129

Xe MRI coronal static ventilation

images were acquired using a 3D fast gradient-recalled-echo (FGRE) sequence with
centric phase-encoding ordering in the y direction and normal sampling in the z direction
during breath-hold of the 1.0 L 129Xe/4He mixture (14s data acquisition, TE/TR/flip angle
= 1.50 ms/6.7 ms/variable flip angle, bandwidth = 15.63 kHz, FOV = 40 × 40 cm, matrix
128 × 128, 14 slices, 15 mm slice thickness, 0 gap). DW images were obtained using a
2D FGRE sequence with centric phase-encoding ordering. Two interleaved images (16s
total data acquisition, TE/TR/flip angle = 10 ms/13.5 ms/9o, bandwidth = 31.25 kHz,
FOV = 40 x 40 cm, matrix 128 x 80, 7 slices, 30 mm slice thickness, 0 gap), with and
without additional diffusion sensitization with b = 12 s/cm2 (maximum gradient
amplitude (G) = 2.90 G/cm, gradient rise and fall time = 0.5 ms, gradient separation = 2
ms, gradient duration = 2.0 ms, diffusion time = 5 ms). The diffusion time of 5ms for
129

Xe MRI was selected based on the theoretical background for optimal gradient

sequence parameters45 and previous findings demonstrating its sensitivity to alveolar
enlargement.46 All scanning was completed within approximately 5 minutes of subjects
first lying in the scanner. Also, based on the calculations for the theoretical diffusion
coefficients for 3He and

129

Xe and the diffusion times used, the characteristic diffusion

length for He (~490μm) is comparable to
3

129

Xe (~460μm), indicating similar spatial

length scales are being investigated.
CT was performed on a 64-slice Lightspeed VCT scanner (GE Healthcare, Milwaukee,
WI USA) using a detector configuration of 64×0.625 mm, 120 kVp, 100 effective mA,
tube rotation time of 500 ms and a pitch of 1.0. A single spiral acquisition of the entire
lung was acquired from the apex to the base with subjects in the supine position and in
breath-hold after inhalation of a 1.0L Tedlar® bag of N2 from FRC. Reconstruction of the
data was performed using a slice thickness of 1.25 mm with a standard convolution
kernel.
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6.2.4
3

He and

Image Analysis
129

Xe MRI semi-automated segmentation was performed, similar to approaches

that have been previously described for quantification of lung volumes,47 using custom
software generated using MATLAB R2007b (The Mathworks Inc., Natick, MA, USA),
as previously described.48 3He MRI of COPD is typically characterized by heterogeneous
signal intensity that reflects gas distribution heterogeneity during the inspiration breathhold scan. To compare the distribution of both 3He and

129

Xe gases within the lung, we

segmented the 3He and 129Xe images based on the pixel signal intensity. Briefly, 3He and
129

Xe MRI static ventilation images were segmented using a K-means approach49 that

classified voxel intensity values into five clusters ranging from signal void (cluster 1, C1
or ventilation defect volume (VDV)) and hypo-intense (cluster 2 or partial volume) to
hyper-intense signal (cluster 5), and therefore generating a gas distribution cluster-map.
For delineation of the ventilation defect boundaries, a seeded region-growing algorithm50
was used to segment the 1H MR images of the thoracic cavity for registration to the
cluster-map and 3He and 129Xe VDP 7 were generated by VDV normalized to the thoracic
cavity volume.

3

He and

129

Xe non-diffusion-weighted (NDW) images were also

segmented using the same approach where NDW images were segmented using K-means
and registered to the corresponding 1H MRI slices for calculation of VDP.49 Apparent
diffusion coefficient (ADC) analysis was performed as previously described.36
signal-to-noise ratio (SNR) for all 3He and

129

The

Xe static ventilation and NDW and DW

images were determined by calculating the mean voxel value within a 5 x 5 cm2 voxel
region of interest (ROI) for four representative ROI within the lung parenchyma, and
dividing by the standard deviation of the voxel values for noise inside for four
representative ROI of the same size within the image background where there was no
lung structure. The ROI within the lung parenchyma and the image background were
selected independently for each slice, with exception of diffusion-weighted imaging
where the ROI was selected independently for each NDW image slice, and the
coordinates of the lung ROI were applied to the diffusion-weighted image slice. SNR
was determined for each slice and then averaged to obtain a single SNR value for each
subject. CT measurements were performed using MATLAB R2007b; the relative area
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with attenuation values below−950 HU (RA

950)

and the 15th percentile (HU15%) were

generated from the frequency distribution of Hounsfield units.

6.2.5

Statistical Methods

Multivariate analysis of variance (ANOVA) and a one-way ANOVA were performed
using IBM SPSS Statistics 20.0 (SPSS Inc., Chicago, IL, USA). A paired two-tailed ttest was used for statistical comparison for normally distributed data and a two-tailed
Wilcoxon signed rank test was used for statistical comparison for non-normally
distributed data for tests between 3He and

129

Xe VDP, ADC, and SNR using GraphPad

Prism version 4.00 (GraphPad Software Inc, San Diego, CA, USA). Normality was
determined using a Shapiro-Wilk test using IBM SPSS Statistics 20.0. A two-way
mixed-effects repeated measures ANOVA was used to determine the interactions for
VDP measured from both 3He and
agreement between 3He and

129

129

Xe MRI and imaging slice using SPSS 20.0. The

Xe VDP was evaluated using Bland-Altman plots51

generated using GraphPad Prism version 4.00. Linear regression (r2) and Pearson
correlation coefficients (r) were used to determine the relationships between and imaging
and other measurements using GraphPad. Correlation coefficients were compared52 by
calculating the Fisher’s z’ transformation for each r as shown in Equation 6-1:
z′ =

1
(log(1 + r ) − log(1 − r ))
2

(1)

where r is the correlation coefficient for 3He MRI (rHe) and 129Xe MRI (rXe). The Z value
was then calculated using Equation 6-2:
Z=

z He − z Xe
1
n−3

(2)

where zHe is the z’ of rHe, zHe is the z’ of rXe and n equals the number of subjects
compared. A Holm-Bonferroni correction53 was used for multiple paired t-tests and all
correlations. The Holm-Bonferroni adjusted p-values were determined by ordering pvalues from smallest to largest, with the smallest p-value multiplied by k, where k is the
number of hypotheses to be tested. If the resulting modified p-value was less than α
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(Type I error rate) the hypothesis was rejected. The next smallest p-value was then
multiplied by k minus 1 and the new modified p-value was compared to α. This process
was repeated until the modified p-value could not be rejected. In all statistical analyses,
results were considered significant when the probability of making a Type I error was
less than 5% (p < 0.05).

6.3

Results

All imaging procedures and maneuvers were well-tolerated and there were no serious or
severe adverse events reported. There was a single adverse event reported by a single
COPD subject (headache seven hours after completion of MRI that resolved without
treatment) and this was judged not-related to 3He or
the safety and tolerability of
tolerability of a 1.0L
40

reported.

129

129

Xe gas inhalation; the details of

Xe MRI for this study are reported elsewhere54 and

129

Xe dose (versus the 50/50 mixture used here) was previously

Table 6-1 shows subject demographics and pulmonary function

measurements for eight healthy volunteers and 10 COPD subjects (GOLD Class I n=1;
GOLD Class II n=6; GOLD Class III n=2; GOLD Class IV n=1).55

The two subject

groups were significantly different with respect to FEV1, FEV1/FVC, RV, RV/TLC, IC,
FRC and DLCO; there were no significant differences between the groups with respect to
age, sex or BMI.
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Table 6-1 Subject Demographics
Healthy Volunteers
COPD
Significance of
(n=8)
(n=10)
Difference (p)
Age yrs (±SD)
67 (10)
74 (4)
0.10
Men
63 (11)
75 (4)
Women
71 (7)
73 (6)
Male Sex n (±SD)
4
8
0.32
BMI kg·m-2 (±SD)
25.9 (2.2)
25.4 (5.0)
0.79
Pack-years yrs (±SD)
0 (0)
62 (15)
FEV1 % pred (±SD)
107 (13)
57 (24)
<0.001
FVC % pred (±SD)
106 (13)
91 (19)
0.08
FEV1/FVC (±SD)
0.75 (.04)
0.46 (.14)
<.0001
TLC % pred (±SD)
106 (11)
115 (8)
0.09
RV % pred (±SD)
105 (19)
159 (46)
0.007
RV/TLC (±SD)
0.39 (0.10)
0.53 (0.14)
0.03
IC % pred (±SD)
120 (25)
85 (31)
0.02
FRC % pred (±SD)
95 (13)
141 (35)
0.002
DLCO % pred (±SD)
103 (13)
41 (17)†
<.0001
SD=Standard Deviation, BMI=Body Mass Index, FEV1= Forced Expiratory Volume in
1s, %pred=Percent Predicted, FVC= Forced Vital Capacity, TLC= Total Lung Capacity,
RV= Reserve Volume, IC= Inspiratory Capacity, FRC= Functional Residual Capacity,
DLCO=Carbon Monoxide Diffusion Capacity of the lung. †n=7.
Significance of difference (p<.05) determined using a multivariate analysis of variance.
Fisher’s exact test was performed for categorical variables.
Figure 6-1 shows the two central coronal 3He and

129

Xe MRI slices, where the trachea

3

and two main bronchi are clearly visible, with He gas distribution displayed in red and
129

Xe gas distribution displayed in purple registered to the grey-scale 1H MRI of the

thorax for each of three representative healthy volunteers and three COPD subjects. For
the COPD subjects, regions of signal void are observed in

129

Xe MRI not qualitatively

apparent in 3He MRI; these regions are readily observed in the right mid apex for COPD
S1 and the right and left apical regions for COPD S2 and S3 for the two slices shown in
Figure 6-1.
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Figure 6-1 3He and 129Xe MRI static ventilation images of healthy volunteers and subjects
with COPD
3
He and 129Xe MRI of the two coronal centre slices, where the trachea and two main bronchi
are clearly visible, with 3He gas distribution displayed in red and 129Xe gas distribution
displayed in purple registered to the greyscale 1H MRI of the thorax for each of three
representative healthy volunteers (S1: 75 yr old female, FEV1=93%pred, FEV1/FVC=70%;
S2: 57 yr old male, FEV1=95%pred, FEV1/FVC=72%; S3: 51 yr old male, FEV1=120%pred,
FEV1/FVC=83%) and three COPD subjects (S1: 77 yr old female, FEV1=50%pred,
FEV1/FVC=20%; S2: 68 yr old female, FEV1=59%pred, FEV1/FVC=53%; S3: 71 yr old
male, FEV1=107%pred, FEV1/FVC=58%).
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Figure 6-2 shows the strong and statistically significant correlations between whole lung
(WL) 3He and

129

Xe VDP (r=.91, p<.0001) and 3He and

Although 3He and

129

129

Xe ADC (r=.97, p<.0001).

Xe VDP were significantly correlated, Bland-Altman analysis

indicates that there was a 9±8% bias (95% limit of agreement: -25%-7%) for higher VDP
for

129

Xe MRI. Table 6-2 shows mean 3He and

measurements.

129

129

Xe MRI gas distribution and ADC

Xe VDP was statistically significantly greater than 3He VDP for the

COPD subjects (p=.0003, uncorrected; p=.03, Holm-Bonferroni corrected), and

129

Xe

signal intensity cluster C3 (p=.002, uncorrected; p=.002 Holm-Bonferroni corrected) was
significantly different.
between

129

For healthy volunteers, there was no significant difference

3

Xe and He VDP (p=.56), however there was a significant difference in C4

(p=.008, uncorrected) although following Holm-Bonferroni correction this difference was
no longer significant (p=.06). For both groups, there was no relationship between the
difference in 3He and

129

Xe VDP and image slice (p=.99), indicating no bias for

differences between 3He and

129

Xe VDP for any specific image slice.

To better

understand the potential impact of any difference in pulse sequence parameters for 129Xe
(3D acquisition) and 3He (2D acquisition) MRI gas distribution measurements, we
compared 3He and

129

Xe VDP measured from NDW images, both acquired using 2D

FGRE sequences. No significant difference was observed between
129

129

Xe VDP (3D) and

Xe VDP measured from NDW images for the healthy volunteers and the COPD

subjects (p=.87) and 3He VDP (2D) and

129

Xe VDP measured from NDW images were

not significantly different for healthy volunteers (p=.50) however they were significantly
different for COPD subjects (p=.002). This result is in agreement with the 2D 3He and
3D

129

Xe MRI results that showed there was no difference between 3He and

for healthy volunteers, but for COPD subjects

129

Xe VDP

129

Xe VDP was significantly greater than

3

He VDP. Mean SNR was significantly lower for

3

He MRI (56±25, p<.0001), however importantly there was no significant correlation for

the difference between 3He and
VDP (r=.26, p=.30).

129

129

Xe MRI (33±17) as compared to

Xe SNR and the difference between 3He and

129

Xe
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Figure 6-2 Relationship between 3He MRI and 129Xe MRI VDP and ADC
A) 3He VDP was significantly and positively correlated with 129Xe VDP (r=.91,
p<.0001, r2=.82, p<.0001, y=1.4x+2.7).
B) The mean bias (±SD) between 3He and 129Xe VDP was -9±8% (lower limit=-25%,
upper limit=7%). Solid lines indicate the mean difference and dotted lines indicate
the 95% limits of agreement.
C) 3He ADC was significantly and positively correlated with 129Xe ADC (r=.97,
p<.0001, r2=.93, p<.0001, y=0.11x+0.03).
Dotted lines represent the 95% confidence intervals of the regression line.

Table 6-2 3He and 129Xe MRI Measurements
Healthy Volunteers (n=8)
129
He
Xe
SDif* (p)
MRI
MRI
3

Gas Distribution
VDP %
4 (2)
(±SD)
C2 % (±SD)
10 (1)
C3 % (±SD)
36 (5)

4 (4)
11 (5)
26 (10)

0.56 (1.00)

3

He
MRI
20 (10)

COPD (n=10)
129
Xe
SDif* (p)
MRI
34 (13)

0.003 (0.03)

0.94 (0.94)
14 (2)
15 (3)
0.30 (1.00)
0.08
34 (5)
22 (6)
0.002 (0.002)
(0.48)
C4 % (±SD)
34 (2)
40 (2)
0.008
23 (7)
20 (9)
0.05 (0.35)
(0.06)
C5 % (±SD)
16 (5)
19 (3)
0.22
10 (4)
9 (4)
0.50 (1.00)
(1.00)
ADC cm2/s
0.246
0.053
0.002
0.481
0.079
<0.0001
(±SD)
(0.021)
(0.002)†
(0.02)
(0.121)
(0.015)
(0.001)
VDP=Ventilation Defect Percent, 2=Cluster 2, C3=Cluster 3, C4=Cluster 4, C5=Cluster
5, ADC=Apparent Diffusion Coefficient
SDif=Significance of difference (p<.05) determined using a two-tailed Wilcoxon signed
rank test for gas distribution measurements and a two-tailed paired t-test for ADC
measurements.
* Holm-Bonferroni adjusted significance values in parentheses
†n = 3
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As shown in Table 6-2, WL hyperpolarized 3He and

129

Xe ADC was significantly

different for the healthy volunteers (p=.002) and the COPD subjects (p<.0001).

Mean

SNR for 3He MRI DW and NDW was 36±16 and 64±29, respectively, and for 129Xe MRI
DW and NDW were 11±6, and 28±19, respectively.
Table 6-3 Relationships between 3He and 129Xe MRI with pulmonary function
measurements
Pearson Correlation Coefficients r (p/p**)
3
129
3
He VDP %
Xe VDP %
He ADC cm2/s 129Xe ADC cm2/s
-0.84
-0.89
-0.75
-0.67
FEV1 % pred (<.0001/<.0001) (<.0001/.001)
(.0007/.002)
(.01/.01)
-0.84
-0.95
-0.86
-0.77
FEV1/FVC
(<.0001/.001)* (<.0001/.001)*
(<.0001/.001)
(.002/.004)
DLCO % pred
-0.83
-0.92
-0.95
-0.93
†
†
‡
(.0001/.001)
(<.0001/.001)
(<.0001/.001)
(<.0001/.001)¥
Significance of difference (p<.05) between 3He and 129Xe MRI correlation coefficients
for each r were calculated using the Fisher’s z transformation. *p=.01
** Holm-Bonferroni adjusted significance values
†
n=15, ‡n = 13, ¥n = 10

Table 6-3 shows Pearson correlations for 3He and

129

Xe VDP and ADC with pulmonary

function measurements. There were significant and similar correlations for 3He and
129

Xe MRI VDP with FEV1, although the relationship between VDP and FEV1/FVC was

significantly stronger for
correlations for 3He and

129

129

Xe MRI (p=.01).

There were also significant and similar

Xe MRI ADC and DLCO (Table 6-3). Figure 6-3 shows the

significant and strong relationships for 3He and

129

Xe ADC with RA950 (r=.90, p=.0005)

and HU15% (r=-.91, p=.0003) for COPD subjects only.
Theoretical diffusion coefficients were generated as previously described42 for 3He/N2
and 129Xe/4He and are summarized in Table 6-S1. The 3He-N2 diffusion coefficient in air
was 0.826cm2/s, whereas for

129

Xe-4He, the diffusion coefficient in air was 0.211cm2/s

and for air, the self-diffusion coefficient of air was 0.218cm2/s.
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Figure 6-3 Relationships between 3He and 129Xe MRI ADC with CT measurements
A) CT HU15 was significantly correlated with 3He ADC (r=-.91, p=.0003, r2=.83,
p=.0003, y=-225x-839) and 129Xe ADC (r=-.91, p=.0003, r2=.82, p=.0003, y=-1815x803).
B) CT RA950 was significantly correlated with 3He ADC (r=.90, p=.0005, r2=.80,
p=.0003, y=105x-32) and 129Xe ADC (r=.87, p=.001, r2=.76, p=.001, y=821x-47).
Dotted lines represent the 95% confidence intervals of the regression line.

6.4

Discussion

We evaluated 3He and

129

Xe MRI acquired within approximately five minutes in healthy

subjects with and without COPD, and made a number of observations: 1) significant and
strong correlations were observed between 3He and
and quantitatively

129

129

Xe MRI VDP, although visually

Xe MRI VDP was worse than 3He MRI VDP in COPD, but not in

healthy subjects, 2) significant and strong correlations were observed that were similar
for 3He and

129

Xe VDP with FEV1, but significantly stronger between

129

Xe VDP and

FEV1/FVC, and, 3) a significant and strong correlation was observed between 3He and
129

Xe ADC, both of which showed similar and significant correlations with DLCO and CT

measurements of emphysema.
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First, in COPD subjects,

129

Xe MRI gas distribution was qualitatively more regionally

heterogeneous than 3He MRI. This was not the case in healthy volunteers, where

129

Xe

and 3He MRI showed homogeneous gas distribution and very low VDP that was not
significantly different. The visually obvious differences between
also quantitatively different with

129

129

Xe and 3He were

Xe VDP significantly greater (worse) than 3He VDP

in COPD subjects, but not healthy volunteers. Importantly, these differences could not be
attributed to differences in the pulse sequences used, nor was there a bias detected for
specific anterior-posterior slices dominating this result. This unexpected result leads to
the simple question: why are these measurements different in COPD? Some explanations
might derive from the different gases themselves.

In COPD, significant airflow

limitation is thought to occur in the small conducting airways <2mm in diameter56
increasing airway resistance with the potential for regional and preferential

129

Xe gas

limitation to the distal airways. Another important consideration relates to the terminal
and respiratory bronchioles, where diffusion dominates, and the lower diffusion
coefficient of

129

Xe relative to 3He may result in slower gas movement into the distal

diseased lung regions.

Another important consideration is the role of collateral

ventilation in COPD. The lower atomic mass and higher diffusivity of 3He relative to
129

Xe may allow for regions of the lung that are not ventilated to gradually fill with 3He

over the time course of the breath-hold scan as has been shown recently by Marshall et.
al.57 Our finding that ventilation defect percent was greater for 129Xe MRI than 3He MRI,
both with 129Xe 3D and 2D image acquisition, suggests that the lower diffusivity of 129Xe
may slow the process of delayed/collateral ventilation beyond a realistic single breathhold time. To try to better understand the properties of the two gases inhaled, we
generated theoretical diffusion coefficients as previously described42 for 3He diluted with
N2 and air and

129

Xe diluted with 4He and air and compared these to the theoretical self-

diffusion coefficient of air. Taken together, these results indicated that air has a similar
estimated diffusion coefficient as

129

Xe diluted with 4He+air (within 3%), and both

diffusion coefficients are much lower than the estimated diffusion coefficient of 3He
diluted with N2+air.
between the

129

Although the exact etiology that may explain the differences

Xe and 3He MRI gas distributions in COPD are not yet established, it is

possible that the differences in diffusion coefficients might provide part of the reason for
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these observed differences and that different gas mixtures may be helpful in probing
different airway and parenchymal abnormalities. For example, the larger

129

Xe VDP in

COPD might reflect the fact that airway narrowing is less easily penetrated by 129Xe/ 4He.
Second, we reported significant and similar correlations between 3He and

129

Xe VDP

with spirometry for all subjects, however the correlation coefficient was significantly
stronger for

129

Xe VDP with FEV1/FVC. We note that during expiration in COPD,

airway narrowing is caused by the combination of many factors, including small-airway
wall thickening and obliteration, and collapse of airways secondary to the loss of lung
tissue within the lungs. FEV1/FVC is reduced in subjects with severe COPD and asthma,
and has been reported to be sensitive to airway narrowing and bronchoconstriction.58 The
finding that the 129Xe VDP correlation with FEV1/FVC was stronger than 3He VDP lends
support to the notion that the differences in diffusion coefficients of the gases might be
helpful in probing different airway and parenchymal abnormalities.
Finally, we also reported strong and significant correlations between 3He and 129Xe ADC
in the same subjects and similar correlation coefficients between 3He and
with DLCO and CT measurements. The relationship between

129

129

Xe ADC

Xe ADC and spirometry

measurements for b=12s/cm2 has been previously reported39 in COPD subjects and
healthy volunteers and similar correlation coefficients for FEV1%pred and FEV1/FVC
were observed here. However, we reported slightly higher ADC values for both healthy
volunteers and COPD ex-smokers and this may be due to the differences in the inspired
gas mixtures between the two different studies. We note that in the previously published
study, a 1.0L

129

Xe dose was used and as shown in Table E1, the estimated diffusion

coefficient of 129Xe in air was 0.138cm2/s in comparison to 129Xe diluted with 4H and air
that was used in this study with an estimated diffusion coefficient of 0.211cm2/s. In
addition, the strong correlations between 129Xe with 3He ADC and the strong and similar
correlations between both

129

Xe and 3He ADC with CT measurements of emphysema

suggest that 129Xe diffusion-weighted imaging with b=12s/cm2 is sensitive to lung microstructural abnormalities. The comparable results we observed with 3He and

129

Xe ADC

suggest that both methods are probing similar spatial dimensions which is important since
the choice of diffusion-weighted gradient can influence the measured ADC. We must
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also note that the COPD subjects investigated here showed varying degrees of
emphysema, with DLCO ranging from 17%pred to 67%pred, indicating that

129

Xe MRI as

employed in this study provided a way to measure varying degrees of emphysema.
Future studies comparing

129

Xe ADC with different b-values to 3He ADC and CT

emphysema measurements, as well as comparing the

129

Xe ADC anterior-posterior

gradients with different b-values, which has been previously shown using 3He MRI to
change following treatment in COPD,36 are required to determine the differences the
diffusion-weighting provides for probing the lung microstructure.
We recognize that there were a small number of subjects used in this study and that most
of the subjects evaluated had moderate to severe COPD. We must also acknowledge that
because all of these measurements and tests were performed in the same small subject
group, extrapolation of these results to a general COPD population cannot be confirmed
until studies with larger sample sizes are performed. Another limitation is the difference
in pulse sequences used for 3He and

129

Xe MRI. However, results obtained using NDW

images, both acquired using 2D FGRE sequences, were in agreement with the 2D 3He
and 3D 129Xe MRI acquisition results indicating that there was no difference between 3He
and

129

Xe VDP for the healthy volunteers, however for COPD subjects

129

Xe VDP was

greater than 3He VDP.
In summary, in healthy volunteers and COPD subjects there were strong correlations
between 129Xe and 3He ADC but significant differences in 129Xe and 3He gas distribution
in COPD reflecting differences in the gases as well as physiological/anatomical
abnormalities in COPD not seen in healthy volunteers.
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6.6

Appendix

Experimental measurements of the diffusion coefficient of

129

Xe (83% enriched) and air

have been previously reported by Kaushik et. al.,39 however the theoretical diffusion
coefficient of

129

Xe diluted with 4He and air has not been reported.

Using the

assumptions described in Chen et. al.,42 we estimated the diffusion coefficient of

129

Xe

diluted with 4He and air and the diffusion coefficient of 3He diluted with N2 and air as
well as the diffusion coefficient of the main gases (N2 and 02) and air.
The diffusion coefficient of gases A and B may be estimated using the following
Equation 6-3
as previously described:42

D 0 AB =

3 (kT ) 3
8
π

(1)

M A + MB
fD
,
2
2M A M B Ρσ AB Ω D

where MA and MB are the respective molecular weights of gas A and B, k is Boltzmann’s
constant, T is the absolute temperature, Ρ is the pressure, ΩD is the collision integral for
diffusion between molecules,59 σAB is the characteristic length (mean free path of a
molecule)59 and fD is a correction term and can be considered to equal 1.
Table 4 shows the estimated self-diffusion coefficients of 3He, 4He,
well as the estimated diffusion coefficient of

129

129

Xe, N2 and air, as

4

Xe diluted with He and air and in

addition, the diffusion coefficient of 3He diluted with N2 and air. The estimated selfdiffusion coefficient of air at 310K and 1 atm was 0.218 cm2/s. The estimated diffusion
coefficient of 129Xe diluted with 4He and air was 0.211 cm2/s and for 3He diluted with N2
and air the diffusion coefficient was 0.826 cm2/s.

179

Table 6-S6-1 Theoretical Diffusion Coefficients
Parameter

M (g/mol)
σ (A)

3

He

4

He

129

Xe

N2

Air

129

3
3
129
XeHeHeXe( He(N2Air
Air
Air)
Air)
3.5050 3.1745
3.131
3.879
61.7984 27.6857 28.3424 134.747
4

3
2.551
10.22

4
2.551
10.22

129
4.047
231.0

28
3.798
71.4

28.85
3.711
78.6

30.34

30.33

1.342 4.3417

3.944

5.0163

11.1971 10.9377

2.3006

0.6225 0.6225 1.257 0.8689 0.8879
2.04
1.77 0.061 0.216 0.218

0.8425
0.211

0.7282
0.826

1.0264
0.138

/k (K)
kT/
ΩD
D0 (cm2/s)
Note:

= energy parameter

0.7310
0.858
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CHAPTER 7
To better understand the morphological determinants for the ventilation differences
observed between hyperpolarized 3He and 129Xe MRI in COPD in Chapter 6, here we
evaluated the same group of COPD subjects using diffusion-weighted MRI.
The contents of this Chapter have been previously published in the Journal of Applied
Physiology and permission to reproduce the article was not required by The American
Physiological Society.
M Kirby, S Svenningsen, N Kanhere, A Owrangi, A Wheatley, HO Coxson, GE Santyr,
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Regional Visualisation of
Hyperpolarized Helium-3 and Xenon-129 Magnetic Resonance Imaging Ventilation:
Differences
in
COPD
and
Relationship
to
Emphysema.
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7

Pulmonary Ventilation Visualized using Hyperpolarized
Helium-3 and Xenon-129 Magnetic Resonance Imaging:
Differences in COPD and Relationship to Emphysema
7.1

Introduction

In chronic obstructive pulmonary disease (COPD), irreversible airflow limitation is a
consequence of increased time constants for lung emptying related to airway
narrowing/occlusion as well as loss of elastic recoil due to emphysematous tissue
destruction.1 Magnetic resonance imaging (MRI) using hyperpolarized helium-3 (3He)
provides high spatial and temporal resolution images of pulmonary ventilation and
ventilation abnormalities2-4 and with the recent advances in polarization physics,5-8
hyperpolarized xenon-129 (129Xe) MRI now also provides high resolution images of
pulmonary ventilation and transmembrane diffusion.6;9-20 The lung micro-structure can
also be probed using diffusion-weighted MRI, which takes advantage of the rapid 3He
and

129

Xe atom Brownian motion to generate apparent diffusion coefficients

(ADC),11;12;16;21-24

now a

well-established

surrogate

measurement

of

alveolar

dimensions.25 In a small group of COPD subjects it was also recently demonstrated that
there were significantly greater ventilation abnormalities measured using

129

Xe as

compared to 3He gas and this was not observed in healthy age-matched subjects.26
Moreover, in this previous work, some COPD subjects had greater 3He-129Xe ventilation
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differences than others, suggesting that patient-specific, disease-related mechanisms
might be responsible for this difference.
We still do not have a clear understanding of the etiology of noble gas MRI ventilation
defects, nor their relationship to patient symptoms, exercise capacity or other outcomes; it
is also unclear what the structural determinants or mechanisms are behind the differences
between 3He and

129

Xe ventilation in COPD.

A large number of studies have

investigated the convective and diffusive gas transport within the lung using multiplebreath washout studies27-30 and it is clear from this previous work that there are many
factors affecting ventilation distribution within the lung including the inhaled gas
physical properties. For example, gas density and viscosity affect flow resistance and
this itself is dependent on airway lumen dimensions.31 In the small airways (<2mm in
diameter) where flow is fully laminar, viscosity provides the main influence on flow
resistance. However, in the large airways where turbulent flow dominates, resistance is
mainly affected by gas density. The major site of airflow limitation in COPD occurs
within the small conducting airways

32

and therefore it is predicted that the gas viscosity

would be the most important gas physical property affecting flow resistance. However,
both the greater density and viscosity of

129

Xe gas (pure 129Xe gas has approximately 40

times greater density and 1.5 times greater viscosity than pure 3He gas)33;34 may result in
greater resistance to flow regardless of the location of airway abnormalities, and therefore
may contribute to greater

129

Xe ventilation abnormalities in comparison to 3He MRI in

COPD. Another potential mechanism responsible for 3He-129Xe ventilation differences in
COPD is the presence of emphysema and the effects of collateral ventilation.35 In
emphysema, lung tissue compliance is increased and resistance to flow through
obstructed airways is higher than through collateral pathways.36;37
To provide a better understanding of the clinical or physiological meaning of MRIderived ventilation abnormalities, we investigated the relationship between emphysema
and airway wall morphology with differences observed between hyperpolarized 3He and
129

Xe MRI gas distribution. As a first step, here we evaluated a small group of COPD

subjects26 and hypothesized that emphysematous lung regions would more readily fill
with 3He as compared to

129

Xe gas under the same physiological conditions. In other
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words, lung regions that could not be accessed by

129

Xe gas would be more

emphysematous, leading to decreased 129Xe MRI ventilation. To test this hypothesis, we
evaluated regional 3He ADC using image registration/segmentation methods38 and x-ray
computed tomography (CT) measurements of airway wall thickness and emphysema to
probe the structure-function relationships in lung regions accessed by both gases and
those that were accessed only by 3He gas.

7.2
7.2.1

Materials and Methods
Subjects

We enrolled 10 COPD subjects in a hyperpolarized 3He and

129

Xe MRI study26 and they

provided written informed consent to a protocol approved by the local research ethics
board and Health Canada, which was compliant with the Personal Information Protection
and Electronic Documents Act (PIPEDA, Canada) and the Health Insurance Portability
and Accountability Act (HIPAA, USA). COPD subjects were ex-smokers 50-85 years of
age and were categorized according to the Global initiative for chronic Obstructive Lung
Disease (GOLD) criteria 1, with a smoking history of at least 10 pack-years.

7.2.2

Pulmonary Function Tests

Spirometry was performed using an EasyOne spirometer (ndd Medizintechnik AG,
Zurich, CH) according to the American Thoracic Society (ATS) guidelines.39 Static lung
volumes and the diffusing capacity for carbon monoxide (DLCO) were measured using a
whole body plethysmograph (MedGraphics Corporation. 350 Oak Grove Parkway St.
Paul, MN USA). All spirometry and plethysmography measurements were performed
approximately 1 hour following administration of 400 μg salbutamol inhaled via a spacer
device.

7.2.3

Image Acquisition

MRI was performed on a whole body 3.0 Tesla Discovery 750MR (General Electric
Health Care, Milwaukee, WI) MRI system.40 Subjects were instructed to inhale a gas
mixture from a 1.0 L Tedlar® bag (Jensen Inert Products, New Jersey, USA) from
functional residual capacity (FRC), and image acquisition was performed during a 8-15s
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breath-hold.

To minimize the potential for differences in the levels of inspiration

between 3He and

129

Xe MRI, extensive coaching was performed prior to the imaging

sessions to ensure subjects could inspire the entire bag and throughout the duration of all
imaging sessions. To ensure that each inhalation was performed from FRC, the subjects
were instructed to perform two tidal breaths prior to inhalation from the bag. The order
of 3He and 129Xe MRI acquisition was also randomized for each subject.
3

He gas was polarized to 30—40% (HeliSpin™) and doses (5mL/kg body weight) were

administered in 1.0L Tedlar® bags diluted with medical grade nitrogen (N2) (Spectra
Gases, Alpha, NJ).

3

He MRI diffusion-weighted images were acquired using a fast

gradient-recalled-echo (FGRE) sequence immediately following inhalation of the 3He/N2
gas mixture during breath-hold conditions.40 Two interleaved images were acquired (14s
total data acquisition, repetition time (TR)/echo time (TE)/flip angle = 7.6 ms/3.7 ms/8o,
field of view (FOV) = 40 x 40 cm, matrix 128 x 128, 7 slices, 30 mm slice thickness, 0
gap), with and without additional diffusion sensitization with b = 1.6 s/cm2 (gradient
amplitude (G) = 1.94 G/cm, rise and fall time = 0.5 ms, gradient duration = 0.46 ms,
diffusion time = 1.46 ms).

129

Xe gas was polarized to 10—60% (XeBox-E10, Xemed

LLC, New Hampshire, USA) and doses (50/50
Tedlar® bags.

129

129

Xe/4He) were administered in 1.0L

Xe MRI diffusion-weighted images were acquired using a FGRE

sequence immediately following inhalation of the 129Xe/4He gas mixture.26

129

Xe gas was

diluted with 4He instead of N2 to try to reduce the differences in the physical properties of
the inhaled 3He and
in air.

129

Xe gas mixtures and better mimic the mixture of gaseous oxygen

Two interleaved images (16s total data acquisition, TE/TR/flip angle = 10

ms/13.5 ms/1o, FOV = 40 x 40 cm, matrix 128 x 80, 7 slices, 30 mm slice thickness, 0
gap), with and without additional diffusion sensitization with b = 12 s/cm2 (G = 2.90
G/cm, rise and fall time = 0.5 ms, gradient duration = 2.0 ms, diffusion time = 5 ms).26 A
low dose CT was performed on a 64-slice Lightspeed VCT scanner (GEHC, Milwaukee,
WI USA) as previously described.26

7.2.4

Image Analysis

Hyperpolarized 3He and

129

Xe MRI ADC maps were generated from diffusion-weighted

and non-diffusion-weighted images as previously described using MATLAB R2007b
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(The Mathworks Inc., Natick, MA, USA).38 To ensure ADC was generated for voxels
corresponding to ventilated lung regions, the non-diffusion-weighted images were
segmented to obtain a binary mask for each slice. The resulting binary masks were
applied to the corresponding non-diffusion-weighted images, and the ADC maps were
generated on a voxel-by-voxel basis. An overview of the image analysis methodology
adapted from38 is provided in Figure 7-1.

3

He and

129

Xe ADC maps were registered

using landmark-based image registration. The trachea and visible major airways were
removed semi-automatically permitting ADC calculation within the lung parenchyma. A
single ADC value was calculated for each subject by averaging the mean ADC for each
slice to obtain a whole lung slice-average (WL) ADC. Following registration of the 3He
and

129

Xe ADC maps, the lung regions of interest (ROI) within the ADC maps accessed

by both gases were identified as the intersection (regions of overlap) of the 3He and 129Xe
ADC maps; mean ADC within those ROI was generated for each slice and then averaged
to obtain a mean 3He ADC value accessed by both gases (ADCHX). Lung ROI accessed
by both 3He and

129

Xe were used as a binary mask on the 3He ADC maps to calculate

mean ADC in 3He only ROI (ADCHO). It is important to note that no lung regions were
accessed only by 129Xe gas. 3He and

129

Xe ventilation volume (VV)41 was generated by

summing the voxels in the segmented non-diffusion-weighted image following the
removal of the trachea and visible major airways.
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Figure 7-1 Regional 3He and 129Xe MRI image analysis methodology.
3
He and 129Xe apparent diffusion coefficient (ADC) maps, binary mask of lung regions of
interest (ROI) probed by both 3He and 129Xe following registration of 3He and 129Xe
ADC maps, 3He and 129Xe ADC maps for lung ROI probed by both 3He and 129Xe
(ADCHX), and 3He ADC maps for 3He only lung ROI (ADCHO) with the computed
tomography (CT) density masks to outline areas with attenuation values <-950 HU.
Subject is 73 yrs old male with Stage IV chronic obstructive pulmonary disease (COPD):
forced expiratory volume in 1 s (FEV1)=26%pred, forced vital capacity (FVC)=66%pred,
FEV1/FVC=29%.
CT airway and emphysema analysis was performed using VIDA’s Pulmonary
Workstation 2.0 (VIDA Diagnostics, Inc., Coralville, IA). Wall area percentage (WA%)
and lumen area (LA) was measured for the 3rd to 7th generation airways.42 The extent of
emphysema was estimated using lowest 15th percentile point of the CT lung density
histogram (HU15%).43

7.2.5

Density and Viscosity Estimates

The density and viscosity of the inspired 29Xe gas diluted with 4He and the inspired 3He
gas diluted with N2 as well as the density and viscosity of the pulmonary gases were
estimated. The density of gases may be estimated using Equation 7-1:

ρ=

MP
RT

(1)
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where M is the molar mass, P is the pressure, R is the universal gas constant and T is the
absolute temperature. The density of a mixture of gases A and B may be estimated using
Equation 7-2:

ρ AB =
where

and

ρ Aν A + ρ Bν B
ν A +ν B

are the densities of gases A and B, and

(2)

and

are the volumes of

gases A and B. The viscosity of gases may be estimated using the Chapman-Enskog
viscosity equation, as previously described33 and shown below in Equation 7-3:

µ = 26.69

1
( MT ) 2

(3)

σ C ΩD
2

where M is the molecular weight, T is the absolute temperature, ΩD is the collision
integral for diffusion between molecules34 and σC is the collision diameter. The viscosity
of a mixture of gases A and B may be estimated using Equation 7-4:
1

µ AB =

X AM

where

and

1

X Aµ AM A 2 + X B µB M B 2
1
A2

+

(4)

1
X BM B 2

are the mole fractions of gases A and B, MA and MB are the molecular

weights of gases A and B and

and

are the respective viscosities of gases A and B.

This equation was selected because it can represent with reasonable accuracy the
viscosity of a gas mixture at low or moderate pressures. For the viscosity calculations of
the 3He-N2 mixture, we used the average volume of 3He gas given to each subject
(390mL) to determine the mole fraction which was approximately 40/60, and for the
129

Xe-4He mixture it was 50/50. We also calculated the characteristic diffusion length

(L1) of the gases and gas mixtures using Equation 7-5:
L1 = 2D0 ∆
where D0 is the diffusion coefficient and Δ is the diffusion time.

(5)
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Density and viscosity calculations for the

3

He-N2 and

129

Xe-4He gas mixtures

administered at 310K and 1 atm are provided in Table 7-1. The estimated density of
3

He-N2 mixture and

129

Xe-4He mixture was 0.61kg/m3 and 2.65kg/m3, respectively, and

the estimated viscosity of 3He-N2 mixture and
2.55x10-4P, respectively.
mixture and

129

129

Xe-4He mixture was 1.99x10-4P and

The estimated characteristic diffusion length for the 3He-N2

Xe-4He mixture was 460μm and 490μm, respectively. The calculations

for the estimated diffusion coefficient of 129Xe diluted with 4He and air and the diffusion
coefficient of 3He diluted with N2 and air were reported elsewhere26 and shown in Table
7-1.
Table 7-1 Density and Viscosity Estimates
3
4
129
129
3
Parameter
He
He
Xe
N2
Air
Xe-4He
He-N2
M (g/mol)
3
4
129
28
28.85
σ (A)
2.551
2.551
4.047
3.798
3.711
3.505
3.175
ΩD
0.623
0.623
1.257
0.869
0.888
0.843
0.728
0
2
D (cm /s)
2.04
1.77
0.061
0.216
0.218
0.211*
0.826*
L1 (μm)
770†
720†
250‡
460‡
470‡
460‡
490†
μ x 10-4 (P)
2.033
2.321
2.593
1.984
2.064
2.552
1.993
ρ (kg/m3)
0.118
0.157
5.071
1.101
1.140
2.651
0.6095
M=molecular weight, σ=collision diameter,Ω D=collision integral for diffusion between
molecules, D0=diffusion coefficient, L1=characteristic diffusion length, μ=viscosity,
ρ=density.
* The diffusion coefficient of 129Xe diluted with 4He and air and the diffusion coefficient
of 3He diluted with N2 and air (21).
† diffusion time=1.46ms, ‡diffusion time=5ms

7.2.6

Statistical Methods

A two-way mixed-effects repeated measures analysis of variance (ANOVA) was used to
determine the interaction between 3He and
3

129

Xe VV as well as the interaction between

He ADC for lung ROI ventilated by both gases (ADCHX) and by 3He gas only (ADCHO)

using IBM SPSS Statistics 20.0 (SPSS Inc., Chicago, IL, USA). Linear regression (r2)
and Pearson correlation coefficients (r) were used to determine the relationships for the
difference between 3He and

129

Xe VV with CT HU15%, spirometry and ADCHO using

GraphPad Prism version 4.00 (GraphPad Software Inc, San Diego, CA, USA). In all
statistical analyses, results were considered significant when the probability of making a
Type I error was less than 5% (p < 0.05).
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7.3

Results

Table 7-2 shows subject demographics and pulmonary function measurements for all 10
COPD ex-smokers (GOLD Class I n=1; GOLD Class II n=6; GOLD Class III n=2;
GOLD Class IV n=1).
Table 7-3 shows a subject listing of mean 3He and

129

Xe WL ADC and VV, as well as

regional ADC measurements. As previously described in the same group of subjects
using static ventilation images,26 3He VV derived from non-diffusion-weighted images
was significantly greater than

129

Xe VV (3He VV=5.17L,

129

Xe VV=4.34L, p<.0001).

There was a significant interaction for VV between inhaled gas (3He and

129

Xe) and

subject (p=.04) and this finding may indicate that some COPD subjects had greater 3He
and

129

and

129

129

Xe ventilation differences than others. Importantly, the difference between 3He
Xe SNR was not significantly correlated with the difference between 3He and

Xe VV (r=-.25, p=.48).

Figure 7-2 shows 3He and 129Xe ADC maps for all slices for two representative subjects.
Visually obvious differences in ventilation between 3He and 129Xe MRI were apparent in
the subject with higher mean ADC for all slices, but to a much lesser extent in the subject
with moderate ADC values.
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Table 7-2 Subject listing of pulmonary function measurements
Subjects

Age Sex
BMI
FEV1
FVC FEV1/FVC TLC
RV
RV/TLC
IC
FRC
DLCO
(yrs)
(kg·m-2) (%pred) (%pred)
(%pred) (%pred)
(%pred) (%pred) (%pred)
1
77
F
19.8
50
76
0.50
114
156
0.63
86
135
22
2
78
M
26.5
59
82
0.52
102
145
0.52
89
112
3
79
M
23.1
52
104
0.36
114
151
0.51
69
153
50
4
76
M
30.6
77
104
0.54
114
140
0.45
128
102
5
73
M
20.8
26
66
0.29
111
229
0.77
27
189
6
77
M
18.4
34
94
0.26
132
221
0.63
54
201
17
7
68
F
23.7
59
86
0.53
115
121
0.45
121
110
43
8
76
M
29.6
35
84
0.31
123
205
0.60
70
168
44
9
67
M
32.1
75
82
0.68
105
134
0.42
92
117
67
10
71
M
29.8
107
135
0.58
115
86
0.27
109
121
42
ALL
74
25.4
57
91
0.46
115
159
0.53
85
141
41
(±SD)
(4)
(5.0)
(24)
(19)
(0.14)
(8)
(46)
(0.14)
(31)
(35)
(17)†
SD=Standard Deviation, BMI=Body Mass Index, FEV1= Forced Expiratory Volume in 1s, %pred=Percent Predicted, FVC=
Forced Vital Capacity, TLC= Total Lung Capacity, RV= Reserve Volume, IC= Inspiratory Capacity, FRC= Functional
Residual Capacity, DLCO=Carbon Monoxide Diffusion Capacity of the lung. †n=7
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Table 7-3 3He and 129Xe MRI WL and Regional ADC for all subjects
Regional 3He ADC
WL 3He MRI
WL 129Xe MRI
(cm2/s)
VV
ADC
VV
ADC
ADCHX
ADCHO
2
2
2
(L)
(cm /s)
(L)
(cm /s)
(cm /s)
(cm2/s)
Subject
1
4.25
0.608
3.70
0.095
0.600
0.645
2
5.13
0.312
5.09
0.058
0.306
0.329
3
6.03
0.534
4.99
0.086
0.511
0.620
4
5.16
0.332
4.90
0.057
0.320
0.381
5
6.06
0.575
4.80
0.092
0.572
0.600
6
5.86
0.622
4.43
0.087
0.610
0.643
7
5.05
0.503
4.39
0.086
0.508
0.474
8
6.24
0.479
4.50
0.080
0.466
0.508
9
3.10
0.290
2.85
0.057
0.274
0.297
10
4.83
0.527
3.77
0.085
0.529
0.536
5.17‡
4.34‡
0.470†
0.503†
ALL
0.478
0.078
(±SD)
(0.97)
(0.124)
(0.71)
(0.015)
(0.125)
(0.119)
WL=Whole lung, VV=Ventilation Volume, ADC=Apparent Diffusion Coefficient,
ADCHX= lung regions of interest with signal at both 3He and 129Xe time-points, ADCHO=
lung regions of interest with signal during the 3He breath-hold only.
‡ Denotes p-value < 0.0001 for comparison between WL 3He and 129Xe MRI VV
† Denotes p-value < 0.0001 for comparison between Regional 3He ADCHX and 3He
ADCHO
Figure 7-3 shows the 3He and

129

Xe ADC maps as well as the ADC map for the ROI

ventilated only by 3He for a subject with moderately severe COPD. As shown in Table
7-3, regional analysis showed that mean ADC for those regions only accessed by 3He gas
(ADCHO=0.503±0.119cm2/s) was significantly greater than mean ADC for those regions
accessed by both 3He and 129Xe gas (ADCHX=0.470±0.125cm2/s, p<.0001). Moreover, to
ensure that

129

Xe ventilation abnormalities in regions of emphysema were not due to

signal attenuation within those regions in the diffusion-weighted images, we compared
ventilation measured from the non-diffusion-weighted images (non-diffusion-weighted
129

Xe VV=4.27±0.76L) and the ADC maps and determined there was no significant

ventilation difference (ADC map

129

Xe VV=4.31±0.69L, p=.80). To determine whether

airways leading to regions accessed only by 3He gas might be abnormally thickened or
obstructed we compared the lung side with the greatest difference between 3He and 129Xe
ventilation with the lung side with the lower 3He-129Xe difference and observed no
significant difference in WA% (ΔWA%=1%, p=.64) or LA (ΔLA=6.7mm2, p=.33).
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Figure 7-2 3He and 129Xe ADC maps for two representative subjects with slices in the
anterior-to-posterior direction
A. Subject is 78 yrs old male with Stage II chronic obstructive pulmonary disease
(COPD): forced expiratory volume in 1 s (FEV1)=59%pred, forced vital capacity
(FVC)=82%pred, FEV1/FVC=52%, relative area with attenuation values below
−950 HU (RA950)=36.70, lowest 15th percentile (HU15)=-975.
B. Subject is a 73 yr old male with Stage IV COPD: FEV1=26%pred, FVC=66%pred,
FEV1/FVC=29%, RA950=5.00, HU15=-930.
The CT density mask shown in green is in the bottom panel for each slice to
highlight the areas with attenuation <-950HU.
In Figure 7-4, the differences between 3He and

129

Xe VV are shown and these were

significantly correlated with CT HU15% (r=-.65, p=.04) and mean 3He ADCHO (r=.70,
p=.02). However, there was no significant correlation for the difference between 3He and
129

Xe VV with CT WA% (r=-.34, p=.33) for all airway generations or for each of the 3rd

to 7th generation airways individually. There was also a significant correlation for the

192

difference between 3He and

129

Xe VV with FEV1/FVC (r=-.79, p=.007), but not with

FEV1 (r=-.48, p=.16) or DLCO (r=-.37, p=.41).

Figure 7-3 Regional 3He and 129Xe ADC
3
He and 129Xe ADC maps with the ADC map for the ROI ventilated only by 3He
registered to the binary ADC map for those regions accessed by both 3He and 129Xe
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Figure 7-4 Correlation for the difference between 3He and 129Xe VV and CT HU15%
Threshold
A. The difference between 3He and 129Xe VV was significantly correlated with the
extent of emphysema as assessed by CT using HU15% threshold (r=-65, p=.04,
r2=.42, p=.04, y=-34.4x-919.2).
B. The difference between 3He and 129Xe VV was significantly correlated with mean
ADC in the 3He only regions of interest (ADCHO) (r=.70, p=.02, r2=.50, p=.02,
y=3.1x-0.7).
Dotted lines represent the 95% confidence intervals.

7.4

Discussion

Hyperpolarized noble gas MRI has been developed over the last two decades because it
has the potential for clinical translation, providing quantitative microstructural and
dynamic pulmonary functional information and measurements. However, while 3He MRI
allows the acquisition of very high quality images, the global availability and costs are
motivating a transition to hyperpolarized
3

with both He and

129

129

Xe MRI. Recently, a pilot study performed

Xe MRI showed there were visually obvious and quantitatively

greater gas distribution abnormalities for

129

Xe MRI in COPD subjects but not healthy

elderly never-smokers.26 The reasons for the difference were not clear and so in the
current evaluation we investigated emphysema as a contributor to the observed
differences in 3He and

129

Xe ventilation. Accordingly, here we report: 1) significantly

greater 3He ADC in regions only accessed by 3He gas (ADCHO) as compared to regions
accessed by both gases (3He ADCHX), and, 2) a significant relationship between the
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difference in 3He and

129

Xe VV and the extent of emphysema assessed by CT but not

with CT airway wall thickness (WA%) measurements.
We observed that mean 3He ADC in pulmonary ROI accessed only by 3He gas were
elevated relative to the mean 3He ADC in the remaining lung. This finding suggests that
more emphysematous or damaged lung was more readily filled with 3He as compared to
129

Xe gas for the duration of the breath-hold imaging performed in this study. We

acknowledge, however, that SNR was lower for 129Xe than with 3He MRI,26 and therefore
there is the potential for regions of the lung with reduced signal intensity to appear as
ventilation defects in low SNR

129

Xe images.
3

observed that the difference between He and
with the difference between 3He and

129

However, for this investigation, we

129

Xe SNR was not significantly correlated

Xe VV.

Moreover, to ensure that

129

Xe

ventilation abnormalities in regions of emphysema were not due to signal attenuation
within those regions in the diffusion-weighted images, we compared ventilation
measured from the non-diffusion-weighted images and the ADC maps and determined
there was no significant ventilation difference. We think, therefore, that it is unlikely that
this finding is due to SNR alone and another possible explanation for this observation is
that the highly diffusive and less dense and viscous 3He gas may readily access the
slower-filling emphysematous lung during the inhalation period and the breath-hold
interval. Alternatively, the 3He gas may fill emphysematous lung regions via collateral
channels.

Collateral channels have been identified in emphysema35 and although

resistance to flow through collateral channels is high in the normal lung, in emphysema
resistance to flow through collateral channels is lower than through obstructed airways.37
Collateral ventilation has been demonstrated with 3He MRI44;45 and more recently,
indirect, non-airway dependent or collateral ventilation was directly visualized using 3He
MRI in COPD46 within a single breath-hold. For

129

Xe gas, however, it is likely that

there are longer time constants for gas filling in emphysematous regions;

129

Xe gas with

its lower diffusion coefficient would diffuse much more slowly into these
emphysematous regions than 3He and therefore have a much shorter diffusion distance
due to the short breath-hold duration, which may contribute to lower
intensity in regions of significant emphysema.

129

Xe signal

Accordingly, we calculated the

characteristic diffusion length for the 129Xe/4He and 4He/N2 gas mixtures and showed that
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the characteristic diffusion length for the

129

Xe atoms is smaller than that for the 3He

atoms. Regardless of the exact mechanisms that are in play, the finding of significant
emphysema in lung regions probed only with 3He gas suggests that these lung regions
cannot be penetrated by 129Xe gas in the same timeframe.
Importantly, we previously showed that the mixture of 129Xe/4He gas administered in this
study better approximates the self-diffusion coefficient of oxygen mixed with air in the
lung,26 suggesting that

129

Xe MRI ventilation may be a better estimate of ground truth

pulmonary ventilation. The 3He/N2 gas mixture has a lower density and viscosity than
air, and studies have previously demonstrated that inspiring oxygen mixed with helium
reduces airway resistance by decreasing turbulent flow.47

This interesting finding

suggests that inhaled 3He gas and its mixtures may be less sensitive to peripheral airway
obstruction. Clearly, there are advantages to utilizing inhaled gases such as

129

Xe and

mixtures thereof that may have increased sensitivity to airway obstruction and
emphysema for targeted treatments and interventions. On the other hand, the increased
density/viscosity and lower diffusion coefficient of

129

Xe may limit signal from those

regions of the lung most affected by emphysema or receiving collateral flow. Clearly,
both gases provide application-specific advantages.
Importantly, we did not detect a significant correlation for the difference in 3He and 129Xe
ventilation and WA%. However, we cannot ascertain whether this might be the case
regionally, wherein specific airways leading to regions accessed only by 3He gas might
be abnormally thickened or obstructed. In other words, it is possible that the whole lung
estimates of WA% might not be representative of regional differences. We investigated
this possibility by regionally comparing the lung side with the greatest difference
between 3He and 129Xe ventilation with the lung side with the lower 3He-129Xe difference
and observed no significant difference in WA% or lumen area. However, we must also
acknowledge that for some subjects, the lung region that showed a 3He-129Xe ventilation
difference was very small and this may have also contributed to the lack of significant
relationship observed with WA%.
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A large number of studies have investigated convective and diffusive gas transport within
the lung using multiple-breath washout studies27-30 and modeling48 and it is evident from
these previous studies that the inhaled gas physical properties are important factors
affecting ventilation distribution within the lung. Clearly there is significant work to be
done to better understand how the different properties of 3He and

129

Xe gas affect

ventilation distribution and most importantly, what information these differences in
ventilation distribution provide us regarding the sensitivity of the different gases and their
mixtures for detecting airway and ventilation abnormalities. Directly visualizing the
distribution of the gases using mixtures of 3He and 129Xe with well-controlled viscosities
and densities during a breath-hold in the same subjects using time-resolved imaging
sequences, as was recently performed with 3He MRI,46 could certainly be utilized to test
some of our important hypotheses regarding delayed/collateral ventilation within
emphysematous lung regions in COPD subjects. Moreover, while several modeling
studies have aimed to evaluate gas transport in the lung using 3He and

129

Xe,49;50 more

studies of this nature are required to fully understand the role of the gas properties on
regional ventilation distribution with noble gas MRI as well as to determine the gas
mixture that best approximates the distribution of typical room air within the lung.
We recognize that this work was limited by the small number of subjects evaluated
meaning that extrapolation of these results to a general COPD population cannot be
confirmed until studies with larger sample sizes are performed. This study was also
limited by the different diffusion times and b-values that were utilized for 3He and

129

Xe

image acquisition, and therefore we may be probing different lung structures. Previous
studies have demonstrated that greater diffusion time results in greater diffusion distances
and there is therefore the potential to probe a fundamentally different spatial scale.51
However, significant and strong correlations have been previously observed between 3He
and

129

Xe ADC,26 suggesting that both methods are probing similar spatial dimensions.

In addition, the acquisition of clinical measurements, such as dyspnea scores and
measurements of exercise tolerance, for direct comparison to 3He and

129

Xe MRI

measurements may have aided in determining the clinical meaning of these differences.
Future studies should aim to evaluate the differences between 3He and

129

Xe MRI in
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terms of their relationships with clinical measurements as well as the relative sensitivities
for detecting improvements following treatment or interventions.
In summary, we used regional hyperpolarized

3

He and

129

Xe ADC image

registration/segmentation methods to quantify ADC in the lung regions accessed by both
gases and the lung regions accessed by 3He gas only. We reported a significantly greater
mean ADC in the lung regions accessed by 3He gas only than in the remaining lung
tissue, and a significant relationship between the difference in 3He and

129

Xe VV and

emphysema. In COPD, the lower resistance to flow within emphysematous lung regions
is a potential determinant of the differences observed in 3He and 129Xe ventilation defects.
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CHAPTER 8
While it is important to demonstrate that 3He MRI measurements relate to important
clinical outcomes, such as disease progression and treatment response, another goal of
imaging is to identify early disease changes. Here we evaluated well-established clinical,
physiological and emerging imaging measurements in ex-smokers with normal
spirometry and abnormal DLCO as well as a group of ex-smokers with normal spirometry
and DLCO and ex-smokers with GOLD stage I COPD.
The contents of this Chapter have been accepted in Thorax and are currently in press.
M Kirby, A Owrangi, S Svenningsen, A Wheatley, HO Coxson, NAM Paterson, DG
McCormack and G Parraga. On the role of abnormal DLCO in ex-smokers without
airflow limitation: Symptoms, exercise capacity and hyperpolarized helium-3 magnetic
resonance imaging. Thorax (Accepted March 28, 2013).

8

On the Role of abnormal DLCO in Ex-smokers Without
Airflow Limitation: Symptoms, Exercise Capacity and
Hyperpolarized Helium-3 Magnetic Resonance Imaging
8.1

Introduction

Chronic obstructive pulmonary disease (COPD) is characterized by chronic, progressive
expiratory flow limitation that develops as a result of the lung’s inflammatory response to
inhaled toxic gases and particles, primarily from tobacco smoke.1 In COPD, airflow
limitation is caused by both small airway disease (obstructive bronchiolitis) and
parenchymal destruction (emphysema),1 however, the relative contributions of these
pathologies vary from person to person.
When COPD is suspected based on symptoms, such as dyspnea, chronic cough or sputum
production, and/or a history of exposure to risk factors,1 airflow limitation is measured
using spirometry and severity is determined according to the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) criteria.1

This approach, however, has been

acknowledged to potentially result in an over-diagnosis of COPD in the elderly,2 as well
as under-diagnosis of mild or early stage COPD 3.
The COPDGene study recently reported low forced expiratory volume in 1 second
(FEV1) and normal FEV1/forced vital capacity (FVC) in ex-smokers with significant
symptoms and decreased six-minute walk distance (6MWD) and defined these patients as
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GOLD-Unclassified (GOLD-U).4 Until now, ex-smokers with GOLD-U or those with
“non-obstructive” or “pure” emphysema without airflow limitation have been
systematically excluded from COPD studies.
emphysema, there have been a few case reports

With respect to non-obstructive
5-7

and pilot studies8 that described

significant smoking history, severe symptoms and abnormal diffusing capacity for carbon
monoxide (DLCO) in patients concomitant with normal expiratory airflow. A recent
study also reported that otherwise normal asymptomatic smokers with abnormal DLCO
showed evidence of endothelial microparticles in the circulation – a marker of early lung
destruction associated with emphysema.9 Although abnormal DLCO in ex-smokers is a
valuable marker of lung function impairment, even in the absence of airflow limitation,
the relationship between DLCO with other functional markers (i.e., symptoms and
exercise limitation) is not well-understood. We hypothesized that subjects with abnormal
DLCO without airflow limitation would have imaging evidence of early or mild
emphysema with measureable functional consequences.
Multi-detector computed tomography (CT) and hyperpolarized helium-3 (3He) magnetic
resonance imaging (MRI) have been used independently to measure emphysema and
airways disease as distinct phenotypes in COPD.10;11 In particular, hyperpolarized 3He
MRI apparent diffusion coefficients (ADC),12;13 provide a way to sensitively measure
regional lung tissue destruction, -the hallmark of emphysema. Abnormally elevated 3He
ADC have previously been reported in asymptomatic smokers without COPD,14;15
although the relationship between 3He MRI ADC in early disease with symptoms and
other physiological measurements has never been reported and their functional impact is
not known. To better understand the consequences of early or mild disease in exsmokers, here we evaluated well-established clinical, physiological as well as emerging
imaging measurements in ex-smokers with normal spirometry but abnormal DLCO as well
as ex-smokers with GOLD stage I COPD and those with normal spirometry and DLCO.
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8.2
8.2.1

Materials and Methods
Study Subjects

All subjects provided written informed consent to the protocol approved by the local
research ethics board and Health Canada, and the study was compliant with the Personal
Information Protection and Electronic Documents Act (Canada) and the Health Insurance
Portability and Accountability Act (USA). Ex-smokers were recruited from a local
tertiary care centre and by advertisement. Thirty-eight subjects were enrolled who were
ex-smokers without a diagnosis of COPD and 15 ex-smokers were enrolled with a
previous diagnosis of GOLD stage I COPD,1 all of whom were 60-85 years of age, with a
smoking history ≥ 10 pack -years. The subjects without a diagnosis of COPD had no
history of previous chronic or current respiratory disease and were classified according to
ATS/ERS recommendations16 on the approximate lower limits of normal for DLCO17 such
that normal DLCO ≥ 75%pred and abnormal DLCO < 75%pred.

8.2.2

Spirometry, Plethysmography and other Tests

Spirometry was performed using an EasyOne spirometer (ndd Medizintechnik AG,
Zurich, CH) according to ATS guidelines.18 Lung volumes were measured using body
plethysmography and DLCO was assessed using the attached gas analyzer (MedGraphics
Corporation. 350 Oak Grove Parkway St. Paul, MN, USA). The St Georges Respiratory
Questionnaire (SGRQ) was administered19;20 and a standard six minute walk test
(6MWT)21 was performed.

8.2.3

Image Acquisition

MRI was performed on a whole body 3.0 Tesla Discovery 750MR (General Electric
Health Care, Milwaukee, WI) MRI system.22

3

He gas was polarized to 30—40%

(HeliSpin™) and doses (5mL/kg body weight) were administered in 1.0L Tedlar® bags
diluted with medical grade nitrogen (N2) (Linde, Ontario, Canada). 3He MRI diffusionweighted images were acquired using a fast gradient-recalled-echo sequence immediately
following inhalation of the 3He/N2 gas mixture during breath-hold conditions.22 Two
interleaved images were acquired (14s total data acquisition, repetition time (TR)/echo
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time (TE)/flip angle = 7.6 ms/3.7 ms/8o, field of view (FOV) = 40 x 40 cm, matrix
128 x 128, 7 slices, 30 mm slice thickness, 0 gap), with and without additional diffusion
sensitization with b = 1.6 s/cm2 (gradient amplitude (G) = 1.94 G/cm, rise and fall time =
0.5 ms, gradient duration = 0.46 ms, diffusion time = 1.46 ms).
CT was performed on a 64-slice Lightspeed VCT scanner (GEHC, Milwaukee, WI USA)
(64×0.625 mm, 120 kVp, 100 effective mA, tube rotation time=500 ms, pitch=1.0). A
single spiral acquisition was acquired in breath-hold after inhalation of 1.0L of N2 from
functional residual capacity. Reconstruction was performed (1.25 mm) using a standard
convolution kernel.
To minimize the potential for differences in the levels of inspiration between 3He MRI
and CT, extensive coaching was performed prior to the imaging sessions to ensure
subjects could completely inspire the contents of the 1.0L bag. The order of 3He MRI
and CT acquisition was randomized for each subject.

8.2.4

Image Analysis

Regions of signal void were quantified as the 3He ventilation defect percent (VDP).23
3

He apparent diffusion coefficient (ADC) maps were also generated as previously

described.24 Regional differences in ADC were evaluated in the anterior-posterior (AP)
direction.25 The AP gradient (APG) was the slope of the line of best fit that described the
change in ADC as a function of distance in centimeters. Analysis of CT was performed
using the Pulmonary Workstation 2.0 (VIDA Diagnostics, Inc., Coralville, IA). Wall
area percent (WA%) was measured for the segmental and subsegmental airways10 and the
relative area with attenuation values below −950 HU (RA950) was generated.26

8.2.5

Statistical Methods

A multivariate analysis of variance was performed using IBM SPSS Statistics 20.0 (SPSS
Inc., Chicago, IL, USA). Univariate comparisons were performed using an unpaired twotailed t-test and Welch’s correction was used when the F-test for equal variances was
significant using GraphPad Prism version 4.00 (GraphPad Software Inc, San Diego, CA,
USA). A Fisher’s exact test was performed for categorical variables. Linear regression
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(r2) and Pearson correlation coefficients ( ) were used to determine correlations using
GraphPad Prism version 4.00. Results were considered significant when the probability
of making a Type I error was less than 5% (p < 0.05).

8.3

Results

We enrolled 53 ex-smokers, 38 subjects without a diagnosis of COPD and 15 subjects
diagnosed with stage I COPD. Of the 38 ex-smokers without COPD, half had normal
DLCO without airflow obstruction (ND, n=19) and the other half had abnormal DLCO
without airflow obstruction (AD, n=19). Table 8-1 shows subject demographic data as
well as the pulmonary function, SGRQ, 6MWD, CT and 3He MRI measurements for all
subjects categorized according to spirometry and DLCO results.
Subjects with abnormal DLCO without airflow obstruction (AD) were not significantly
different from ex-smokers with normal DLCO (ND) and stage I COPD subjects with
respect to age, BMI, pack-years, years since smoking cessation, the change in SpO2 after
the 6MWT, CT WA% and 3He VDP. However, there were significantly more female AD
subjects than ND (p=.02) and stage I COPD (p=.01) subjects.
Figure 8-1 shows the central coronal 3He MRI static ventilation image and 3He MRI
ADC map for subjects with ND, AD and stage I COPD. As shown in Table 8-1, AD
subjects had significantly worse 3He ADC (0.30±0.03cm2/s, p=.01), 6MWD (341±95m,
p=.008) and SGRQ total score (29±21, p=.01) compared with ND subjects, but no
significant difference for RA950 (p=.53). In comparison with stage I COPD, AD subjects
had a significantly reduced 6MWD (341±95m, p=.005), FVC (93±12%pred, p=.001),
RA950 (1.6±1.1, p=.0008) and ADC (0.30±0.03cm2/s, p=.02), and a significantly greater
FEV1/FVC (80±7%, p<.0001) and no significant difference for SGRQ total score (p=.59).
Figure 8-2A shows the mean ADC on a slice-by-slice basis in the anterior to posterior
direction for ND, AD and stage I COPD subjects. For AD ex-smokers, the ADC gradient
in the anterior-posterior direction (ADC APG) was significantly lower than for ND
(p=.02) and not significantly different from COPD subjects (p=.20). Figure 8-2B shows
the significant correlation between ADC APG and the 6MWD (r=-.51, p=.0002).
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Figure 8-3 shows the correlations between 3He ADC and CT RA950 with DLCO, SGRQ
and 6MWD. There was a significant correlation between 3He ADC and DLCO (r=-0.55,
p<0.0001) and SGRQ (r=0.34, p=0.02), but not 6MWD (r=-.17, p=0.24), and as shown in
Figure 8-2B, the ADC APG was significantly correlated with 6MWD.

RA950 was

significantly correlated with DLCO (r=-0.31, p=0.03); but not SGRQ (r=0.24, p=0.10); or
6MWD (r=0.0013, p=0.99).
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Table 8-1 Clinical, functional and radiographic measurements of asymptomatic exsmokers with normal DLCO and abnormal DLCO and with GOLD stage I COPD
ND
AD
Stage I
Significance of
(n=19)
(n=19)
COPD
Difference (p)
(n=15) ND-AD AD-COPD
Subject Demographics
Age yrs (±SD)
71 (7)
74 (7)
77 (5)
0.09
0.30
Female Sex
3
11
2
0.02
0.01
2
BMI kg/m (±SD)
29.5 (3.4)
28.6 (4.0) 28.4 (4.0) 0.46
0.91
Pack yrs (±SD)
25 (12)
32 (23)
49 (36)
0.25
0.11
Yrs since quit (±SD)
26 (9)
24 (14)
21 (14)
0.63
0.63
Pulmonary Function Tests
FEV1 %pred (±SD)
107 (13)
99 (12)
95 (13)
0.07
0.34
FVC %pred (±SD)
98 (12)
93 (12)
108 (14)
0.16
0.001
FEV1/FVC (±SD)
80 (6)
80 (7)
63 (5)
0.73
<0.0001
IC %pred (±SD)
112 (17)
103 (22)
103 (17)
0.17
0.99
RV %pred (±SD)
103 (17)
107 (25)
114 (29)
0.58
0.45
TLC %pred (±SD)
101 (10)
101 (15)
109 (13)
0.96
0.12
RV/TLC %pred (±SD)
101 (13)
104 (16)
103 (18)
0.49
0.77
DLCO %pred (±SD)
89 (9)
59 (13)
68 (19) <0.0001
0.12
6MWT
Pre 6MWT Sp02 % (±SD)
97 (2)
95 (2)¥
95 (2)
0.06
0.57
¥
Δ 6MWT Sp02 % (±SD)
0 (2)
0 (2)‡
-1 (3)
0.55
0.25
Distance m (±SD)
430 (99)
341 (95)
417 (41) 0.008
0.005
SGRQ
Symptoms (±SD)
18 (17)¥
36 (30)‡
36 (22)
0.99
0.04
+
Activity Score (±SD)
19 (21)‡
41 (24)
36 (25)
0.54
0.006
+
Impact Score (±SD)
6 (11)‡
17 (18)
15 (13)
0.68
0.04
Total Score (±SD)
12 (14)*
29 (21)‡
25 (17)+
0.59
0.01
CT Measurements
RA950 (±SD)
1.36 (1.25)¥ 1.60 (1.06) 5.50 (3.16) 0.53
0.0008
WA% (±SD)
57 (4)
59 (2)
58 (2)
0.17
0.23
3
He MRI Measurements
ADC cm2/s (±SD)
0.27 (0.03) 0.30 (0.03)* 0.36 (0.08) 0.01
0.02
VDP % (±SD)
6 (3)‡
7 (4)*
9 (5)
0.40
0.07
ND=Normal DLCO, AD=Abnormal DLCO, COPD=Chronic Obstructive Pulmonary
Disease, BMI=Body Mass Index, FEV1=Forced Expiratory Volume in 1sec, FVC=Force
Vital Capacity, IC=Inspiratory Capacity, RV=Residual Volume, TLC=Total Lung
Capacity, DLCO=Diffusion capacity of the Lung for Carbon monoxide, 6MWT=6-min
Walk Test, Sp02=Peripheral Oxygen Saturation, SGRQ=St. George’s Respiratory
Questionnaire, RA950=Relative Area with attenuation values below −950 HU, HU15=
lowest 15th percentile from the frequency distribution of HU, WA%=Wall area percent,
ADC=Apparent Diffusion Coefficient, VDP=Ventilation defect percent. *n=16, ‡n=17,
¥
n=18, +n=14.
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Figure 8-1 3He MRI static ventilation images and 3He ADC maps for a representative
ND and two representative AD and COPD stage I ex-smokers.
ND subject is a 70 yr old male FEV1=101%pred, FEV1/FVC=0.75, DLCO=113%pred, 3He
ADC=0.26cm2/s, CT RA950=1.25. AD subject 1 is a 74 yr old male FEV1=89%pred,
FEV1/FVC=0.77, DLCO=41%pred, 3He ADC=0.31cm2/s, CT RA950=1.52; AD subject 2 is
a 74 yr old male FEV1=95%pred, FEV1/FVC=0.85, DLCO=63%pred, 3He ADC=0.29cm2/s,
CT RA950=0.52. GOLD stage I COPD subject 1 is a 74 yr old male FEV1=86%pred,
FEV1/FVC=0.59, DLCO=45%pred, 3He ADC=0.37cm2/s, CT RA950=6.14; GOLD stage I
COPD subject 2 is a 78 yr old male FEV1=118%pred, FEV1/FVC=0.62, DLCO=71%pred,
3
He ADC=0.38cm2/s, CT RA950=5.52.
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Figure 8-2 Regional 3He MRI ADC Anterior-Posterior Gradients (APG) for ND, AD and
stage I COPD subjects and Correlation between 3He ADC APG with 6MWD
A. Mean APG was statistically significantly different for AD and ND subjects (AD:
APG=-3.55x10-4 ± 4.85x10-4 cm2/s/cm, ND: APG= -7.03x10-4 ± 3.03x10-4
cm2/s/cm, p=0.02), but not between the AD and Stage I COPD subjects (COPD:
APG=-5.58x10-4 ± 3.73x10-4 cm2/s/cm, p=0.20). Error bars represent the ADC
standard deviation for each image slice.
B. 3He APG ADC was significantly correlated with 6MWD (r=-0.51, p=0.0002,
r2=0.26, p=0.0002, y=-0.02x+4.4). Dotted lines represent the 95% confidence
intervals of the regression.
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Figure 8-3 Correlation between 3He ADC and CT RA950 with DLCO, SGRQ and 6MWD
for ND, AD and stage I COPD subjects.
A. 3He ADC was significantly correlated with DLCO (r=-0.55, p<0.0001, r2=0.31,
p<0.0001, y=-0.0018x+0.44), SGRQ (r=0.34, p=0.02, r2=0.12, p=0.02,
y=0.0012x+0.28), but not 6MWD (r=-0.17, p=0.24, r2=0.03, p=0.24, y=0.00013x+0.36).
B. CT RA950 was significantly correlated with DLCO (r=-0.31, p=0.03, r2=0.09,
p=0.02, y=-0.040x+5.42), but not with SGRQ (r=0.24, p=0.10, r2=0.06, p=0.10,
y=-0.034x+1.71) and 6MWD (r=0.0013, p=0.99, r2<0.0001, p=0.99,
y=0.00003x+2.5).
Dotted lines represent the 95% confidence intervals of the regression.
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8.4

Discussion

To better understand the relationship between lung structural markers, symptoms and
physiological measurements in ex-smokers, we evaluated 53 ex-smokers including 38
subjects who did not have a diagnosis of COPD and 15 subjects with stage I COPD, and
observed: 1) 19/38 ex-smokers showed normal spirometry and CT but abnormal DLCO
and 19/38 ex-smokers showed normal spirometry, CT and DLCO, 2) subjects with
abnormal DLCO had significantly worse 6MWD compared to stage I COPD ex-smokers
and significantly worse 3He ADC, SGRQ and 6MWD compared to subjects with normal
DLCO, and, 3) subjects with abnormal DLCO had significantly smaller 3He MRI ADC
anterior-posterior gradients compared to subjects with normal DLCO.
We were surprised that half of the ex-smokers without COPD showed abnormal DLCO
and significantly worse 3He ADC, but with normal CT, which based on previous
studies,14;15 was an unexpected result. Although we were not able to confirm significant
disease other than emphysema that could account for these findings, we note that a
previous evaluation14 of 10 younger asymptomatic smokers (mean age=47 years,
range=23-73) showed that 3 of 5 subjects aged 60yr or older also reported DLCO <
75%pred. In ex-smokers, abnormal DLCO is thought to reflect diminished lung surface
area available for gas exchange, although DLCO also reflects the volume of blood in the
pulmonary capillaries and thickness of the alveolar capillary membrane,27 related to
bronchiectasis and interstitial lung disease.28 Abnormally low DLCO is also consistent
with pulmonary vascular disease,29 and such patients exhibit normal spirometry, dyspnea
upon exertion30 and a decline in oxygen saturation with exertion.31 In the current study,
AD subjects did not show reduced oxygen saturation during the 6MWT nor did they
report a history of pulmonary vascular disease, so there was no evidence to support the
notion that pulmonary vascular disease was responsible for the abnormal exercise
performance and dyspnea observed here. Although DLCO is a very sensitive marker of
emphysema in smokers,8 reproducibility can be low, and in some cases, low to moderate
correlations have been reported between DLCO and pathological assessments of
emphysema.32;33
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Previous work by Woods and Hogg34 compared 3He ADC with histology measurements
of emphysema in explanted lungs and showed that ADC values could be used to
distinguish normal from emphysematous lung tissue with greater precision than the mean
linear intercept measurement from histology samples. Another previous study in COPD
showed that while 3He ADC correlated significantly with CT measurements (i.e., RA950),
stronger correlations were observed for 3He ADC and DLCO than for RA950 and DLCO.35
In asymptomatic smokers, 3He ADC was shown to correlate with DLCO, but there was no
significant correlation between DLCO and CT RA950.14 Finally, abnormally elevated 3He
ADC values were previously observed in never-smokers exposed to significant secondhand-smoke36 as compared to never-smokers with no such exposure. Taken together,
these previous findings support the observation here that elevated 3He ADC in exsmokers with abnormal DLCO may reflect mild emphysema not detected by CT. Our
observations are also consistent with previous reports5-8;37 and the identification of mild
emphysema using histology that was not predicted using preoperative CT.38;39 While we
cannot rule out the presence of small airways disease in subjects with AD, there was no
significant difference between the AD and ND subjects for 3He VDP and CT WA%, both
of which provide estimates of airways disease. Taken together, these results suggest that
3

He ADC is sensitive to very mild emphysema in subjects with abnormal DLCO who have

no CT evidence of airways disease or emphysema.
Concomitant with significantly elevated 3He ADC, we observed significantly worse
6MWD in AD as compared to COPD and ND ex-smokers. This is an important finding
and the first to provide evidence of a relationship between 3He MRI ADC reflective of
early or mild emphysema and exercise capacity. It is also important to note that the ratio
of female/male ex-smokers with AD was 11/8 (1.4) and for ND, this ratio was 3/16 (0.2).
Although the current study was not powered to evaluate sex differences, previous
evidence suggests that female sex is significantly associated with early-onset COPD.40;41
However, previous studies have also shown that emphysema dominates in males as
compared to females,42 whereas here, the sex ratio was reversed. We note that imaging
was performed at a fixed volume and because there were more females in the AD group
(who potentially had smaller lungs), we investigated the relationship between lung size
and 3He ADC and observed no correlation for 3He ADC with height (r=-.36, p=.18), TLC
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(r=.33, p=.21) or thoracic cavity volume (r=-.20, p=.45). Therefore the elevated ADC in
the AD subjects observed here was not related to lung size, and cannot explain the
preponderance of female subjects in the AD subgroup. Consistent with our findings, the
6MWD in COPD was also previously shown to be lower for FEV1-matched females
versus males.43
We took advantage of the fact that 3He MRI diffusion-weighted images were acquired in
the supine position and measured compression of the dependent lung due to gravity.
Several sites have reported smaller 3He ADC in the dependent lung (or posterior slices)
relative to the non-dependent lung,25;44;45 likely due to gravitational compression of the
parenchyma. In COPD subjects,25;45 this anterior-to-posterior difference is significantly
smaller and this is thought to be due to regional gas trapping that counteracts
gravitational compression of the dependent regions.

Here, we observed that these

gradients were significantly smaller in AD subjects compared to ND subjects suggesting
that regional gas trapping was greater in the AD subgroup.
Finally, we showed that 3He ADC was significantly correlated with SGRQ and that 3He
ADC AP gradients were significantly correlated with the 6MWD.

The significant

relationships between 3He ADC with respiratory symptoms and exercise capacity suggest
that in early emphysema, symptomatic changes can go unnoticed in older patients even
when standardized tests report significant changes in health-related quality of life and
exercise capacity. While elevated 3He ADC in asymptomatic ex-smokers was previously
described,14;15 the imaging-to-exercise capacity and imaging-to-symptoms correlations
observed here in very early emphysema are novel findings. The unexpected finding of
3

He ADC anterior-posterior gradient correlations with 6MWD also provides more

evidence about the role of mild emphysema and regional gas trapping that may together
lead to exercise limitation even in early disease. AD ex-smokers also reported SGRQ
that was not significantly different from the stage I COPD ex-smokers, and worse than
ND subjects, which supports previous reports of compromised health-related quality of
life 46 and reduced work capacity in very early disease.47
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This study was limited by the relatively small number of subjects evaluated, although we
note that this is the single largest prospective study that directly compared CT,
symptoms, exercise capacity and 3He MRI in ex-smokers with and without airflow
obstruction.

We admit that we were surprised to find such a large proportion of

asymptomatic ex-smokers without airflow limitation and abnormal DLCO in this study.
This finding raises the important question as to whether this subgroup is atypical or
perhaps this is a unique finding because “asymptomatic” ex-smokers are rarely
administered SGRQ or the 6MWT.

Importantly, the selection criteria, manner and

location for subject recruitment are those we have previously used for the recruitment of
older ex-smokers, and typical of other studies. It is possible that in this unique subgroup,
patients were less likely to recognize and report symptoms. Our results certainly raise
many intriguing questions regarding whether these subjects are unusual or whether we
have simply uncovered a group of older ex-smokers with both unrecognized mild
emphysema and functional limitations.
In summary, we evaluated 38 ex-smokers without airflow limitation and 15 ex-smokers
with COPD. In the absence of spirometry or CT abnormalities, half of the ex-smokers
without COPD showed abnormal DLCO and abnormally elevated 3He ADC consistent
with early or mild emphysema. These subjects had significantly and markedly worse
6MWD and SGRQ compared to ex-smokers with normal ADC and DLCO, and worse
6MWD than subjects with COPD. These findings provide a better understanding of
abnormal DLCO in ex-smokers without COPD.
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CHAPTER 9

9

Conclusions and Future Directions

In this final chapter, I will provide an overview and summary of the important findings
and conclusions of Chapters 2-8. I will also address the study specific limitations as well
as general limitations of the hyperpolarized gas MRI studies presented and provide some
potential solutions. Finally, based on the findings and limitations discussed, I will
outline a roadmap for future hyperpolarized gas MRI studies.

9.1

Overview and Research Questions

COPD is currently ranked the 4th leading cause of death worldwide,1 and despite the fact
that the global burden of many other leading causes of deaths are declining,1 COPD
remains largely under-diagnosed and under-treated.2;3 When COPD is suspected based
on symptoms, such as dyspnea, chronic cough or sputum production, and/or a history of
exposure to risk factors,4 airflow limitation is measured using spirometry and the
presence of a post-bronchodilator FEV1/FVC <0.70 confirms the diagnosis of COPD.4;5
However, this approach is limited for several reasons. First, although it is utilized due to
diagnostic simplicity and ease of use in the primary care setting, the fixed FEV1/FVC cut
off has been acknowledged to potentially result in an over-diagnosis of COPD in the
elderly,6 whom are expected to have a decline in lung function due to the normal aging
process.7 Second, spirometry may be insensitive to mild or early disease changes.8 It is
well known that the airways < 2mm in diameter are the major site of airway obstruction
in COPD,9 and therefore disease may accumulate and progress to more severe states
before detection with FEV1. Third, chronic airflow limitation in COPD may be caused
by small airways disease (obstructive bronchiolitis) or parenchyma destruction
(emphysema) or some mixture of both of these underlying disease mechanisms.
Therefore, FEV1 alone does not provide any information regarding the underlying disease
mechanism responsible for the lung function impairment. Finally, FEV1 measures the
overall disease burden, and does not provide any information regarding which regions of
the lung are most severely affected. Clearly, it is important to identify the disease in its
earliest possible stages for smoking cessation interventions to slow disease progression.
For developing and evaluating treatments and interventions it is also critically important
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to identify the underlying disease mechanisms and target the regional disease. Therefore,
it is because of these limitations that there is a continued need for the development of
sensitive imaging approaches for regional and surrogate measurements of COPD.
Chest x-ray was the first imaging modality introduced for the evaluation of COPD and
although it is widely available, inexpensive, and allows visualisation of pulmonary
structures, because chest x-ray is a planar imaging modality, it is not useful to establish a
diagnosis of COPD5 and has been shown to be insensitive to early disease stages where
disease-related structural changes may be subtle.10 Although there is no question that CT
is superior to conventional x-ray imaging because it provides high resolution anatomical
images and in three-dimensions, it provides no information regarding lung function and
the radiation exposure from thoracic CT has been a major concern. Although CT is not
routinely recommended, it is useful in the differential diagnosis in COPD where
concomitant diseases are present.5 Currently, the only clinical means for imaging lung
ventilation is with lung scinitigraphy, however, it is limited by the need to inhale a
radioactive substance and has low spatial resolution.

Therefore, a high resolution

imaging method that does not involve the use of ionizing radiation that can evaluate both
lung structure and function is needed.
MRI with the inhaled hyperpolarized gases 3He and

129

Xe provides high resolution

images of pulmonary structure and function and does not require the use of x-rays or
other ionizing radiation.

The overarching objective of this thesis was to generate

hyperpolarized gas MRI measurements and measurement tools for the regional
quantitative evaluation of hyperpolarized gas MRI with sufficient precision to evaluate
COPD disease progression and treatment response.

The specific research questions

investigated here included: 1) Are longitudinal changes in 3He MRI measurements in the
COPD ex-smokers similar to those observed in elderly healthy never-smokers (Chapter
2)?; 2) Can 3He MRI measurements derived from semi-automated segmentation methods
be developed that have significantly reduced inter- and intra-observer variability than
manual measurements and are not statistically significantly different from manual
measurements (Chapter 3)?; 3)

Can the semi-automated 3He MRI measurements

developed in Chapter 3 provide the necessary sensitivity as well as precision to detect any
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potential regional functional lung changes after bronchodilator therapy in COPD subjects
regardless of spirometry-based responder classification (Chapter 4)?; 4) Are the regions
of the lung that were newly ventilated following bronchodilator therapy in the same
subjects evaluated in Chapter 4 more emphysematous than the remaining lung tissue, and
can

3

He ADC measure significant reductions in regional gas trapping following

bronchodilator therapy (Chapter 5)?; 5) Do the different properties of 129Xe gas result in
significant differences in 129Xe compared to 3He gas distribution measurements in COPD
(Chapter 6)?; 6) Are the greater ventilation abnormalities for

129

Xe compared to 3He

MRI in COPD observed in Chapter 6 spatially correlated to emphysema (Chapter 7)?;
and, 7) Do ex-smokers with normal spirometry but abnormal DLCO have significantly
worse symptoms, exercise capacity and 3He MRI ADC than ex-smokers with normal
DLCO?

9.2

Summary and Conclusions

In Chapter 2 we quantitatively evaluated a small group of 15 COPD ex-smokers and five
healthy volunteers over 2 years using hyperpolarized 3He MRI. For COPD subjects,
significant increases in 3He VDP and ADC were detected whereas there was no
significant change in FEV1; healthy never-smokers showed no significant change in
imaging or pulmonary function measurements at follow-up. This finding suggests that
regional 3He MRI measurements provide adequate sensitivity for detecting COPD
changes over relatively short time periods, before significant changes in FEV1 can be
detected.
In Chapter 3 we aimed to improve intra- and inter-observer variability of 3He MRI
segmentation by developing a semi-automated segmentation method. The objective of
this work was to compare the reproducibility of manual and semi-automated
segmentation of 3He MRI ventilation measurements in subjects with a range of
respiratory conditions (i.e., asthma, COPD and cystic fibrosis). In 15 subjects we found
that manual measurements and semi-automated measurements of 3He VDV were not
significantly different and were strongly and significantly correlated. The semi-automated
VDV had high inter-observer reproducibility and intra-observer reproducibility was
significantly higher for semi-automated compared to manual measurements.

These
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findings indicate that 3He MRI semi-automated segmentation provides excellent inter/intra-observer precision with high quantitative agreement with manual measurements
enabling its use in longitudinal and serial studies.
In Chapter 4 we evaluated a group of 14 COPD subjects using the 3He MRI semiautomated measurements developed in Chapter 3 prior to and immediately following
bronchodilator therapy. Post-salbutamol, we observed significant improvements in 3He
gas distribution measurements for all subjects. Although five subjects were classified as
bronchodilator responders and nine subjects were bronchodilator non-responders
according to ATS/ERS criteria, there was no significant difference in the magnitude of
the 3He MRI changes post-salbutamol between responder groups. These results indicate
that significant gas distribution improvements occur even in COPD subjects with
minimal FEV1 or FVC response to bronchodilator therapy which is relevant to our
understanding of the regional and functional effects of bronchodilators.
In Chapter 5 we evaluated the same group of COPD ex-smokers evaluated using 3He
MRI pre- and post-bronchodilator therapy in Chapter 4 using 3He MRI diffusionweighted imaging.

Using image registration/segmentation methods developed for

quantifying ADC regionally, we found that the newly ventilated lung regions did not
have significantly elevated ADC compared to the lung regions participating in ventilation
before bronchodilator administration.

We also measured statistically significant

differences between ADC in the most anterior and most posterior image slices postsalbutamol, suggesting a reduction in regional gas trapping following bronchodilator
therapy. Regional evaluation of tissue microstructure using hyperpolarized 3He MRI
ADC provides insights into lung alterations that accompany improvements in regional
3

He gas distribution after bronchodilator administration.

In Chapter 6 we quantitatively compared hyperpolarized 3He and

129

Xe MRI acquired

within a few minutes in 8 healthy volunteers and 10 subjects with COPD, and evaluated
the correlations between 3He and

129

Xe MRI measurements with standard measurements

of pulmonary function. We found that there were significant and strong correlations
between 129Xe and 3He VDP for all subjects, however, for the COPD subjects 129Xe VDP
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was significantly greater than 3He VDP. We also found there were similar and strong
correlation for

129

Xe and 3He VDP with FEV1 and for

These findings suggest that the differences between

129

129

Xe and 3He ADC with DLCO.

Xe and 3He MRI VDP in COPD

may reflect differences in the properties of the gases and physiological/anatomical
abnormalities in COPD that are not seen in healthy volunteers.
In Chapter 7 we aimed to better understand the morphological determinants for the
ventilation differences observed between hyperpolarized 3He and

129

Xe MRI in COPD

found in Chapter 6 using 3He MRI diffusion-weighted imaging. In the same 10 COPD
ex-smokers in Chapter 6 and using the image registration/segmentation methods for
quantifying ADC on a regional basis developed in Chapter 5, we found that the mean
ADC in lung regions accessed by 3He gas only were statistically significantly greater than
the mean ADC for lung regions accessed by both gases.

We also found that the

difference between 3He and 129Xe ventilation was significantly correlated with the extent
of emphysema measured using CT. These findings indicate that the regions of decreased
129

Xe ventilation were spatially and significantly correlated with regions of increased

pulmonary emphysema. Therefore, it is most likely that the highly diffusive and less
dense and viscous 3He gas may readily access the slower-filling emphysematous lung
than 129Xe gas during the inhalation period and the breath-hold interval.
In Chapter 8 we aimed to evaluate well-established clinical, physiological and emerging
imaging measurements in 38 ex-smokers without airflow limitation and compared them
with 15 ex-smokers with COPD. In the absence of spirometry or CT abnormalities, half
of the ex-smokers without COPD showed abnormally elevated 3He ADC and abnormal
DLCO consistent with early or mild emphysema. These subjects had significantly and
markedly worse exercise capacity and symptoms compared with ex-smokers with normal
ADC and DLCO, and worse exercise capacity than the subjects with COPD. These novel
findings provide evidence for the impact of mild or early stage emphysema and a better
understanding of abnormal DLCO and hyperpolarized 3He MRI in ex-smokers without
COPD.
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9.3

Limitations

In this section I will discuss some of the most significant limitations of the 3He MRI
studies presented in Chapters 2-8, although the more detailed description of the study
limitations were presented within the Chapters. I will also outline how these limitations
may be overcome in future studies. Finally, I will end this section by describing the more
general limitations common to each of these Chapters and introduce work that has yet to
be done to overcome these limitations.

9.3.1

Study Specific Limitations

In the longitudinal study presented in Chapter 2, we did not acquire more established
clinical measurements (ie., symptom scores and exercise tests) and therefore it is
unknown whether these subjects had symptomatic worsening or a decline in exercise
capacity over the two years that could be attributed to their disease progression. In
addition, CT images were also not acquired and therefore our results could not be directly
compared to more established CT measurements, such as the percentage of low
attenuation pixels (LAA%) as a measurement of the extent of emphysema or WA% as a
measurement of airway wall thickness.

Clearly, a direct comparison of CT and

hyperpolarized 3He MRI measurements in the same subjects would allow for a better
understanding of the differences in measurement sensitivity these imaging modalities
provide. Moreover, the relatively small group of COPD subjects and healthy neversmokers evaluated, and the relatively short period of follow-up certainly limits the
applicability of our results. Also, the comparison of current smokers with COPD, exsmokers with COPD and never-smokers may help to establish and directly compare rates
of lung structural and functional decline. Another important limitation of this study was
the use of manual segmentation approaches. Manual segmentation introduces inter- and
intra-observer variability and therefore there is the potential for the changes measured
over time to be due to the measurement error. Although in this study, two independent
observers evaluated the measurements at the baseline and the 2 year follow-up time point
and both demonstrated statistically significant changes, segmentation methods with high
precision are required to ensure that the changes measured over time represent
physiological changes. To overcome these limitations, larger studies of current and ex-
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smokers with COPD and healthy never-smokers should be followed longitudinally over
multiple time-points and evaluated using hyperpolarized gas MRI and CT with automated
segmentation approaches, as well as with symptom scores (St. George’s Respiratory
Questionnaire) and tests of functional capacity (6 minute walk test).
In Chapter 3, one of the important limitations of Chapter 2 was addressed. We developed
a semi-automated 3He MRI segmentation algorithm that provided excellent inter-/intraobserver precision with high spatial and quantitative agreement with manual
measurements enabling its use in longitudinal studies.

However, this segmentation

algorithm is not without its own limitations. First, the algorithm is not fully automated
and therefore it requires some user intervention to remove the trachea as well as to
manually select landmarks for registration. Although this segmentation method has clear
advantages over manual segmentation, automating these steps would clearly improve the
reproducibility of the technique and reduce segmentation time. One way to improve this
technique is the simultaneous acquisition of 3He and 1H MRI,11 which would eliminate
the registration step and improve reproducibility.
In Chapter 4 and 5 we evaluated COPD subjects pre- and post-bronchodilator and
demonstrated significant improvements in gas distribution to regions of the lung that
were not more emphysematous than the remaining lung participating in gas distribution
before bronchodilator use, however we did not acquire more established clinical
measurements to determine whether these improvements in gas distribution were related
to improvements in symptoms or exercise capacity. Importantly, although 3He MRI in
COPD has been shown to have high reproducibility for same-day repeat imaging as well
as imaging over one week,12 the prospective inclusion of a control group would have
strengthened the conclusion that the changes post-bronchodilator were directly
attributable to bronchodilator treatment. Also, studies have previously demonstrated
significant changes in CT airway morphology measured in COPD after administration of
a bronchodilator,13 and therefore acquiring CT in these subjects would have provided
support for these findings as well as provide a better understanding of the relative
sensitivities these imaging modalities provide for detecting changes following treatment.
Also, the relatively small group of COPD subjects and the fact that the analysis was
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restricted mainly to subjects with stage II and III COPD certainly limits the applicability
of our results.

To overcome these limitations, larger studies evaluating COPD ex-

smokers randomized to either a control (pre- and post-placebo) or treatment group (preand post-bronchodilator) should be performed using hyperpolarized gas MRI and CT as
well as symptom scores and tests of exercise capacity.
Although Chapter 6 and 7 had the inclusion of CT measurements which were strengths of
these studies, the acquisition of clinical measurements for direct comparison to 3He and
129

Xe MRI measurements were not acquired and may have aided in determining the

clinical meaning of the differences observed. Future studies should aim to evaluate the
differences between 3He and

129

Xe MRI in terms of their relationships with clinical

measurements as well as the relative sensitivities for detecting improvements following
treatment or interventions. Also, there is significant work to be done to better understand
how the different properties of 3He and 129Xe gas affect ventilation distribution and most
importantly, what information these differences in ventilation distributions provide us
regarding the sensitivity of the different gases and their mixtures for detecting airway and
ventilation abnormalities.
mixtures of 3He and

129

Directly visualizing the distribution of the gases using

Xe with well-controlled viscosities and densities during a breath-

hold in the same subjects using time-resolved imaging sequences, as was recently
performed with 3He MRI,46 could certainly be utilized to test some of our important
hypotheses regarding delayed/collateral ventilation within emphysematous lung regions
in COPD subjects. These studies should be performed in a larger group of COPD
subjects with varying stages of disease severity.
In Chapter 8, we prospectively included 3He MRI, CT, SGRQ and the 6MWT which was
an important strength of this study. However, this study was limited by the relatively
small number of subjects evaluated and due to the small subject number we were unable
to evaluate sex differences. Larger studies evaluating subjects with abnormal and normal
DLCO without airflow limitation is required to evaluate whether emphysema dominates in
females in early disease and whether females are more susceptible to develop early on-set
COPD. Moreover, it would be very important to longitudinally evaluate these subjects to
determine whether the subjects with abnormal DLCO develop airflow limitation.

232

9.3.2

General Limitations

Although in the last chapter of this thesis we prospectively acquired CT, SGRQ and the
6MWT concurrently with 3He MRI, all of the previous studies in this thesis would have
been strengthened by the inclusion of these more established measurements. Moreover,
although 3He ADC and CT measurements have been directly compared and shown to be
significantly correlated in COPD subjects14 and asymptomatic smokers,15 there have been
limited comparisons between

3

He ventilation measurements and CT airway wall

measurements in COPD.16 An important aim of future work should be to directly
compare 3He MRI functional measurements and CT structural airway measurements in a
large group of COPD subjects.
Another important limitation of this work is that we do not have a clear understanding of
the etiology of noble gas MRI ventilation defects. It is hypothesized that 3He ventilation
defects are caused by narrowed or constricted/occluded small airways, however, there is
also the possibility that the ventilation abnormalities are due to mucous plugs. Previous
studies have demonstrated 3He MRI ventilation defect measurements were highly
reproducible over 7-days in COPD,12 while poor 3He MRI reproducibility was shown in
cystic fibrosis subjects over 7-days17 which was thought to be related to defective mucus
clearance. 3He ventilation abnormalities in COPD may also be related to bullous disease
or severe emphysema which would indicate that 3He ventilation defects reflect structural
changes in the lung parenchyma rather than changes in the small airways. Therefore,
investigating the etiology of hyperpolarized MRI ventilation defects is important for our
understanding of what this measurement represents in COPD subjects.

9.4
9.4.1

Future Directions
Airway Morphology and Hyperpolarized 3He MRI Ventilation
Defects

Although 3He MRI ventilation abnormalities in subjects with pulmonary disease has been
shown to spatially correlate with ventilation abnormalities seen on xenon-133
scintigraphy18 and correlate significantly with spirometric measurements of airflow
limitation,19 we still do not have a clear understanding of the etiology of noble gas MRI
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ventilation defects. Depending on the respiratory disease, 3He ventilation defects could
be caused by narrowed or constricted/occluded small airways, mucous plugs, bullous
disease, severe emphysema or any combinations of these pathologies.

Therefore,

investigating the etiology of hyperpolarized MRI ventilation defects is important for our
understanding how this measurement can be used to monitor disease progression and
response to treatment.
Clearly, investigating the etiology of hyperpolarized gas MRI ventilation defects will
require direct comparison with histology to fully uncover the underlying pathologies.
Studies performed by Jason Woods and Jim Hogg20 have previously compared the 3He
ADC with histology in explanted human lungs. Explanted lungs from patients who
underwent lung transplantation for advanced COPD and donor lungs that were not used
for transplantation were evaluated using 3He diffusion-weighted MRI and histology.
Woods and colleagues20 showed that the 3He ADC was significantly correlated with
histology measurements (mean linear intercept and the surface area to lung volume ratio).
Importantly, normal control lungs could be more clearly separated from emphysematous
lungs using the 3He ADC compared to histology measurements, suggesting the 3He ADC
is very sensitive to mild and moderate emphysematous tissue destruction. Studies of this
nature are required comparing 3He static ventilation imaging and histology in the
ventilation defect regions as well as the regions of hypointense signal. In addition, it
would be useful to evaluate the airway dimensions using histology in airways proximal to
3

He ventilation abnormalities to confirm that 3He ventilation defects are due to narrowed

or constricted/occluded small airways.
However, before comparison between 3He MRI and histology is performed, comparisons
between 3He MRI functional airway measurements (i.e., VDP) and CT structural airway
measurements (i.e., WA%) may begin to tease apart the contributions of these different
underlying disease changes. Although in COPD, 3He ventilation defects may be caused
by disease changes in either the lung parenchyma, the airways, or both, asthma is solely
an airways disease.

In the following sections I will outline research that could be

performed using MRI-CT comparisons to better understand the etiology of
ventilation defects in asthma and COPD.

3

He

234

9.4.1.1

CT Airway Morphology and
Ventilation Defects in Asthma

Hyperpolarized

3

He

MRI

Asthma is a complex inflammatory disorder of the airways that is characterized by
airway hyper-responsiveness and variable airflow obstruction. The primary consequence
of airway inflammation in asthmatic patients is airway smooth muscle hyperplasia and/or
hypertrophy.21 This airway smooth muscle hyperplasia and hypertrophy, as well as
epithelial basement membrane thickening, mucous gland and goblet cell hyperplasia, are
part of the airway remodeling process that occurs in asthma that contributes to airway
wall thickening and to a decrease in lumen diameter.
There have been several studies performed in asthma using CT to investigate the
relationship between airway remodeling with functional limitation.22-30 These studies
haves shown strong relationships between CT structural airway measurements with
inflammation,22;23 spirometry,22-27 and air trapping.22;28-30 Hyperpolarized 3He MRI has
also been used to visualize heterogeneous and abnormal gas distribution in asthma28;31
and 3He MRI gas distribution measurements were shown to significantly correlate with
spirometry28;32;33 and disease severity. 32;34
Therefore, in asthma the hypothesis is that the functional abnormalities observed with
3

He MRI are related to airways that are remodeled and/or constricted. Using CT, the

percentage of the total airway that was airway wall (WA%) and lumen area can be
measured35 up to the 6th generation airways.36 By registering hyperpolarized 3He MRI
and CT acquired in the same asthmatic subjects at the same lung volume, the following
research questions can be addressed:
1) In asthmatics following 3He MRI and CT registration, can the CT airways feeding
the regions of the lung where 3He MRI ventilation defects are observed be
identified?
2) Are the CT-derived airway wall measurements greater in asthmatics proximal to
3

He MRI ventilation defects compared to non-asthmatics and asthmatics with no

ventilation defects?
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3) Is there a significant relationship between the extent of airway wall thickening
measured using CT with the volume of the 3He MRI ventilation defects in asthma?
In a small proof-of-principle study of 18 asthmatics and 5 healthy volunteers, 3He MRI
and CT in a region-of-interest (ROI) spatially related to 3He MRI ventilation defects was
acquired, as shown in Figure 1. Since there were no ventilation defects for the healthy
volunteers, the CT ROI was selected at random. CT analysis in the ROI showed that
WA% was significantly greater (p=.002) and lumen area was significantly reduced
(p=.02) for the asthmatics in comparison to the healthy volunteers. Moreover, the extent
of airway wall thickening measured using CT was significantly correlated with the extent
of ventilation abnormalities measured using 3He MRI (r=.43, p=.04). These findings
provide a better understanding of the underlying airway spatial structure-function
relationships in asthma and, importantly, suggest that there is a relationship between
airways that are remodeled and/or constricted and

3

He ventilation abnormalities.

However, larger studies are required to confirm these important findings. Also, the
acquisition of whole lung CT images will allow for registration of the three-dimensional
airway tree to 3He MRI for identification of the specific airway that feeds the 3He MRI
ventilation defect region. The identification of 3He MRI functional abnormalities and the
airways responsible for these functional abnormalities may help guide therapy or airway
interventions in asthmatic subjects, as well as aid in the evaluation of the airway
interventions over time.

Figure 9-1 CT and 3He MRI in Asthma
A partial CT (as shown registered to the 3He MR image) was acquired in a region of
interest that was selected based on the location of hyperpolarized 3He MRI ventilation
defects for quantification of structural abnormalities.
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9.4.1.2

CT Airway Morphology and
Ventilation Defects in COPD
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As described above, and in contrast to asthma, 3He ventilation defects in COPD may be
caused by narrowed or constricted/occluded small airways, mucous plugs, bullous
disease, severe emphysema or any combinations of these pathologies. Much of our
understanding of small airways disease is from the early studies by Hogg and Macklem9
that identified the small airways as the major site of airflow resistance in COPD. The
authors observed that the bronchioles were often narrowed and occluded with mucus
plugging and defined these changes in the small airways as “small airways disease.”
More recently, Hogg and colleagues37 evaluated the pathology of the small airways in
relation to COPD severity, as measured by the GOLD COPD stages.5 These authors
found that although the degree to which the lumen was filled with mucous significantly
correlated with COPD severity, the strongest association with progression of COPD from
GOLD state 0 to GOLD stage IV was with thickening of the airway wall.37 Therefore, it
is hypothesized that in COPD subjects there is a significant relationship between airway
wall thickness measured using CT and 3He MRI ventilation abnormalities. Since bullous
disease and emphysematous tissue destruction may also result in 3He gas distribution
abnormalities in the lung, we hypothesize that the relationship between airway wall
thickness measured using CT and 3He MRI ventilation abnormalities would be strongest
in subjects without emphysema.

By registering hyperpolarized 3He MRI and CT

acquired in the same COPD subjects at the same lung volume, the following research
questions can be addressed:
1) In COPD following 3He MRI and CT registration, can the CT airways feeding the
regions of the lung where 3He MRI ventilation defects are observed be identified?
2) Are the CT-derived airway wall measurements greater in COPD subjects
proximal to 3He MRI ventilation defects compared to COPD subjects with no
ventilation defects in the same lung region?
3) Is there a significant relationship between the extent of airway wall thickening
measured using CT with the volume of the 3He MRI ventilation defects in COPD?
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4) Is the relationship between airway wall thickness measured using CT and 3He
MRI ventilation abnormalities stronger in COPD subjects without emphysema
compared to COPD subjects with emphysema?
As part of a larger longitudinal study of 200 ex-smokers with and without COPD, we
performed a preliminary analysis in the first 21 subjects comparing the functional
abnormalities measured using 3He MRI with CT structural airway measurements and
found that there was a significant relationship between 3He MRI VDV with CT airway
wall area (Aaw) for the 5th generation (r=.72, p=.002) and 6th generation (r=.56, p=.03)
airways, as shown in Figure 2.16 The quantitative evaluation of 3He MRI functional
measurements with CT structural measurements in this large group of COPD subjects
with varying stages of COPD and with varying extents of emphysema will provide a
better understanding of the underlying disease changes responsible for the 3He ventilation
defects in COPD.

Figure 9-2 Evaluation of CT and 3He MRI in COPD
A preliminary comparison of 3He MRI and CT in COPD subjects (A) showed a
statistically significant correlation between 3He VDV and CT airway wall area (Aaw) for
5th (r=.72, r2=.52, p=.002) and 6th (r=.56, r2=.31, p=.03) generation airways (B).

9.4.2

Hyperpolarized 3He MRI and CT COPD Phenotypes

Although it is well known that the underlying disease mechanisms in COPD is small
airways disease or emphysema, or some combination of both, patient-specific
phenotyping continues to be a critical unmet clinical need that may help to guide patient
therapy and management. Moreover, spirometry provides only a global measurement of
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lung function and therefore the limitation of spirometry for differentiating these
underlying pathologies or phenotypes has motivated the use of non-invasive imaging.
Previous studies have demonstrated that these emphysema and airways disease dominant
phenotypes can be distinguished by measuring LAA% as a measurement of emphysema
and the WA% as a measurement of airways disease.35 It has been shown that although
the combination of CT emphysema and airways measurements had the strongest
correlation with FEV1, both measurements were also independently correlated.35
However, thickening and narrowing of the small airways < 2 mm in diameter leads to the
most important functional limitation in COPD,9 and CT is severely limited in that
measurement of the small peripheral airways is not possible due to the CT resolution
limits.
Hyperpolarized noble gas MR imaging also has the potential to distinguish these distinct
underlying phenotypes. The 3He ADC has been shown to correlate significantly with
histology measurements of emphysema in explanted lungs,20 and shown to correlate
significantly with CT measurements and DLCO in COPD subjects14 and in asymptomatic
smokers.15 Although the exact pathology underlying 3He ventilation defects has yet to be
determined, as described above, significant correlations with xenon-133 scintigraphy18
and FEV119 have been observed. It is therefore hypothesized that 3He ventilation defects
reflect airflow limitation that is caused by small airways disease. Importantly, we have
previously demonstrated in a small proof-of-principle study evaluating 20 subjects
ranging from stage I to stage IV COPD evidence of either 3He VDP or ADC providing
the main contribution to 3He MRI measured disease, or in other words, these COPD
subjects showed evidence of having a single dominant disease phenotype.19 It was also
suggested that the subjects with an imaging dominant phenotype showed decreased
disease severity as measured by FEV1. This interesting finding suggests that subjects
may develop one disease phenotype in the early disease stages and then progress to a
mixed disease phenotype and more severe disease over time.
This very interesting hypothesis should be tested in a larger group of COPD subjects,
ranging from stage I to stage IV disease. The acquisition of CT for these subjects would
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also allow for the relationship between 3He MRI and CT measurements of airways and
emphysema phenotypes to be directly compared. Importantly, the relationship between
these imaging phenotypes with pulmonary function test measurements, symptom scores,
and measurements of exercise tolerance would provide important information regarding
the functional effect these underlying disease phenotypes have on the subject. Also,
these subjects should be followed longitudinally to determine how and if phenotypic
dominance occurs in early disease and progresses to more severe mixed disease over
time.

9.4.3

Hyperpolarized 3He MRI Phenotypes of COPD: Relationship to
Exacerbations

In Appendix B we reported serial hyperpolarized 3He MRI over a four year period in a 77
year old COPD ex-smoker prior to and following treatment for an acute exacerbation
(AE) of COPD. In this case study, 3He MRI showed improvements in gas distribution
prior to improvements reflected by FEV1. Importantly, it was also suggested that this
subject had a worsening of 3He gas distribution 6 months prior to the exacerbation,
although there was no change in the subjects clinical status until approximately one
month before hospitalization when the subject complained of symptoms. We suggested
that 3He MRI may have reflected regional pulmonary decline before, or even in the
absence of changes in FEV1. From this case report several hypotheses and questions
arose related to the time-course of COPD exacerbations that should be tested in a larger
study that follows COPD subjects longitudinally. The research questions that should be
tested are:
1) Is there a relationship between symptomatic and 3He MRI improvements following
therapy, before changes in FEV1 are measured?
2) Do COPD patients with specific imaging phenotypes have a propensity for increased
exacerbation frequency?
In a study currently underway, we aimed to determine if subjects that experienced an AE
prior to or following hyperpolarized 3He MRI had a greater propensity for a specific
imaging phenotype in comparison to subjects that did not experience an AE, and whether
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there was a relationship between these imaging measurements with symptoms and
functional limitation. Based on the findings of the case report presented in Appendix B
the demonstrated VDP worsening prior to an AE, we hypothesized that subjects that
experienced an AE following the 3He MRI study would have significantly worse VDP
than subjects that did not experience an AE. To date 94 COPD subjects have underwent
3

He MRI, CT, spirometry/plethysmography, the St. George’s Respiratory Questionnaire

(SGRQ) and the six-minute walk test (6MWT). We defined an AE as a worsening of
COPD symptoms that required hospitalization and was determined by examining patient
records for up to 2 years prior to or following the study visit. Subjects were divided into
three groups: no AE, AE prior to study visit and AE following study visit. In this
preliminary investigation we found that of the 94 COPD subjects evaluated, 8 subjects
experienced a single AE 13±9 months prior to the study visit and 10 subjects experienced
a single AE 7±8 months following the study visit.

Interestingly, we showed those

subjects that experienced an AE following the study visit reported a significantly worse
SGRQ score (p=.05), 6MWD (p=.02) and 3He VDP (p=.02) than the subjects that did not
experience an AE (Figure 3), lending support to the hypothesis that 3He VDP may
worsen prior to exacerbations in COPD. However, the 2 year follow-up period is not
complete for most of the COPD subjects evaluated and therefore it is important to
continue to follow these subjects to determine the frequency of exacerbations as well as
to determine if 3He MRI gas distribution improves following exacerbation treatment.
This finding may have important implications for future COPD imaging studies
evaluating the association between COPD phenotypes and exacerbation risk. Clearly,
predicting those COPD patients that are at the greatest risk for acute exacerbations will
enable the targeting of these individuals for preventive therapy, or at least more
aggressive monitoring.
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Figure 9-3 3He MRI static ventilation images and ADC maps for a representative
subject that had an exacerbation and a representative subjects that did not have an
exacerbation.
Blue arrows indicate the large ventilation defects visually apparent in the subject that
experienced an exacerbation.

9.4.4

Hyperpolarized Noble Gas MRI of Pediatric Lung Disease

A major strength of MRI is that it does not require the use of ionizing radiation and
provides regional structural and functional information simultaneously. This is important
for all longitudinal studies of lung disease, but this is especially the case in children with
chronic life-threatening pulmonary disease. Therefore, hyperpolarized noble gas MRI
can be used to measure lung structure and function in young subjects and at multiple
time-points. However, despite the fact that the imaging procedure has been demonstrated
to be feasible and well-tolerated in healthy non-sedated infants and children38;39 and
infants and children with asthma and cystic fibrosis (CF),38;40-44 most 3He and 129Xe MRI
studies to date have been performed in adults and experience in children has been largely
limited to CF. There is clearly considerable potential for hyperpolarized gas MRI to be
used to evaluate CF and asthma, as well as other chronic lung diseases in the pediatric
population, and therefore larger MRI studies in children are required.
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9.4.4.1

Hyperpolarized Noble Gas MRI in Pediatric Cystic Fibrosis

Although hyperpolarized 3He MRI experience is limited in the pediatric population and
only moderate correlations have been shown between 3He MRI and spirometry in
pediatric CF subjects,42;45 possibly due to the fact that children have difficulty performing
the manoeuvres, 3He MRI has demonstrated regional changes in gas distribution in
children following chest physiotherapy,43;44 following treatment with a bronchodilator
and after mechanical airway clearance treatment.45

More recently, dramatic

improvements in 3He gas distribution were visualized in children with CF following
treatment with Ivacaftor, the first investigation to use hyperpolarized gas MRI to assess
an investigational CF drug.40;46
Although pulmonary function tests are still the mainstay for monitoring disease status and
progression, and FEV1 is still the primary endpoint used and accepted by regulatory
authorities for clinical trials of CF therapies, the limitations of standard pulmonary
function test measurements and the clear advantages to using sensitive imaging
biomarkers for evaluating the efficacy of novel therapies suggest this is likely a target
application for hyperpolarized gas MRI. It is clear from these previous 3He MRI studies
in CF that the advantages of MRI for the quantitative, sensitive and regional evaluation of
lung structure and function intensively in serial and longitudinal studies necessitates
further investigation of pulmonary MRI in pediatric therapy studies.

9.4.4.2

Hyperpolarized Noble Gas MRI in Pediatric Asthma

Asthma is the most common chronic disease in the pediatric population and the
prevalence of asthma continues to rise.47 Despite advances in drug therapy, a significant
proportion of health care expenditure, morbidity and excess mortality are related to a
small but significant number of patients with severe asthma symptoms that remain
unresponsive to current treatments. The development of new and improved asthma
therapies and interventions are required to improve asthma symptoms and reduce the
morbidity and mortality associated with asthma. Moreover, the development of new
therapies is going to require evaluation using sensitive tools that provide useful
information regarding the effects of treatment on lung structure and function.
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In preliminary studies utilizing hyperpolarized 3He MRI in asthmatics with abnormal
spirometry, ventilation defects were observed that resolved and reappeared over a three
week period.48

Other studies using 3He MRI in asthmatics also demonstrated 3He

ventilation defects and showed that these defects increased in number and extent
following an exercise challenge and methacholine administration.49 Importantly, 3He
ventilation defect measures correlated significantly with spirometry32;49 and disease
severity.32 It has also been demonstrated that many of the ventilation defects visible with
3

He MRI persist or recurred in the same location over time or with repeated

bronchoconstriction,50;51 suggesting airway abnormalities are regional in nature.
In a study by Fain and colleagues28 comparing hyperpolarized 3He MRI with chest CT in
asthmatics, regions of the lung with 3He MRI ventilation defects were shown to spatially
correlate with regions of hyperlucency on CT. The authors also obtained inflammatory
markers using bronchoscopy in these ventilation defect regions and detected an increase
in inflammatory cell counts,28 suggesting these regional ventilation defects are likely
related to airway inflammation and obstruction. Another recent study52 showed that 3He
ventilation defect measurements correlated significantly with specific airway resistance,
symptoms and exhaled nitric oxide, also lending support to the notion that ventilation
defects are likely related to inflammation and narrowing/obstruction of the airways.
From this work it is clear that hyperpolarized gas MRI has many potential clinical
applications in asthma. The direct visualization of ventilation defects that recur in the
same locations following provocation may help guide airway treatments and
interventions to the regions within the lung or the specific airways that are hyperresponsive. However, nearly all 3He MRI studies have been performed with adult asthma
subjects and therefore further studies evaluating regional 3He MRI structural and
functional measurements at baseline and following provocation and treatment are
required in the pediatric population.
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Importantly, studies in healthy pediatric subjects showed that 3He MRI ADC increases
with age,39 suggesting that diffusion-weighted MRI can be used to assess lung growth
and alveolar enlargement.

Lung growth was also recently investigated using

3

hyperpolarized He diffusion-weighed MRI by Butler and colleagues53 in a 33-year-old
woman and demonstrated that this woman had an apparent 64% increase in the number of
alveoli in her left lung 15 years following a right-sided pneumonectomy. These very
exciting studies suggest that diffusion-weighted MRI has the potential to evaluate lung
growth and development in children and in particular, it may be used to evaluate noninvasively and in vivo chronic lung diseases in children that affect the development of
normal lung microstructure, such as bronchopulmonary dysplasia (BPD).

Although

diffusion-weighted MRI has yet to be exploited in larger studies of pediatric diseases
such as BPD, the promise remains for a non-invasive measurement that may regionally
and longitudinally assess normal and abnormal lung growth and development.
We believe that these important studies in children demonstrate the feasibility of
hyperpolarized gas MRI to non-invasively measure disease morphological and functional
consequences and to explore disease pathophysiology in vivo to potentially provide an
improved understanding of pediatric lung disease.

9.5

Significance and Impact

Although FEV1 remains the primary outcome measure for assessing COPD progression
and response to treatment, it is well recognized that COPD is a multi-component disease
and, while FEV1 has its strengths, there is a continued and urgent need for additional
pulmonary biomarkers for assessing COPD outcomes. Here, we have demonstrated that
regional 3He MRI measurements provide adequate sensitivity for detecting two important
outcomes in COPD, namely evaluating significant changes over relatively short periods
of time and evaluating changes following treatment.

Importantly, these 3He MRI

measurement changes occurred in the absence of FEV1 changes, thus suggesting that 3He
MR imaging biomarkers may have increased sensitivity to measuring outcomes in
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COPD.

In this regard, we also identified ex-smokers with 3He MRI evidence of

emphysema, symptoms and reduced exercise capacity with “normal” spirometry. Taken
together, these findings suggest that 3He MRI may provide the opportunity for measuring
early disease changes in subjects with symptomatic changes, as well as measuring
longitudinal and treatment changes, in the absence or possibly before changes in FEV1.
In order to measure these important COPD outcomes, hyperpolarized gas MRI
measurement tools for the regional quantitative evaluation with sufficient precision were
needed.

We

developed

reproducible

and

robust

hyperpolarized

gas

MRI

registration/segmentation methods for generating measurements of pulmonary gas
distribution that could be applied across many respiratory conditions, and also be used for
larger scale pulmonary functional MRI studies. We also developed image analysis tools
for hyperpolarized gas diffusion-weighted MRI that provided a way to evaluate regional
lung microstructure, and provided important insights into pulmonary structure-function
on a regional basis. These important findings indicate that hyperpolarized gas MRI can
be used to improve our understanding of lung structural and functional changes in COPD.
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APPENDIX A
In Appendix A we aimed to establish imaging measurement reproducibility in adult cystic
fibrosis subjects over a short period of time (7 ± 2 days) in the absence of therapeutic
intervention using hyperpolarized 3He MRI.
The contents of this Chapter have been previously published in Academic Radiology and
permission to reproduce the article was granted by John Wiley and Sons and is provided
in Appendix C.
M Kirby, S Svenningsen, H Ahmed, N Paterson and G Parraga. Quantitative Evaluation
of Hyperpolarized Helium-3 Magnetic Resonance Imaging of Lung Function Variability
in Cystic Fibrosis. Acad. Radiol. 2011; 18(8):1006-13.

A

Quantitative Evaluation of Hyperpolarized Helium-3
Magnetic Resonance Imaging of Lung Function
Variability in Cystic Fibrosis
A.1 Introduction

High resolution computed tomography (HRCT) is currently the gold standard imaging
method for providing quantitative morphological measurements of lung abnormalities
associated with cystic fibrosis (CF).

Scoring systems have been developed,1 for

radiological interpretation of various pulmonary abnormalities, including bronchiectasis,
mucous plugging, airway wall thickening, and air trapping.

Such scoring systems

correlate with chest radiograph scores,1 pulmonary function tests,2 and clinical findings3
and have been shown to be more sensitive than spirometry for detecting disease
worsening.4

Despite these important advantages, the risk associated from repeated

radiation exposure, particularly in monitoring disease progression and serial imaging in
therapy studies, limits the use of CT in CF. In addition, the relationship between lung
functional changes and the structural, anatomical and morphological changes reflected by
quantitative HRCT is still not completely understood.
Hyperpolarized Helium-3 (3He) magnetic resonance imaging (MRI) provides high spatial
and temporal resolution images of both lung structure and function5-10 without ionizing
radiation. Regional ventilation abnormalities can be clearly visualized as decreased or
absent 3He signal in the lung that can be evaluated using quantitative scoring systems or
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volumetric approaches.9;11

These measurements are sensitive to the pathological

changes that accompany CF,12-18 have high same-day reproducibility in pediatric CF
patients,18 and changes are clearly visible despite clinically normal spirometry results.12
Because of previous same-day reproducibility18 and treatment12;16;18 studies in CF
patients, we hypothesized that 3He MRI would provide the necessary and sufficient
spatial and temporal sensitivity to detect day-to-day changes in lung function.
There is an urgent requirement for precise and sensitive measurements or surrogates that
can be used to determine pulmonary response to treatment and to monitor disease
progression; imaging methods may be ideally positioned to provide some of these
measurements.

Establishing imaging measurement reproducibility over time in the

absence of therapeutic intervention is essential for future studies that aim to evaluate
treatment changes. Accordingly, the objective of this study was to evaluate lung function
over a relatively short period of time (7 ± 2 days) using spirometry, plethysmography and
hyperpolarized 3He MRI in adult CF patients with moderate lung function. To our
knowledge, this is the first reported study that quantitatively evaluates short-term lung
functional variability in CF using 3He MRI.

A.2 Materials and Methods
A.1.1 Subjects
Study subjects provided written informed consent to the study protocol approved by the
local research ethics board and Health Canada.

The study was compliant with the

Personal Information Protection and Electronic Documents Act (PIPEDA, Canada) and
the Health Insurance Portability and Accountability Act (HIPAA, USA).

Subjects

between the ages of 18 and 45 years, without claustrophobia or MRI contraindications
and with baseline FEV1%pred > 60% at their last clinical visit were enrolled. Study
participation was also limited to those CF patients experiencing no more than three
previous exacerbations (change in medication or hospitalization for CF) within the last 12
months, as an indication of appropriate disease control. A baseline and 7-day repeat
testing paradigm was chosen to differentiate the day-to-day changes common in CF from
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longer term alterations in lung physiology that accompany CF lung disease progression.
All subjects were evaluated using spirometry and plethysmography 30 minutes prior to
MRI and all subjects were evaluated on two separate occasions within 7 ± 2 days. Digital
pulse oximetry was used to measure arterial oxygen saturation (Sa02) for all subjects
during scanning sessions. An adverse event was considered to have occurred when Sa02
decreased below 88% at any time during the scanning session. Study withdrawal was
required when Sa02 decreased to 80% for 10 seconds or longer.

A.1.2 Pulmonary Function Tests
Spirometry was performed using an ndd EasyOne spirometer (ndd Medizintechnik AG,
Zurich, CH) reporting forced expiratory volume in 1 second (FEV1) and forced vital
capacity (FVC) with a minimum of three acceptable spirometry maneuvers with the best
FEV1 and FVC selected for analysis according to the American Thoracic Society (ATS)
guidelines. Total lung capacity (TLC), inspiratory capacity (IC), residual volume (RV),
functional residual capacity (FRC), and diffusing capacity of carbon monoxide (DLCO)
were measured using body plethysmography (MedGraphics Corporation, 350 Oak Grove
Parkway St. Paul, MN USA).

A.1.3 Image Acquisition
MRI was performed on a whole body 3.0 Tesla (3T) Excite 12.0 MRI system (GEHC,
Milwaukee, WI USA) with broadband imaging capability as previously described.10 All
helium imaging employed a whole body gradient set with maximum gradient amplitude
of 1.94 G/cm and a single channel, rigid elliptical transmit/receive chest coil (RAPID
Biomedical GmbH, Wuerzburg Germany). The basis frequency of the coil was 97.3
MHz and excitation power was 3.2 kW using an AMT 3T90 RF power amplifier (GEHC,
Milwaukee WI USA). Subjects were positioned supine in the MR scanner and Sa02 was
used to monitor arterial blood oxygenation levels during all MRI maneuvers. For both 1H
and 3He MRI, subjects were instructed by a pulmonary function technologist to inhale a
gas mixture from a 1.0 L Tedlar bag (Jensen Inert Products, Coral Springs, FL) from
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FRC, and image acquisition was performed under breath-hold conditions– a period of 8
to 15s.
Coronal proton (1H) MRI was performed prior to hyperpolarized 3He MRI with subjects
scanned during breath-hold after inspiration of a 1.0 L 4He/N2 gas mixture using the
whole body radiofrequency (RF) coil and 1H fast spoiled gradient recalled echo sequence
(16s total data acquisition, repetition time (TR) / echo time (TE) / flip angle = 4.7 ms /
1.2 ms / 30o, field-of-view (FOV) = 40 x 40 cm, matrix 256 x 128, 14 slices, 15 mm slice
thickness, 0 gap), as previously described.10
Prior to 3He MRI, a polarizer system (HeliSpin™, GEHC, Durham, NC) was used to
polarize 3He gas to 30-40 %. As previously described,10 hyperpolarized 3He MRI coronal
static ventilation images were acquired in breath-hold after inspiration of a 1.0 L 3He/N2
mixture (does 5 mL/kg body weight) (14s data acquisition, TR / TE / flip angle = 4.3 ms /
1.4 ms / 7o, bandwidth = 31.25, FOV = 40 x 40 cm, matrix 128 x 128, 14 slices, 15 mm
slice thickness, 0 gap).

A.1.4 Image Analysis
All 3He measurements were repeated four times to estimate observer reliability according
using the approximation method developed by Walter et. al.

19

All measurements were

performed by a single observer blinded to subject and time-point with both subjects and
time-points randomized between each of the four repeated measurement trials to reduce
any potential memory bias. Additionally, each randomized time-point was analyzed
independently and one day apart to minimize observer memory bias.
The signal-to-noise ratio (SNR) for all images acquired was determined by calculating
the mean signal intensity value within a 5 x 5 voxel region of interest (ROI) for four
representative ROI within the lung parenchyma, and dividing by the standard deviation of
the mean signal intensity values for noise inside a ROI of the same size within the image
background where there was no lung structure. SNR was determined for each slice and
then averaged to obtain a single SNR value for each subject and time-point.
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He MRI pulmonary ventilation segmentation was performed with a semi-automated

method generated using MATLAB R2007b (The Mathworks Inc., Natick, MA, USA), as
previously described.20 Briefly, 3He MRI ventilation images were evaluated using a kmeans cluster algorithm,21 similar to previously described methods for 3He MRI
segmentation,22-24 to classify the 3He MRI pixel intensity values into clusters ranging
from 1 to 5, representing gradations of ventilation from unventilated to hyperventilated.
To obtain the external contour of the thoracic cavity to differentiate ventilation defects
from the edge of the lung, 1H MR images were segmented using a seeded region growing
algorithm25 and registered to the segmented 3He MR ventilation images as previously
described.26 The segmented 1H thoracic cavity volume was used to generate ventilation
defect percent (VDP),9 representing a normalized 3He ventilation defect volume (VDV10
or volume of cluster 1) for the lung.

A.1.5 Statistical Methods
Mean VDV and VDP for baseline and 7-days was calculated using the mean and standard
deviation (SD) of four repeated measurements.

The smallest detectable difference

(SDD), defined as the smallest difference that can be measured with prospectively
determined confidence that is not due to measurement error (variability), was calculated
using the baseline repeated 3He measurements according to Eliasziw et. al.27 and shown
in Equation A1:
SDD ≥ zα 2 SEM int ra

(1)

where zα is 1.96 corresponding to a significance level of α =.05 and SEM int ra is the
standard error of measurement due to intra-observer variability and is calculated as
shown in Equation A2:
SEM int ra = σˆ e 2

(2)

where σˆ e 2 is the intra-observer repeated measures variance. Multivariate analysis of
variance (MANOVA) was performed for comparison of baseline and 7-day pulmonary
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function measurements using SPSS 16.00 (SPSS Inc., Chicago, IL, USA LEAD
Technologies, Inc., Chicago, IL). For 3He MRI measurements, a three-way mixed design
repeated measures analysis of variance (ANOVA) was used to determine the interactions
between time-point (baseline and 7-day), repetition (four repeated measurements) and
subject using SPSS 16.00. The agreement between time-points for both pulmonary
function and

3

He MRI measurements was evaluated using Bland-Altman plots28

generated using GraphPad Prism version 4.00 (GraphPad Software Inc, San Diego, CA,
USA). Linear regression (r2) and Spearman correlation coefficients (r) were used to
determine the relationship between pulmonary function and 3He MRI measurements
using SPSS 16.00. A sample size ( n ) calculation29 was also performed to determine the
number of subjects required in a controlled trial to detect a significant difference (δ) for
VDP between baseline and follow-up with 95% confidence (α = 0.05, Z α = 1.96 ) and
80% power ( β = 0.20 , Z β = 0.84 ), according to Equation A3:

n=

2( Z α + Z β ) 2 SD Diff 2

(3)

δ2

where SD Diff is the standard deviation of the difference between baseline and follow-up.
In all statistical analyses, results were considered significant when the probability of
making a Type I error was less than 5% (p < 0.05).

A.3 Results
The demographic characteristics for 12 CF subjects enrolled (n=5 males, mean
age=26±8, BMI=24±4) are provided in Table A1. The first study visit was in September
2007 and the last visit was in January 2010. All subjects completed both scanning
sessions and there were no serious or severe breath-hold-related or other adverse events
reported, nor were there any other adverse events that required subjects to withdraw from
the study. Approximately one year after subject scanning, a single subject (Table A3,
subject 1, female, age 24) died due to respiratory complications related to underlying CF.
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Table A1 Subject Demographics
Subjects (±SD) [range]
(n= 12)
Age yrs
26 (8) [18-41]
Male Sex
5
-2
BMI kg·m
24 (4) [18-30]
FEV1 L
2.68 (0.66) [1.70-3.58]
FEV1%pred
72 (14) [50-96]
FVC L
3.87 (0.97) [2.87-5.65]
FVC %pred
87 (12) [74-103]
FEV1/FVC %
70 (12) [45-87]
FEV1/FVC %pred
84 (13) [54-99]
TLC L
6.52 (1.22) [5.15-8.95]†
TLC %pred
108 (12) [96-128]
IC L
2.98 (0.63) [1.88-3.67]†
IC %pred
101 (20) [80-149]†
FRC L
3.60 (1.04) [2.05-4.71]†
FRC %pred
116 (28) [77-156]†
RV L
2.51 (0.79) [1.51-3.82]†
RV %pred
168 (41) [122-232]†
DLCO
30.64 (6.39) [21.49-40]‡
DLCO%pred
105 (18) [87-138]‡
BMI=Body Mass Index, DLCO=Carbon Monoxide Diffusion Capacity of the lung,
FEV1=Forced Expiratory Volume in 1s, FRC=Functional Residual Capacity, FVC=
Forces Vital Capacity, IC= Inspiratory Capacity, %pred=Percent Predicted, RV= Reserve
Volume, SD=Standard Deviation, TLC=Total Lung Capacity, ‡n=6, †n=9.
Table A2 shows mean baseline and 7±2 day pulmonary function and 3He MRI
measurements and Table A3 shows a subject listing of all pulmonary function and 3He
MRI measurements for all subjects. For baseline repeated measurements, the intraobserver CV for both VDV and VDP was 0.04. Based on the baseline intra-observer
variance, the SDD or the minimum change in VDV and VDP that could be measured
confidently in individual subjects that was not due to technological or observer
measurement variability (measurement error) was 120ml and 2%, respectively.

As

shown in Table A3, 8 of 12 subjects showed changes in both VDV and VDP over 7 days
greater than or equal to the SDD.

259

Table A2 Baseline and 7-day pulmonary function and 3He MRI measurements
Baseline
7-day
Mean
Parameter
(n=12)
(n=12)
Difference [p]*
Pulmonary Function Measurements
FEV1 (L) (±SD)
2.68 (0.66)
2.69 (0.54)
-0.01 (0.19) [NS]
FEV1%pred (±SD)
72 (14)
72 (12)
0 (6) [NS]
FVC %pred (±SD)
87 (12)
86 (10)
0 (4) [NS]
FEV1/FVC (± SD)
70 (12)
71 (11)
-1 (4) [NS]
TLC %pred (±SD)
108(12)†
113 (16)†
-5 (7) [NS]
IC %pred (±SD)
101 (20)†
103 (19)†
-2 (14) [NS]
FRC %pred (±SD)
116 (29)†
125 (32)†
-9 (7) [NS]
RV %pred (±SD)
168 (41)†
176 (58)†
-8 (37) [NS]
DLCO (%pred) (± SD)
106 (18)‡
111 (13)‡
-5 (8) [NS]
Hyperpolarized 3He MRI
VDV L (±SD)
1.06 (0.56)
0.93 (.59)*
0.13 (0.25) [<.0001]
*
VDP % (±SD)
20 (10)
17 (10)
3 (4) [<.0001]
DLCO=Carbon Monoxide Diffusion Capacity of the lung, FEV1=Forced Expiratory
Volume in 1s, FRC=Functional Residual Capacity, FVC=Forces Vital Capacity,
IC=Inspiratory Capacity, %pred=Percent Predicted, RV=Reserve Volume, SD=Standard
Deviation, TLC=Total Lung Capacity, VDP=Ventilation Defect Percent,
VDV=Ventilation Defect Volume, ‡n=8, †n=9.
*
Significance of difference (p<.05) was determined using a repeated measures ANOVA.
There was no significant difference for pulmonary function measurements (p=.56)
between time-points. As shown in Table A2, significant differences were detected after
7-days for both 3He VDV (130 ± 250ml, p<.0001) and VDP (3%± 4%, p<.0001), and a
significant interaction between the changes measured after 7-days and subject was also
observed (p<.0001, Figure A1), indicating that not all subjects showed a change over this
time frame. To underscore this point, Figure A1 shows center slice 3He ventilation
images for three representative subjects at baseline and 7-days with subject numbers that
correspond to the subject numbers shown in Table A2. For subject (S1), very little
change in 3He gas distribution is observed between the time-points, however the change
in gas distribution after 7-days is readily apparent in subjects S2 and S3. However, it is
important to note that after conservatively comparing the 95% confidence intervals (CI)
for baseline and 7-day 3He measurements, baseline and 7-day 95% CI overlapped for
both VDV (baseline: [95% CI, 0.74L-1.38L], 7-day: [95% CI, 0.60L-1.26L]) and VDP
(baseline: [95% CI, 15%-25%], 7-day: [95% CI, 12%-23%]). Image signal-to-noise ratio
(SNR) for all baseline and 7-day image pairs was not statistically significantly different
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(p=.47), nor was there a significant relationship between the change in SNR and the
change in VDV (r=-.29, p=.35).

Figure A1 Baseline and 7-day 3He MRI static ventilation images for three representative CF
subjects.
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Shown in Figure A2, Bland-Altman analysis was also performed to evaluate differences
between time-points for FEV1 (mean difference ( d )=0.01L, 95% CI =-0.37-0.39L) and
no systematic bias was detected and differences were within the 95% limits of agreement
for all but one subject. However, Bland-Altman analysis also showed 7-day differences
for 3He VDV ( d =-0.13L, 95% CI =-0.63–0.36L) and VDP ( d =-3%, 95% CI =-11–5%)
with large 95% limits of agreement between the measurements.

Figure A2 Bland-Altman plots of the
differences between baseline and 7-day
measurements.
Scatterplots show the differences between
baseline and 7-day FEV1, VDV and VDP
for all subjects, against their mean. The
mean difference (±SD) was 0.01L
(0.19L) for FEV1 (lower limit=-.37L,
upper limit=.39L) (A), -0.13L (0.25L) for
VDV
(lower
limit=-.63L,
upper
limit=.36L) (B), and -3% (4%) for VDP
(lower limit=-11%, upper limit=5%) (C).
Solid lines indicate the mean difference
and dotted lines indicate the 95% limits
of agreement.
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Table A3 shows the relationship between the baseline and 7-day pulmonary function and
3

He MRI measurements. Figure 3 also shows the significant and moderate Spearman

correlation between FEV1%pred and VDV (r=-.65, p=.001) and VDP (r=-.68, p<.0001).
The relationship between baseline and 7-day measurements (Figure A3) was evaluated
and showed a significant correlation for FEV1%pred (r=-.89, p<.0001), 3He VDV (r=.85,
p=.001), and VDP (r=.94, p<.0001). There were no significant correlations between the
baseline and 7-day change in pulmonary function and the change in 3He measurements.
Table A3 Subject listing of baseline and 7-day pulmonary function and hyperpolarized
3
He MRI measurements
Subject
1
2
3 4
5
6
7
8
9 10 11 12 Mean (± SD)
Pulmonary Function Measurements
Baseline
FEV1 (L)
2.11 3.55 1.70 2.53 2.83 3.58 3.56 2.79 2.22 2.28 1.93 3.04 2.68 (0.66)
FEV1%pred 50 78 54 74 79 81 79 82 69 55 61 96
72 (14)
FVC (L)
3.41 4.87 3.06 2.92 3.55 5.65 4.88 3.52 2.87 5.02 2.96 3.77 3.87 (0.97)
FVC%pred
65 89 79 75 87 103 90 90 74 103 81 103
87 (12)
7-day
FEV1 (L)
2.17 3.39 2.2 2.7 2.66 3.46 3.4 2.69 2.36 2.32 1.85 3.04 2.69 (0.54)
FEV1%pred 51 74 69 79 75 78 75 79 73 56 58 96
72 (12)
FVC (L)
3.69 4.75 3.39 3.05 3.49 5.31 4.82 3.34 3.05 4.87 2.83 3.76 3.86 (0.85)
FVC%pred
70 87 87 78 85 96 89 86 79 100 77 102
86 (10)
3
He MRI Measurements
Baseline
VDV (L) 1.70 1.49 1.15 0.52 0.62 1.79 0.87 0.38 0.98 1.38 1.71 0.15 1.06 (0.56)
VDP (%)
30 24 22 13 13 27 17 10 21 24 34 3
20 (9)
7-day
VDV (L) 1.80 1.16 1.61 0.30 0.46 1.31 0.52 0.33 0.65 1.36 1.51 0.14 0.93 (0.59)
VDP (%)
30 18 27 7 10 25 10 8 11 22 31 3
17 (10)
FEV1=Forced Expiratory Volume in 1s, FVC= Forced Vital Capacity, %pred=Percent
Predicted, VDP=Ventilation Defect Percent, VDV=Ventilation Defect Volume
We generated sample sizes required to detect significant differences in VDP in an
interventional study. Instead of assuming there would be no change in VDP over time in
the absence of treatment, we used the mean difference over 7 days and the standard
deviation of that difference measured in this study to generate sample sizes for the use of
VDP. Accordingly, to detect a significant 5%/7%/10% absolute change in VDP for a
treatment group would require 60/15/5 subjects per group.
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Figure A3 Relationship between baseline and 7-day for FEV1, 3He VDV and VDP.
Baseline is significantly correlated with 7-day for FEV1 (r=-.89, p<.0001, r2=.84, p<.0001,
y=0.79x+15) (A) and 3He VDP (r=.94, p<.0001, r2=.84, p<.0001, y=1.0x-3) (B). Baseline
and 7-day FEV1 is significantly correlated with 3He VDV (r=-.65, p=.001, r2=.49,
p=.0001, y=-0.03x+3.23) (C) and VDP (r=-.68, p<.0001, r2=.55, p<.0001, y=-.54x+59)
(D). Dotted lines indicate the 95% confidence intervals.

A.4 Discussion
Functional imaging methods such as 3He MRI provide a way to perform intensive serial
studies in individual patients to monitor therapy effects and disease changes and as well
as repeated measurements in patient groups for therapy trials. However, before 3He MRI
measurements can be used as a complement to established endpoints, measurement
sensitivity and precision must be determined. In order to determine and compare the
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variability of lung function measurements in CF, we evaluated 12 adult CF subjects with
moderate lung function, using spirometry, plethysmography and 3He MRI, twice over 7
days. We made a number of important observations and report: 1) the SDD in 3He VDV
and VDP for individual subjects, 2) highly correlated baseline and 7-day VDV and VDP
but significant change in 3He MRI VDV and VDP, not reflected by changes in
spirometric or plethysmographic measurements, 3) a significant and moderately strong
relationship between FEV1 and 3He MRI functional measurements but not between the
difference between time-points in FEV1 and 3He MRI measurement, and 4) sample sizes
required to detect significant changes in 3He MRI VDP in a controlled clinical study.
First we calculated the SDD for 3He VDV and VDP for an individual CF subject that was
not due to measurement variability.

The relatively low SDD for 3He ventilation

measurements was likely a consequence of the high precision of the 3He MRI
measurement and the semi-automated image segmentation method used.
Second, we observed statistically significant changes in mean 3He measurements in 7
days, however no significant differences were detected using spirometry or
plethysmography (and this study was not powered to detect such changes). Although
previous studies have demonstrated high same-day reproducibility in pediatric CF
subjects,18 significant differences over short time periods in individuals with CF was not
unexpected because the movement of mucus plugs and subsequent alterations of airway
patency, could certainly result in 3He gas distribution changes. However, the statistically
significant and visually obvious change in 3He measurements we observed must be
examined in light of previous reports of excellent 7-day 3He MRI reproducibility in
COPD.7 The 7-day functional variability finding may reflect the greater contribution of
defective mucus clearance to CF physiological variability and is important to consider
when planning pulmonary functional imaging studies including 3He and
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Xe MRI that

evaluate long-term treatment interventions. The possibility exists that the differences
measured, though small, were due to lung structural and functional changes that occurred
over a one week period. Certainly serial 3He MRI in COPD has revealed changes over a
two-year time period with no concomitant change in FEV1.6 The results of the current
study in CF indicate that 3He MRI sensitively quantified gas distribution changes that
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occurred without changes detected in FEV1 suggesting it is possible to measure
physiological changes that occur over short periods of time in CF. Importantly, over half
of the individual subjects (8/12) studied experienced a change in VDP and VDV greater
than or equal to the SDD, over 7 days and these measurement changes were therefore
unlikely due to measurement error. The clinical meaning of this variability may be
related to day to day variations in mucus redistribution. As suggested by Bannier et.
al.,12 mucus movement over short periods of time can potentially result in many small
ventilation defects that traditional scoring or defect counting methods may not have the
sensitivity to detect.
In support of the finding of significant changes in mean 3He measurements over 7-days,
Bland-Altman plots also identified a bias or improvement in 3He measurements between
time-points. This was unexpected as there was no significant difference between SNR
for the image pairs to account for this difference and there was approximately a three
year gap between the first and last subject imaging sessions, making it unlikely that the
bias detected was due to technical or hardware issues at the second time-point for all
subjects. Whether the mean improvement in 3He gas distribution was due to the small
number of subjects evaluated or related to improved therapy compliance for some
subjects because of the 1-week study design cannot be ascertained by this study.
We also reported a significant relationship between FEV1 and

3

He functional

measurements and this finding agrees with previous studies that have demonstrated the
relationship between FEV1 and 3He measurements within a single day in both adult CF15
and in pediatric CF patients.17;18

It is still unclear what the clinical meaning that

ventilation distribution has in CF because 3He MRI measurements have not been
validated using histology. However it is possible that the ventilation measurements
reported in this study reflect regional lung function and functional changes that occur on
a day-to-day basis in CF.
Finally, to use the current results as a guide for future studies, we estimated sample sizes
required to detect significant differences in 3He VDP. Relatively small sample sizes of
60/15/5 subjects were estimated to be required per group to detect significant
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5%/7%/10% absolute changes in VDP. This suggests that 3He MRI can be considered
when small sample sizes are necessitated such as in rare diseases with small patient
populations, or in high cost per patient study designs.
We acknowledge that this pilot study is limited by the small number and type of CF
subjects studied. The study subjects were recruited to represent CF subjects that would
be appropriate candidates for therapy trials based on their FEV1, and therefore caution
should be exercised in extrapolating these results to a pediatric population with less
severe disease. In addition, the interpretation and full understanding of the clinical
relevance and meaning of 3He MRI measurements in CF patients is incomplete. For
example, the distribution of 3He gas within the lungs of CF patients is hypothesized to be
related to mucous plugging and perhaps inflammation of the airways causing disruption
in regional airflow. However, histological validation or cross modality comparisons,
such as with HRCT and the lung clearance index, are urgently required to identify the
specific airway pathologies in and around ventilation defects.

We must also

acknowledge that although we have taken into account the variability of the measurement
technique over 7-days, we did not determine the reproducibility of the 3He measurements
within the same-day, which is required to ensure that the differences observed here over
7-days were not attributable to differences in the breath-hold maneuver, patient effort, or
patient positioning between acquisitions.

However, a previous study evaluating

measurement reproducibility in CF showed high same-day reproducibility,

18

lending

strong support to the findings in this study over 7-days. It is also important to note that
while volumetric approaches may be more sensitive than visual scoring for quantifying
changes in CF patients, certainly a regional analysis of the changes in ventilation
distribution, as was recently shown by Woodhouse et. al.,18 would increase the sensitivity
for detecting change and may be relevant in guiding therapies. Another consideration is
the limited 3He MRI access, although the development of hyperpolarized
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Xe MRI a

less expensive and more readily available approach, is a promising alternative with which
these reported findings can be directly tested.
During progressive disease in CF, it is believed that adaptive remodeling of the lung
airways and tissue occurs in response to bacterial/viral/fungal colonization, inflammation
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and mucous plug occlusions. Clinical research studies of CF continue to focus on FEV1,
and in some cases high resolution or multi-detector x-ray CT methods to evaluate novel
interventions and disease progression. The results of the current study suggest that 3He
MRI provides another imaging tool for the assessment of both airway and airspace
changes in CF with sufficient precision and sensitivity to physiological lung functional
changes for clinical research studies. While much noble gas MRI pulmonary research is
transitioning to 129Xe MRI, we believe the current results are applicable to its use as well.
Moreover, both methods provide a relatively rapid and safe method of visualizing and
quantifying both spatial and temporal lung structural and functional dynamics related to
pulmonary disease. In conclusion, our results indicated that 3He MRI detected significant
changes in gas distribution in CF patients over a short 7-day period and these
measurements can be considered as potential intermediate endpoints for evaluating
functional lung changes with relatively small sample sizes.
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APPENDIX B
A case report of a COPD ex-smoker that was evaluated serially over 4 years using
hyperpolarized 3He MRI, twice prior to and twice following an acute exacerbation
requiring hospitalization is provided in Appendix B
The contents of this Chapter have been previously published in the Journal of Magnetic
Resonance in Medicine and permission to reproduce the article was granted by John
Wiley and Sons and is provided in Appendix C.
M Kirby, N Kanhere, R Etemad-Rezai, DG McCormack and G Parraga. Hyperpolarized
Helium-3 Magnetic Resonance Imaging of Chronic Obstructive Pulmonary Disease
Exacerbation: Case Report. JMRI doi: 10.1002/jmri.23896. [Epub ahead of print Nov 2
2012]

B

Hyperpolarized Helium-3 Magnetic Resonance Imaging
of Chronic Obstructive Pulmonary Disease Exacerbation
B.1 Introduction

Chronic obstructive pulmonary disease (COPD) is the 4th leading cause of death
worldwide and COPD exacerbations constitute a major burden on the health care
system,1 and are associated with disease progression2 and reduced quality of life.3 The
need for sensitive regional and surrogate measurements of COPD exacerbation risk and
response to therapy continues to motivate the development of non-invasive and sensitive
imaging approaches, such as hyperpolarized helium-3 (3He) magnetic resonance imaging
(MRI). Numerous studies have shown that 3He MRI measurements in COPD are highly
reproducible,4;5 sensitive to early lung micro-structural changes,6;7 and significantly
correlate with established measurements of pulmonary function,6;8 multi-slice computed
tomography (CT) measurements9 and histology measurements of emphysema.10
Furthermore, longitudinal 3He MRI of COPD has highlighted the sensitivity of the
method to progressive worsening11 and shown regional improvements postbronchodilator12;13 and following interventions such as stent supported airway bypass.14
Unfortunately, there have been few reports of the effect of such novel imaging results on
therapeutic and patient care decision making. Here, we report serial hyperpolarized 3He

273

MRI over a four year period in a 77 year old COPD ex-smoker including images acquired
prior to and following treatment for an acute exacerbation (AE) of COPD.

B.2 Case Report
A 77 year old male with GOLD stage III COPD and a 20 pack-year smoking history,
having ceased smoking 10 years prior, provided written informed consent to a
longitudinal 3He MRI study that was Health Insurance Portability and Accountability Act
(HIPAA) compliant and approved by a local ethics board. Hyperpolarized 3He static
ventilation and diffusion-weighted MRI was performed 25 minutes after 400μg
salbutamol administration in breath-hold after inspiration of a 1.0L gas mixture of 3He
(5mL/kg body weight) and N2 gas from functional residual capacity (FRC) as previously
described.15

3

He gas was polarized to 30—40 % using a polarizer system (HeliSpin™,

GEHC, Durham, NC). Static ventilation images were acquired using a fast-gradientrecalled-echo (FGRE) sequence (14s data acquisition, TR / TE / flip angle = 4.3 ms / 1.4
ms / 7o, bandwidth = 31.25, FOV = 40 × 40 cm, matrix 128 × 128, 14 slices, 15 mm slice
thickness, 0 gap) and diffusion-weighted images were acquired using a FGRE sequence
with centric k-space sampling; two interleaved images were acquired (14s total data
acquisition, TR/TE/flip angle = 7.6 ms/3.7 ms/8o, FOV = 40 x 40 cm, matrix 128 x 128, 7
slices, 30 mm slice thickness), with and without additional diffusion sensitization (G =
1.94 G/cm, rise and fall time = 0.5 ms, gradient duration = 0.46 ms, Δ = 1.46 ms, b = 1.6
s/cm2). It is important to note that pulse oximetry was used to measure arterial oxygen
saturation (Sa02) during all imaging sessions. No adverse events occurred during any
imaging session for this subject and Sa02 remained above 88% at all times. Proton (1H)
MRI was also acquired with the same breath-hold volume within 5 min of 3He MRI as
previously described15 to obtain an anatomical thoracic image to enable clear delineation
of the thoracic cavity. Registration and semi-automated segmentation of the 3He MRI
functional and 1H MRI anatomical image for each time-point provided a way to generate
the lung ventilation defect percent (VDP) as previously described.16;17

3

He apparent

diffusion coefficients (ADC) were generated from 3He diffusion-weighted imaging and
ADC maps as previously described.13

Hyperpolarized

3

He MRI measurement

reproducibility in COPD was previously shown to be high at a number of independent
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sites,4;5;9 and these results clearly provided good support for its use in serial studies of
COPD.
Approximately 2.5 years pre-AE, as shown in Table B1, the forced expiratory volume in
1sec (FEV1) was 1.48L (41%pred), forced vital capacity (FVC) was 3.19L (66%pred),
inspiratory capacity (IC) was 2.42L (64%pred) and FRC was 3.74L (95%pred). As shown
in Figure B1, 3He MRI revealed heterogeneous and abnormal gas distribution (whole
lung VDP=16%) reflective of airway obstruction and Figure B2 provides an ADC map
(whole lung ADC=0.34cm2/s) reflective of regional emphysema.
Table B1 3He MRI and pulmonary function measurements in a single subject pre- and
post-exacerbation
Pre-Exacerbation
Post-Exacerbation
days [months]
days [months]
Parameters
- 886 [29]
- 169 [6]
+8
+ 477 [16]
Pulmonary Function Tests
FEV1 (%pred)
41
47
45
54
FEF25% (%pred)
19
23
34
FEF50% (%pred)
18
15
17
FVC (%pred)
66
70
68
76
FEV1/FVC (%)
46
49
48
51
TLC (%pred)
78
73
78
74
IC (%pred)
64
35
44
40
FRC (%pred)
95
105
106
91
RV (%pred)
94
76
113
85
DLCO (%pred)
36
34
Hyperpolarized 3He MRI
VDP (%)
16
29
20
14
ADC (cm2/s)
0.34
0.38
0.34
FEV1 = forced expiratory volume in one second, FEF25% = forced expiratory flow at 25%
forced vital capacity (FVC), FEF50% = forced expiratory flow at 50% FVC, SVC = slow
vital capacity, TLC = total lung capacity, IC = inspiratory Capacity, FRC = functional
residual capacity, RV = residual volume, DLCO = carbon monoxide diffusion capacity of
the lung, VDP = ventilation defect percent, ADC = apparent diffusion coefficient.
Approximately 6 months pre-AE, 3He MRI (Table B1 and Figure B1) showed increased
heterogeneity of gas distribution and increased VDP, suggestive of progressive
worsening. As shown in Figure B2, the elevated 3He ADC 6 months pre-AE was
dominated by the contributions of the posterior lung slices. Previous studies7 evaluating
the anatomical distribution of

3

He ADC in COPD and healthy volunteers have

275

demonstrated that the anterior-posterior gradient is significantly greater in healthy
volunteers than in severe COPD subjects, suggesting dependent lung region gas trapping
in contrast to progressive worsening of emphysema. At the same time, measurements of
gas trapping such as IC were also worse (Table B1). Although there was worsening of
both 3He MRI VDP and ADC, there was no change in the subject clinical status between
the 29 and 6 months pre-AE time-points. It is also important to note that there was
sufficient image signal-to-noise-ratio (SNR) at all time-points (SNR>20).
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Figure B1 Hyperpolarized 3He MRI pre- and post-exacerbation
Hyperpolarized 3He MRI static ventilation images with the ventilation defect
percent (VDP) shown below for the three centermost slices for a COPD subject 29
and 6 months prior to hospitalization for an acute exacerbation with pneumonia
and 8 days and 16 months following hospitalization. The length of time prior to
and following the acute exacerbation is provided in days and months in square
brackets. 3He MRI shows a heterogeneous and abnormal gas distribution with
signal voids or “defects” reflective of airway obstruction 29 months prior to
hospitalization that was visually more heterogeneous 6 months prior to
hospitalization. Improvements in 3He gas distribution were observed 8 days postexacerbation that persisted 16 months post-exacerbation.
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Figure B2 Hyperpolarized 3He MRI ADC of COPD subject pre- and postexacerbation
A. 3He MRI ADC maps for the centermost slice for COPD subject 29 and 6 months
prior to hospitalization for an acute exacerbation with pneumonia and 16 months
following hospitalization. The subject was unable to perform 3He MRI ADC 8 days
following hospitalization.
B. 3He ADC histograms for each slice in the posterior to anterior direction at the preand post-exacerbation time-points.
C. Mean 3He ADC was 0.34cm2/s (mean ADC=0.34cm2/s, 95% confidence interval
(CI)=0.32cm2/s-0.36cm2/s; linear regression slope=0.01, 95% CI=-0.002-0.02) at 29
months pre-exacerbation and was elevated (mean ADC=0.38cm2/s, 95%
CI=0.35cm2/s-0.40cm2/s; slope=-0.01, 95% CI=-0.03-0.008) at 6 months preexacerbation. The elevated ADC in the posterior slices suggests dependent lung
region gas trapping. At 16 months post-exacerbation, ADC values returned to
baseline (mean ADC=0.34cm2/s, 95% CI=0.32cm2/s-0.34cm2/s; slope=0.005, 95%
CI=-0.002-0.01).
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Twenty-eight days prior to hospitalization, the subject complained of symptomatic
worsening of COPD, characterized by increased shortness of breath and cough. He was
evaluated by a primary care physician and treated with levofloxacin 500mg for 10 days.
Eighteen days later, he attended the emergency department with worsening symptoms
and was hospitalized for COPD AE and treated with a course of 50mg of prednisone for 6
days, 500mg of cefuroxime for 14 days and 250mg of erythromycin for 7 days. Four
days after discharge from hospital, the subject returned for 3He MRI and pulmonary
function tests. Although pulmonary function measurements were unchanged compared
to 6 months prior (FEV1=45%pred, FEV1/FVC=48%), 3He MRI (Figure B1, 8 days postAE) showed gas distribution and VDP (VDP=20%) improvements. Because of technical
difficulties, 3He diffusion-weighted imaging was not performed at this time-point and
therefore no ADC measurements were acquired.
Approximately 16 months post-AE, visibly obvious improvements in gas distribution
persisted and there was improved VDP, and improved FEV1, FVC, IC and FRC. In
addition, mean ADC also decreased to values that were the same as nearly 4 years earlier
with a more normalized anterior-posterior ADC gradient reflecting diminished gas
trapping7 compared to 6 months pre-AE.

B.3 Discussion
In this hyperpolarized 3He MRI study we evaluated a single COPD ex-smoker over
nearly four years, including scans 6 months prior to and immediately following treatment
for an acute exacerbation of COPD. We observed visibly obvious improvements in 3He
gas distribution immediately following exacerbation treatment, likely while the subject
was still recovering, although no improvements were reflected by FEV1. Improvements
in 3He MRI VDP and ADC were also evident 16 months post-AE and these imaging
improvements were mirrored by improved spirometry measurements. Importantly, the
change in the 3He VDP 6 months prior to the exacerbation compared to all other timepoints exceeded the smallest detectable difference of the measurement as previously
reported,17 suggesting that the patient could have been worse 6 months before the
exacerbation, although there was no change in the subjects clinical status until
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approximately one month before hospitalization when the subject complained of
symptoms. It is important to note that the acute exacerbation may have been caused by
infection since improvement was seen only after broad-spectrum antibiotic treatment, and
therefore 3He MRI might not have predicted the exacerbation onset. However, IC was
also reduced 6 months prior to the exacerbation, and previous studies have demonstrated
that IC can be used to reliably detect changes in end expiratory lung volume during
COPD exacerbations.18

Taken together this suggests that MRI may have reflected

regional pulmonary decline before, or even in the absence of changes in FEV1.
Moreover, immediately after treatment for a COPD AE, spirometry measurements were
relatively unchanged, although MRI showed substantive improvements.
Several hypotheses and questions arise from our results that are related to the time-course
of exacerbation treatment such as: 1) Is there a relationship between symptomatic and
3

He MRI improvements following therapy, before changes in FEV1 are measured?; 2)Do

COPD patients with specific imaging phenotypes have a propensity for increased
exacerbation frequency? We note that the potential for imaging surrogate endpoints as
markers of future clinical outcomes was recently demonstrated in cystic fibrosis (CF),
whereby the relationship between high-resolution computed tomography measurements
and CF exacerbations was shown.19 Improvements in 3He gas distribution have also been
demonstrated in the absence of concomitant improvements in spirometry in CF patients
following chest physical therapy.20 We think these previous results and the current case
study highlight the discordance between spirometry and exacerbations and the potential
predictive relationship between imaging and clinical outcomes many years later. In
particular for hyperpolarized noble gas imaging, high short term reproducibility 4 coupled
with the high sensitivity in longitudinal11 and other acute therapy studies,12;13 suggest that
this may be an ideal imaging approach to study or identify COPD patients at high risk for
exacerbation.
We must acknowledge that this study was limited because 3He MRI and pulmonary
function measurements were not acquired more close in time to the onset of the AE.
Clearly, acquiring 3He MRI at time-points more closely timed to the clinical course
would strengthen the findings of this investigation. The limited and high cost of 3He gas
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that which has restricted translation to specialized MR physics centers is another
important limitation. However, the development of hyperpolarized

129

Xe MRI21;22 is a

promising alternative with which these findings can be directly tested in a larger COPD
patient population.
It is nearly 2 decades since the potential for pulmonary functional imaging using inhaled
noble gases was first described,21 and it is yet unclear what role this novel imaging tool
might play in the management of patients with COPD.

Hyperpolarized 3He MRI is

highly reproducible in COPD4;5;9 with a modest smallest detectable difference
(SDD=0.16L for VDV)17 and this bodes well for serial studies in individual patients to
monitor or perhaps predict disease worsening.

However, it has not yet been

demonstrated how such structure-function measurements can be used to make or alter
therapy decisions, nor do we fully understand the clinical meaning of 3He or

129

Xe gas

distribution measurements or the clinical relevance of their apparent worsening. In this
regard, the current case provides evidence that serial 3He MRI measurements of airway
function (VDP) and parenchyma microstructure can be used to visualize regional changes
in COPD subjects, with the potential to modify therapy. However, it must be also noted
that for the forseeable future, this imaging approach cannot be generalized to routine care
or screening. Clearly, however, larger scale studies are required to evaluate the effect on
COPD outcomes of incorporating pulmonary functional imaging into regular clinical
monitoring and visits.
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Evaluation of COPD Airway Function and Structure using Hyperpolarized 3He
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Magnetic Resonance Imaging and x-ray Computed Tomography. 1st Annual
Canadian Thoracic Society Poster Competition, Denver, Colorado, USA (05/11)
35. S Svenningsen, M Kirby, H Ahmed, N Paterson, G Parraga. Evaluation of Short
Term Reproducibility of Hyperpolarized Helium-3 Magnetic Resonance Imaging
in Adult Cystic Fibrosis using a Semi-Automated Segmentation Tool.
International Society for Magnetic Resonance in Medicine, Montreal, Quebec,
Canada (05/11)
36. M Kirby, R Etemad-Rezai, DG McCormack and G Parraga. Evaluating
Bronchodilator Effects in Chronic Obstructive Pulmonary Disease using
Hyperpolarized Helium-3 Magnetic Resonance Imaging. International Society
for Magnetic Resonance in Medicine, Montreal, Quebec, Canada (05/11)
37. M Kirby, L Mathew, M Heydarian, R Etemad-Rezai, DG McCormack and G
Parraga. Evaluating Bronchodilator Effects in Chronic Obstructive Pulmonary
Disease Quantified using Hyperpolarized Helium-3 Magnetic Resonance
Imaging. Margaret Moffat Research Day, London, Ontario, Canada (03/11)
38. L Mathew, M Kirby, R Etemad-Rezai, D G McCormack, G Parraga.
Hyperpolarized 3He Magnetic Resonance Imaging Biomarkers of Bronchoscopic
Airway Bypass in COPD. 5th International Workshop for Pulmonary Functional
Imaging, Awaji, Japan (01/11)
39. SE Costella, S Choy, M Kirby, A Wheatley, R Etemad-Rezai, DG McCormack,
G Parraga. Hyperpolarized 3He MRI Apparent Diffusion Coefficients as a Probe
of Airway Function in Asthma After Methacholine Challenge and Recovery. 5th
International Workshop for Pulmonary Functional Imaging, Awaji, Japan (01/11)
40. M Heydarian, M Kirby, S Choy, A Wheatley, S Costella, R Etemad-Rezai, DG
McCormack, G Parraga. Semi-Automated Segmentation of Lung Ventilation
using Hyperpolarized Heliium-3 Magnetic Resonance Imaging, Biomedical
Engineering Society, Austin, Texas, (09/10)
41. M Kirby, L Mathew, A Wheatley, DG McCormack and G Parraga. InterObserver Reproducibility of Longitudinal Hyperpolarized Helium-3 Magnetic
Resonance Imaging of Chronic Obstructive Pulmonary Disease. London Imaging
Discovery Day, London, Ontario, Canada (06/10)
42. L Mathew, M Kirby, R Etemad-Rezai, DG McCormack, G Parraga.
Characterization of Hyperpolarized Helium-3 Magnetic Resonance Imaging
Phenotype Dominant COPD. International Conference of the American Thoracic
Society, New Orleans, Louisiana, USA (05/10)
43. M Kirby, L Mathew, A Wheatley, DG McCormack and G Parraga. InterObserver Reproducibility of Longitudinal Hyperpolarized Helium-3 Magnetic
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Resonance Imaging of Chronic Obstructive Pulmonary Disease. International
Society for Magnetic Resonance in Medicine, Stockholm, Sweden (05/10)
44. M Kirby, L Mathew, A Wheatley, DG McCormack and G Parraga. InterObserver Reproducibility of Longitudinal Hyperpolarized Helium-3 Magnetic
Resonance Imaging of Chronic Obstructive Pulmonary Disease. Margaret Moffat
Research Day, London, Ontario, Canada (03/10)
45. M Kirby, L Mathew, A Wheatley, DG McCormack and G Parraga. InterObserver Reproducibility of Longitudinal Hyperpolarized Helium-3 Magnetic
Resonance Imaging of Chronic Obstructive Pulmonary Disease. Lawson
Research Day, London, Ontario, Canada (03/10)
46. A Wheatley, H Ahmed, S Choy, M Kirby and G Parraga. Development and
Application of Texture Analysis Tools for Hyperpolarized Helium-3 Magnetic
Resonance Lung Imaging, The International Workshop for Pulmonary Functional
Imaging, Boston, Massachusetts, USA (09/09)
47. M Kirby, L Mathew, A Wheatley, DG McCormack and G Parraga. Chronic
Obstructive Pulmonary Disease Progression Detected by Hyperpolarized Helium3 Magnetic Resonance Imaging, London Imaging Discovery Day, London,
Ontario, Canada (06/09)
48. M Kirby, A Wheatley, DG McCormack and G Parraga. Hyperpolarized Helium3 Magnetic Resonance Imaging Ventilation Heterogeneity in Chronic Obstructive
Pulmonary Disease, London Imaging Discovery Day, London, Ontario, Canada
(06/09)
49. M Kirby, A Wheatley, DG McCormack and G Parraga. Hyperpolarized Helium3 Magnetic Resonance Imaging Ventilation Heterogeneity in Chronic Obstructive
Pulmonary Disease, International Conference of the American Thoracic Society
Meeting, San Diego, California, USA (05/09)
50. M Kirby, L Mathew, A Wheatley, DG McCormack and G Parraga. Longitudinal
Hyperpolarized Helium-3 Magnetic Resonance Imaging of Chronic Obstructive
Pulmonary Disease: Two year Follow-up Evaluation, International Conference of
the American Thoracic Society Meeting, San Diego, California, USA (05/09)
51. H Ahmed, M Kirby*, L Mathew, S Choy, A Wheatley, G Santyr, R McFadden,
NAM Paterson, J Lewis, R Veldhuizen, G Rodrigues, G Bauman, C Licskai, R
Etemad-Rezai, DG McCormack and G Parraga. Hyperpolarized 3He Magnetic
Resonance Imaging: Novel Imaging Endpoints for Respiratory Research,
Canadian Respiratory Conference, Toronto, Ontario, Canada (04/09)
52. M Kirby, L Mathew, A Wheatley, DG McCormack and G Parraga. Chronic
Obstructive Pulmonary Disease Progression Detected by Hyperpolarized Helium-
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3 Magnetic Resonance Imaging, Margaret Moffat Research Day, London,
Ontario, Canada (03/09)

F. Invited Presentations (4)
1. M Kirby, N Kanhere, D Pike, A Wheatley, N.A. Paterson, D.G. McCormack and
G Parraga. Hyperpolarized Helium-3 Magnetic Resonance Imaging Phenotypes
of Chronic Obstructive Pulmonary Disease: Relationship to Exacerbations. 3rd
Annual Canadian Thoracic Society Poster Competition, Philadelphia,
Pennsylvania, USA (05/13)
2. M Kirby, A Wheatley, DG McCormack, G Parraga. Imaging of lung function
using hyperpolarized helium. European Respiratory Society, Vienna, Austria
(09/12)
3. M Kirby, L Mathew, A Wheatley, DG McCormack, G Parraga. Hyperpolarized
Helium-3 Magnetic Resonance Imaging of Chronic Obstructive Pulmonary
Disease. A.C. Burton Day, London, Ontario, Canada (04/11)
4. M Kirby, N. Krowchuk, A Wheatley, DG McCormack, H Coxson, G Parraga.
Evaluation of COPD Airway Function and Structure using Hyperpolarized 3He
Magnetic Resonance Imaging and x-ray Computed Tomography. 1st Annual
Canadian Thoracic Society Poster Competition, Denver, Colorado, USA (05/11)

POST-GRADUATE EDUCATION DEVELOPMENT
Oct. 2012 –
Graduate Student Supervisor
Nov. 2012
Resident: Aasim Hasany, 2nd year Internal Medicine, UWO
6 Week Project:
‘Longitudinal Study of Oscillatory Positive
Expiratory Pressure (oPEP) in Stable COPD’
Poster Presentation ImNO: N Kanhere, A Hasany, M Kirby, J
Suggett, DG McCormack, G Parraga. Hyperpolarized 3He Magnetic
Resonance Imaging following Oscillatory Positive Expiratory Pressure
Treatment in GOLD stage II and III COPD. Imaging Network Ontario
Symposium, Toronto, Ontario, Canada (02/13)
May 2012 –
Aug. 2012

Graduate Student Supervisor
Medical Student: Lauren Villemaire, 2nd year Medicine, UWO
Project: ‘Hyperpolarized Helium-3 Diffusion-Weighted Magnetic
Resonance Imaging of Cystic Fibrosis’
Poster Presentation ATS: M Kirby, L Villemaire, H Ahmed, N.A.
Paterson, D.G. McCormack, J.F. Lewis and G Parraga. DiffusionWeighted Hyperpolarized Helium-3 Magnetic Resonance Imaging in
Adult Cystic Fibrosis. International Conference of the American
Thoracic Society Meeting, Philadelphia, Pennsylvania, USA (05/13)
Manuscript in Preparation: M Kirby, L Villemaire, H Ahmed, NAM
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Paterson, DG McCormack JF Lewis and G Parraga. DiffusionWeighted Hyperpolarized Helium-3 Magnetic Resonance Imaging of
Cystic Fibrosis. JAP
Jan. 2012 –
Feb. 2012

Graduate Student Supervisor
Resident: Yaj Shukla, 2nd year Internal Medicine, UWO
6 Week Project: ‘Hyperpolarized 129Xe Magnetic Resonance Imaging:
Tolerability in Healthy Volunteers and Subjects with Pulmonary
Disease’
Published Manuscript: Y Shukla, A Wheatley, M Kirby, S
Svenningsen, A Farag, G Santyr, NAM Paterson, DG McCormack and
G Parraga. Hyperpolarized 129Xe Magnetic Resonance Imaging:
Tolerability in Healthy Volunteers and Subjects with Pulmonary
Disease. Acad. Radiol. 2012; 19(8):941-51.

Jan. 2012 –
Feb. 2012

Graduate Student Supervisor
Resident: Andrew Youn, 2nd year Internal Medicine, UWO
6 Week Project: ‘Hyperpolarized Helium-3 and Xenon-129 Magnetic
Resonance Functional Imaging in Adult Cystic Fibrosis’
Oral Presentation ATS: A Youn, M Kirby, A Wheatley, J Lewis, DG
McCormack and G Parraga. Hyperpolarized Helium-3 and Xenon-129
Magnetic Resonance Functional Imaging in Adult Cystic Fibrosis.
International Conference of the American Thoracic Society Meeting,
San Francisco, California, USA (05/12)

Jun. 2011

3D Slicer Workshop
Instructor: Dr. Ron Kikinis
Objective: Introduction to the 3D Slicer environment, as well as to
illustrate the ability to integrate with ITK and Python modules.

Jun. 2011 –
Aug. 2011

Graduate Student Supervisor
Medical Student: Casey Neron, 2nd year Medicine, UWO
8 Week Project: ‘Evaluating the Relationship between Atherosclerosis
and Lung Function in Subjects with Smoking Histories’
Poster Presentation ATS: M Kirby, C Neron, JD Spence, NAM
Paterson, D Buchanan, A Wheatley, HO Coxson, DG McCormack and
G Parraga Hyperpolarized Helium-3 Magnetic Resonance Imaging of
Pulmonary Structure and Function in Ex-smokers with Carotid
Atherosclerosis. International Conference of the American Thoracic
Society Meeting, San Francisco, California, USA (05/12)
Manuscript in Preparation: D Pike, M Kirby, C Neron, D Buchanan,
JD Spence, NAM Paterson, A Wheatley, HO Coxson, DG McCormack
and G Parraga. Hyperpolarized Helium-3 Magnetic Resonance
Imaging of Pulmonary Structure and Function in Ex-smokers with
Carotid Atherosclerosis. Respirology
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Sep. 2010 –
Apr. 2011

Graduate Student Supervisor
Undergraduate Student:
Sarah Svenningsen, 4th year Medical
Biophysics, UWO
Thesis Project: ‘Quantitative Evaluation of Hyperpolarized Helium-3
Magnetic Resonance Imaging of Lung Function Variability in Cystic
Fibrosis’
Poster Presentation ISMRM: S Svenningsen, M Kirby, A Wheatley,
A Ouriadov, GE Santyr, DG McCormack and G Parraga.
Reproducibility of Hyperpolarized Helium-3 Magnetic Resonance
Imaging in Adult Cystic Fibrosis using a Semi-Automated
Segmentation Tool. Imaging Network Ontario, Toronto, Ontario,
Canada (02/12)
Published Manuscript: M Kirby, S Svenningsen, H Ahmed, N
Paterson and G Parraga. Quantitative Evaluation of Hyperpolarized
Helium-3 Magnetic Resonance Imaging of Lung Function Variability
in Cystic Fibrosis. Acad. Radiol. 2011; 18(8):1006-13.

Sep. 2010 –
Dec. 2010

Graduate Teaching Assistant
3505F Mathematical Transform Applications in Medical Biophysics
Department of Medical Biophysics
The University of Western Ontario, London, Ontario, Canada

Sep. 2009 –
Dec. 2009

Graduate Teaching Assistant
3505F Mathematical Transform Applications in Medical Biophysics
Department of Medical Biophysics
The University of Western Ontario, London, Ontario, Canada

RELEVANT GRADUATE COURSES
Department of Medical Biophysics
The University of Western Ontario, London, Ontario, Canada
Sep. 2009 –
Apr. 2010

BIOPHYS 9663
BIOPHYS 9516
BIOPHYS 9662
BIOPHYS 9509

MRI Physics
Imaging Principles
Nuclear Magnetic Resonance Imaging
Digital Image Processing

Sep. 2008 –
Apr. 2009

BIOPHYS 9515
VASCPROG 9560
VASCPROG 9603
BIOPHYS 9513
BIOPHYS 9522

Medical Imaging
Vascular Imaging
Research Ethics
Scientific Communication
Inferencing from data analysis

PROFESSIONAL MEMEBERSHIPS
2010 – 2011
Biomedical Engineering Society
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2009 – present
2008 – present
2008 – present
2008 – present

Student Member
Canadian Thoracic Society
Student Member
American Thoracic Society
Student Member
International Society of Magnetic Resonance in Medicine
Student Member
Canadian Organization of Physicists in Medicine
Student Member

LEADERSHIP and VOLUNTEER ACTIVITIES
2013 Volunteer, Let’s Talk Science
Member, Biomedical Imaging Research Centre (BIRC)
Member, Network of Imaging Students (NOISe)
2012

Volunteer, Canadian Cancer Society, Relay for Life
Volunteer, Let’s Talk Science
Member, Biomedical Imaging Research Centre (BIRC)
Member, Network of Imaging Students (NOISe)

2011

Volunteer, Let’s Talk Science
Member, Biomedical Imaging Research Centre (BIRC)
Member, Network of Imaging Students (NOISe)

2010

Member, Biomedical Imaging Research Centre (BIRC)
Member, Network of Imaging Students (NOISe)

2009

Volunteer, Doors open London, Robarts Research Institute
Member, Network of Imaging Students (NOISe)

2008

Member, Network of Imaging Students (NOISe)

